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Abstract 
MicroRNAs are a class of small non-coding RNAs that negatively regulate gene 
expression. Several microRNAs have been implicated in altering hematopoietic cell fate 
decisions. Importantly, deregulation of many microRNAs can lead to deleterious 
consequences in the hematopoietic system, including the onset of cancer, autoimmunity, or 
a failure to respond effectively to infection. As such, microRNAs fine-tune the balance 
between normal hematopoietic output and pathologic consequences. In this work, we 
explore the role of two microRNAs, miR-132 and miR-125b, in regulating hematopoietic 
stem cell (HSC) function and B cell development. In particular, we uncover the role of 
miR-132 in maintaining the appropriate balance between self-renewal, differentiation, and 
survival in aging HSCs by buffering the expression of a critical transcription factor, 
FOXO3. By maintain this balance, miR-132 may play a critical role in preventing aging-
associated hematopoietic conditions such as autoimmune disease and cancer. We also find 
that miR-132 plays a critical role in B cell development by targeting a key transcription 
factor, Sox4, that is responsible for the differentiation of pro-B cells into pre-B cells. We 
find that miR-132 regulates B cell apoptosis, and by delivering miR-132 to mice that are 
predisposed to developing B cell cancers, we can inhibit the formation of these cancers and 
improve the survival of these mice. In addition to miR-132, we uncovered the role of 
another critical microRNA, miR-125b, that potentiates hematopoietic stem cell function. 
We found that enforced expression of miR-125b causes an aggressive myeloid leukemia by 
downregulation of its target Lin28a. Importantly, miR-125b also plays a critical role in 
inhibiting the formation of pro-B cells. Thus, we have discovered two microRNAs with 
important roles in regulating normal hematopoiesis, and whose dregulation can lead to 
deleterious consequences such as cancer in the aging hematopoietic system. Both miR-132 
and miR-125b may therefore be targeted for therapeutics to inhibit age-related immune 
diseases associated with the loss of HSC function and cancer progression. 
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C h a p t e r  1  
Chapter 1: Introduction to immune system development 
and microRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
Overview of thesis 
In this thesis we explore the role of a class of noncoding RNAs, called microRNAs, in fine-
tuning hematopoietic cell fate decisions and function. MicroRNAs are key post-
transcriptional regulators of gene-expression and we seek to understand how these 
microRNAs control the balance between normal and pathological hematopoiesis with age. 
Aging of the hematopoietic system leads to an increased incidence of several hematopoietic 
diseases, including cancer, autoimmune function, and a general failure to combat 
infections. We uncover the role of two microRNAs that, when altered, severely affect stem 
cell and B cell development, function, and survival in the immune system.  
 
The first chapter will present background information on the normal function of 
hematopoietic stem cells and B cells. We then delve into how aging may lead to 
pathological hematopoiesis and the development of immune cell cancers. Next, we explore 
microRNA biogenesis and the contribution of microRNAs to hematopoietic cell fate 
decisions. In chapter 2, we describe the role of a previously unappreciated microRNA 
cluster, miR-212/132, in hematopoietic stem cells. We find that miR-212/132 buffers the 
expression of its target Foxo3 with age, and in doing so allows these stem cells to maintain 
a critical balance between self-renewal, differentiation, and survival. When altered, miR-
212/132 can lead to poor stem cell function with age, and possibly to the onset of 
pathological consequences such as anemia and cancer. In chapter 3, we continue the 
exploration of miR-212/132 in the aging hematopoietic system by elucidating its role in B 
cell development and the treatment of B cell cancers. We find a novel target for mIR-
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212/132, the transcription factor Sox4, and demonstrate that when altered this microRNA 
cluster severally inhibits B cell development and survival. We next take advantage of this 
role of miR-212/132 in B cell development to alter the progression of B cell cancer, thus 
revealing a potential therapeutic application of this microRNA. In chapter 4, we continue to 
explore the role of microRNAs with potential therapeutic applications in blood cancers by 
uncovering a mechanism by which miR-125b, another regulator of HSC function, causes 
myeloid leukemia and inhibits B cell development by targeting the pluripotency factor 
Lin28a. We consider the future directions and potential implications of this work in chapter 
5, and discuss ongoing work to investigate the heterogeneous nature of young and aged 
HSCs in order to understand the mechanisms underlying age-associated hematopoietic 
diseases. 
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Overview of hematopoiesis 
Normal functions of the hematopoietic system 
We begin this introduction with an overview of normal hematopoietic function. The 
hematopoietic system is remarkable in its ability to produce millions of cells every second 
(Orkin and Zon, 2008). Each cell originates from a single hematopoietic stem cell (HSC) 
that has the unique ability to self-renew (create identical copies of itself) and to 
differentiate into more committed progenitors that lose their ability to self-renew but 
eventually lead to all other cell types in the immune system (Figure 1) (Orkin and Zon, 
2008). The goal of the hematopoietic system is to produce a balanced output of functional 
Figure 1. The hematopoietic tree. Adapted from (Orkin and Zon, 2008). 
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red blood cells, myeloid cells (such as macrophages and granulocytes, which largely 
govern innate immune function) and lymphoid cells such as B cells and T cells, which are 
primarily responsible for adaptive immune function (Orkin and Zon, 2008). As such, 
lineage commitment and cell fate in this system is governed by a complex set of gene 
regulatory pathways, epigenetic changes, and post-transcriptional modifications (Cabezas-
Wallscheid et al., 2014; Laurenti et al., 2013; O'Connell et al., 2010b; Sun et al., 2014). The 
developmental intermediates, or hematopoietic progenitors, that lead to each of these cell 
types are being actively explored. While several lineage-committed progenitors such as the 
common myeloid progenitor (CMP) and common lymphoid progenitor (CLP) have been 
identified, it is becoming extremely clear that the hematopoietic tree is intricate and 
complex, with several overlapping intermediates that maintain some potential to produce 
more diverse cell types than originally anticipated (Orkin and Zon, 2008). We focus this 
review on two particular cells in the hematopoietic stem cell relevant to the work discussed 
later. These are the hematopoietic stem cell and the B cell.  
 
Hematopoietic stem cells 
The origin of all blood cells in the body is the hematopoietic stem cell (HSC) (Orkin and 
Zon, 2008). HSCs must maintain an intricate balance between self-renewal and 
differentiation throughout the course of our life (Morrison and Weissman, 1994; Rossi et 
al., 2012). As such, many different genes, epigenetic modifications, and other intrinsic 
factors regulate them (Cabezas-Wallscheid et al., 2014; Sun et al., 2014). Importantly, 
HSCs reside in the bone marrow niche and are also strongly influenced by extrinsic signals, 
such as cytokines and growth factors (Orkin and Zon, 2008). It is also becoming 
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increasingly apparent that HSCs might respond directly to foreign material, such as 
pathogens, that enter the body (Nagai et al., 2006; Zhao et al., 2014).  
 
At the peak of the cellular hierarchy is what is known as the long-term HSC (LT-HSCs). 
These LT-HSCs are essential for maintaining a life-long supply of blood. Immediately 
downstream of these cells are slightly more committed progenitors, known as short-term 
HSCs (ST-HSCs) and multipotent progenitors (MPPs). ST-HSCs and MPPs have lost the 
Figure 2. Cell cycle regulation of hematopoietic stem cells. Adapted from (Rossi et al., 
2012). 
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ability to self-renew; however, they maintain the ability to differentiate into all cell types. 
Downstream of the MPPs are several lineage-restricted progenitors, which then give rise to 
mature cells (Figure 1) (Orkin and Zon, 2008).  
 
The majority of HSCs reside in the bone marrow in a quiescent state. It is believed that it is 
these HSCs that have the best long-term reconstitution potential upon bone marrow 
transplant (Morrison and Weissman, 1994; Orkin and Zon, 2008; Rossi et al., 2012). HSCs 
that become activated cycle more rapidly, and this active proliferation is closely related to 
differentiation (Morrison and Weissman, 1994; Rossi et al., 2012). Furthermore, many 
HSCs periodically circulate in the peripheral blood and hone back to the bone marrow 
eventually. Several genes regulate HSC cycling, including genes that control cell cycle 
check-points such as p21, p27, and p57, as well as several other factors (Figure 2) 
(Morrison and Weissman, 1994; Rossi et al., 2012).  Other factors that alter HSC function 
include those that regulate the ability of HSCs to stay in the bone marrow niche, such as 
Mmp9, those that affect survival, such as Foxo3, and others that alter signaling in HSCs, 
such as the Wnt pathway (Rossi et al., 2012).  
 
B cells 
B cells are the primary producers of immunoglobulin and play a critical role in adaptive 
immunity (Mauri and Bosma, 2012). The maintenance of proper B cell output from early 
hematopoietic progenitors, along with the production of an appropriate antibody repertoire, 
is critical in maintaining the balance between normal immune function and diseases such as 
autoimmunity and cancer. Therefore, B lymphopoiesis requires the intricate interplay of 
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many different transcription factors in a complex gene regulatory network that controls 
lineage specification and commitment (Mandel and Grosschedl, 2010; Matthias and 
Rolink, 2005; Nutt and Kee, 2007).  
 
Antigen-independent B cell development begins with the differentiation of lymphoid 
primed multipotent progenitors (LMPPs) to common lymphoid progenitors (CLPs), a 
process driven by the expression of PU.1 and Ikaros (Matthias and Rolink, 2005; Nutt and 
Kee, 2007), both of which may play a role in regulating Flt3 and IL-7R expression 
(DeKoter et al., 2002; Yoshida et al., 2006).  These early progenitors also express Rag1 and 
Rag2, and thus begin the process of rearrangement of the immunoglobulin heavy chain 
(IgH) locus (Igarashi et al., 2002). Lineage specification to the next stages of B cell 
development, the pre-pro-B cell and pro-B cell, involves the upregulation of several genes 
controlled by E2A and Ebf1 (O'Riordan and Grosschedl, 1999), including Pax5 (Cobaleda 
et al., 2007). Pax5 is essential for B cell lineage commitment, as it represses genes that are 
inappropriate for B cell development (Souabni et al., 2002). The transition to pre-B cells, 
the stage at which immunoglobulin light chain (IgL) rearrangement begins, and immature 
B cells, involves many factors including Sox4 (Sun et al., 2013), which has also been 
implicated in regulating the expression of the Rag genes (Mallampati et al., 2014).  
 
The aging hematopoietic system 
Aged HSCs are characterized by increased self-renewal potential, loss of long-term 
reconstitution capability, myeloid-biased differentiation, and a change in niche localization. 
As a consequence, aged mice demonstrate an accumulation of phenotypically defined 
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HSCs with a poor ability to hone to the bone marrow niche (Geiger et al., 2013). These 
aged HSCs also develop a requirement for basal autophagy for survival, because replication 
stress and the accumulation of reactive oxygen species have harmful consequences on HSC 
numbers and function with age (Flach et al., 2014; Tothova et al., 2007). The loss of critical 
autophagic factors is often associated with altered cell cycling of HSCs, and leads to 
apoptosis and a rapid loss of HSC numbers in aged mice (Miyamoto et al., 2007; 
Rubinsztein et al., 2011; Warr et al., 2013). A critical balance between cell cycling and 
differentiation, and survival of aged HSCs must therefore be established to maintain normal 
hematopoietic output. 
 
Hematopoietic malignancies 
Deregulation of hematopoietic stem cell function or immune developmental processes can 
have deleterious consequences, including the development of leukemias and lymphomas 
(O'Connell et al., 2010b). MiR-125b is up-regulated in a range of human leukemias, 
including acute myeloid leukemia (AML) (Bousquet et al., 2008; Enomoto et al., 2011), 
chronic myeloid leukemia (CML) (Enomoto et al., 2011), acute megakaryocytic leukemia 
(AMKL) (Klusmann et al., 2010), childhood acute lymphoblastic leukemia (ALL) with the 
ETV6/Runx1 fusion protein (Gefen et al., 2010), and Philadelphia-chromosome positive B-
cell precursor ALL (Enomoto et al., 2011). Indeed, over-expression of miR-125b alone in 
the bone marrow of mice is sufficient to induce leukemia (Bousquet et al., 2010; Enomoto 
et al., 2011; O'Connell et al., 2010a). Recent in vitro work has also uncovered a role for 
miR-125b in the development of plasma cells (Gururajan et al., 2010) and effector T cells 
(Rossi et al., 2011), suggesting that miR-125b regulates immune cell development in 
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addition to promoting leukemia.  
Overview of microRNAs 
MicroRNA biogenesis 
miRs are ~18-22 nucleotide non-coding RNAs that negatively regulate gene expression 
through translational inhibition and mRNA degradation (Friedman et al., 2009; Guo et al., 
2010a). They are transcribed by PolII and sequentially cleaved by the enzymes Drosha and 
Dicer before being incorporated into the RNA-induced silencing complex (RISC) in their 
mature form (He and Hannon, 2004). Current evidence suggests that miRs base-pair with 
the 3’ untranslated region (UTR) of their mRNA targets, and this interaction is mediated by 
a 6-8 nucleotide “seed sequence” at the 5’ end of the miR (Friedman et al., 2009). miRs 
serve as “fine-tuners” of gene expression, and when deregulated they can drastically alter 
the balance of dynamic biological processes, such as hematopoietic cell fate decisions 
(O'Connell et al., 2010a; O'Connell et al., 2008; O'Connell et al., 2011).  
 
MicroRNAs that regulate hematopoietic stem cell function 
A number of microRNAs regulate the function of HSCs in a cell-intrinsic fashion. Our lab 
has demonstrated that miR-125b potentiates the function of HSCs by increasing their 
ability to hone to the bone marrow niche, engraft the bone marrow, and fully reconstitute a 
mouse immune system (O'Connell et al., 2010a). It has also been demonstrated that miR-
125b may lead to an expansion of the number of HSCs in the bone marrow by targeting the 
pro-apoptotic genes Bmf and Klf13 (Ooi et al., 2010). Enforced expression of the miR-
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125b family member, miR-125a, analogously leads to an accumulation of HSCs in the 
bone marrow by targeting the apoptosis gene Bak1 (Guo et al., 2010b). 
 
Other microRNAs regulate HSC function and longevity through different mechanisms. 
Loss of miR-126 has been shown to lead to an accumulation of HSCs, and over-expression 
to a loss of HSCs through alteration of cycling (Lechman et al., 2012). It is believed that 
miR-126 does this by targeting several different mRNAs that are implicated in the PI3-
kinase/AKT axis (Lechman et al., 2012). Two other microRNAs, miR-146a, a tumor 
suppressor, and miR-22, an oncomir, have also been shown to regulate cell cycling of 
HSCs (Song et al., 2013; Zhao et al., 2013). The inhibition of miR-22 leads to decreased 
HSC proliferation through upregulation of its target TET2 (Song et al., 2013). Conversely, 
the loss of miR-146a leads to hyperporliferation and exhaustion of HSCs with age. This 
hyperproliferation is linked to a defect in bone marrow reconstitution capability of HSCs 
(Zhao et al., 2013). 
 
MicroRNAs that regulate B cell development 
Several microRNAs regulate key checkpoints in B cell development and the loss of a 
microRNA processing protein, Dicer, results in a block in the pro-B to pre-B cell transition 
(Koralov et al., 2008). In particular, both miR-150 and miR-34a regulate this transition by 
targeting c-Myb and Foxp1, respectively (Rao et al., 2010; Xiao et al., 2007; Zhou et al., 
2007). Another example is miR-148a, which regulates plasma cell differentiation by 
targeting Bach2 (Jordan et al., 2015). In addition, miR-181 and miR-155 play an important 
role in B cell immune function by targeting AID to regulate class-switching and somatic 
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hypermutation (de Yebenes et al., 2008; Teng et al., 2008; Thai et al., 2007). 
Importantly, deregulation of the expression of many microRNAs important in B cell 
development and function results in autoimmunity (Xiao et al., 2008) and the onset of B 
cell cancers (Calin et al., 2008; Costinean et al., 2006; Eis et al., 2005; Puissegur et al., 
2012; Xiao et al., 2008).  
 
The microRNA-212/132 cluster 
MiR-132 is highly conserved among vertebrates and is expressed in a cluster with miR-
212, with which it shares an identical seed sequence (Ucar et al., 2010; Wanet et al., 2012). 
In mice, miR-132 is transcribed from the first intron of a non-coding transcript on 
chromosome 11; however, a recent report has demonstrated that it is also expressed on the 
second exon of an alternatively spliced transcript variant, which is prevalent in immune 
cells (Ucar et al., 2010). Since the discovery of miR-132, most studies have focused on its 
role in neuronal development and in angiogenesis (Anand et al., 2010; Smith et al., 2011; 
Wanet et al., 2012). Our lab first identified the potential importance of miR-132 in immune 
function after observing that it was induced in response to toll-like receptor 4 (TLR4) 
signaling in a human acute monocytic leukemia cell line (THP-1) (Taganov et al., 2006). 
Recent reports have confirmed this finding, showing miR-132 is induced five-fold in 
human macrophages in response to lipopolysaccharide (LPS) and CpG stimulation, and 
approximately three-fold in the spleen and bone marrow of mice injected with LPS 
(Shaked et al., 2009). Importantly, miR-132 negatively regulates acetylcholinesterase 
expression in this context, and has thus been implicated in the inhibition of peripheral 
inflammation (Shaked et al., 2009).  
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MiR-132 has also been implicated in a broad range of other immunological processes. The 
induction of miR-132 by immunoglobulin E (IgE) activation in mast cells leads to negative 
regulation of heparin-binding epidermal growth factor (HB-EGF), which is important in 
cell proliferation, migration, and wound healing (Molnar et al., 2012). Similarly, induction 
of miR-132 by IL-12 in natural killer cells is responsible for tolerance to long-term IL-12 
signaling through repression of STAT4 (Huang et al., 2011). A recent report also suggests 
that miR-132 is induced in THP-1 cells in response to infection with herpes virus family 
members, and that it plays a role in suppressing the host inflammatory response by 
targeting the transcriptional co-activator p300 (Lagos et al., 2010). These results highlight 
the importance of this miR as a breaking mechanism for uncontrolled activation of various 
immune functions. To this end, miR-132 is also deregulated in human samples of acute 
myeloid leukemia and B-cell chronic lymphocytic leukemia (Calin et al., 2004).  
 
MicroRNA-125b and Lin28a 
Our lab started studying miR-125b after noticing that it was enriched in hematopoietic stem 
cells (HSCs) and conferred on them a competitive advantage for bone marrow engraftment 
(O'Connell et al., 2010a). miR-125b is the mammalian homologue of the first discovered 
miR, lin-4, found in C. elegans. Lin-4 has been shown to regulate the transition from the 
early L1 stage of larval development to later stages, and does so by repressing its target 
genes, the transcription factor Lin14 and the RNA-binding protein Lin28 (Feinbaum and 
Ambros, 1999; Ha et al., 1996; Lee et al., 1993; Moss et al., 1997; Wightman et al., 1993). 
Lin28 in turn regulates expression of another miR, let-7, by binding a motif in the terminal 
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loop of the let-7 precursor (pre-let-7) (Heo et al., 2008; Loughlin et al., 2012; Newman et 
al., 2008; Viswanathan and Daley, 2010; Viswanathan et al., 2008). In mammals, Lin28 
has two homologs, Lin28 and Lin28B. Lin28 recruits a terminal uridylyl transferase and 
marks pre-let-7 for degradation, preventing Dicer from processing pre-let-7 into its mature 
form, whereas Lin28B prevents processing of primary let-7 transcripts by Drosha (Heo et 
al., 2008; Newman et al., 2008; Piskounova et al., 2011; Van Wynsberghe et al., 2011; 
Viswanathan and Daley, 2010). Importantly, the lin-4:Lin28:let-7 axis is conserved in 
mammals (Viswanathan et al., 2008; Wu and Belasco, 2005). 
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Abstract 
MicroRNAs are critical post-transcriptional regulators of hematopoietic cell-fate decisions, 
though little remains known about their role in aging hematopoietic stem cells (HSCs). The 
microRNA-212/132 cluster (miR-212/132) is enriched in HSCs and is up-regulated during 
hematopoietic aging. Both over-expression and deletion of microRNAs in this cluster leads 
to inappropriate hematopoiesis with age. Enforced expression of miR-132 in the bone 
marrow compartment of mice led to rapid HSC cycling followed by HSC depletion. A 
genetic deletion of the miR-212/132 cluster in mice resulted in HSCs that had altered 
cycling, function, and survival in response to growth factor starvation. We found that miR-
212/132 exerts its effect on aging HSCs by targeting the transcription factor FOXO3, a 
known aging associated gene. Our data demonstrates that miR-212/132 plays a role in 
maintaining balanced hematopoietic output by buffering FOXO3 expression. We have thus 
identified a novel target that may play a role in age-related hematopoietic defects.  
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Introduction 
Hematopoietic stem cells (HSCs) are the source of most all the immune cells in our body 
(Orkin and Zon, 2008). A complex gene regulatory network tightly regulates the function 
and survival of HSCs to ensure balanced and appropriate hematopoietic output 
(Novershtern et al., 2011). Alteration of the HSC niche and deregulation in cell-intrinsic 
properties such as HSC self-renewal and cycling, metabolism, and survival can have drastic 
consequences on hematopoietic output (Passegue et al., 2005; Suda et al., 2011; Takubo et 
al., 2010). As an organism ages, the balance between HSC self-renewal, function, and 
survival is drastically altered (Geiger et al., 2013), and this may lead to deleterious 
consequences such as the inability to effectively combat infection, and the onset of 
autoimmune disease or hematologic cancers (Frasca and Blomberg, 2011; Henry et al., 
2011).  
 
Several genetic and epigenetic factors have been identified as important regulators of 
hematopoietic stem cell aging (Geiger et al., 2013; Rossi et al., 2012; Sun et al., 2014). To 
date, however, little is known about the role of noncoding RNAs in the regulation of 
hematopoietic stem cells with age. MicroRNAs, a class of small-noncoding RNA 
molecules, are important post-transcriptional regulators of hematopoietic cell-fate decisions 
(Baltimore et al., 2008; Chen et al., 2004; Gangaraju and Lin, 2009). They alter cell fate by 
negatively regulating gene expression through direct binding to the 3’untranslated regions 
of target mRNAs (Filipowicz et al., 2008). Importantly, as post-transcriptional regulators 
they function to buffer the protein expression of their targets and confer robustness to 
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biological processes such as lineage commitment (Ebert and Sharp, 2012; Mukherji et 
al., 2011; Strovas et al., 2014).  
 
Several microRNAs have been found to regulate normal function of HSCs, including cell 
cycling and engraftment potential (Guo et al., 2010; Lechman et al., 2012; Ooi et al., 2010; 
Song et al., 2013; Zhao et al., 2013). However, it is unclear what role microRNAs might 
play in regulating stem cell function in the aging hematopoietic system. In this work, we 
study a previously unappreciated microRNA cluster, miR-212/132, that is enriched in 
HSCs and up-regulated with age. These two microRNAs share a seed sequence and 
therefore target many of the same genes. Several groups have demonstrated that the miR-
212/132 is an important regulator of immune function (Lagos et al., 2010; Nakahama et al., 
2013; Ni et al., 2014; Shaked et al., 2009). We now show that the miR-212/132 cluster 
plays a critical role in maintaining the balance between function and survival of aged 
HSCs. It does this by buffering the expression of its target FOXO3, one of only a few 
known genes associated with human longevity (Willcox et al., 2008).  
 
Results 
Enforced expression of miR-132 leads to depletion of HSCs and extramedullary 
hematopoiesis 
To understand the role of the microRNA-212/132 cluster (miR-212/132) in hematopoiesis, 
we first examined the expression of both microRNAs during hematopoietic differentiation. 
We determined that miR-132 is enriched in early hematopoietic progenitors (Lineage- 
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Sca1+ cKit+; LSK cells) and in long-term hematopoietic stem cells in particular (HSCs: 
LSK CD150+ CD48-; Figure 1A). We initially focused on miR-132 since it was the more 
enriched of the two microRNAs (Supplemental Figure 1A). To investigate the function of 
miR-132 in these progenitors, we used a retroviral vector to ectopically express miR-132 in 
hematopoietic stem and progenitor cells (HSPCs) and transferred these miR-132 over-
expressing cells into lethally irradiated wild-type (WT) C57BL/6 recipient mice 
(Supplemental Figure 1B-D). We then monitored mature cell output in the peripheral blood 
of these mice using flow-cytometry to detect the cell-surface markers that identify each cell 
type. Mice over-expressing miR-132 in the bone marrow compartment (herein referred to 
as WTmiR-132) when compared to empty vector controls (WTMG) demonstrated a rapid 
accumulation of CD45+ peripheral blood leukocytes at 2 months post-reconstitution, 
followed by a progressive decline in the number of these cells by 4 months (Figure 1B). A 
closer inspection of the bone marrow compartment at 2 months post-reconstitution revealed 
that WTmiR-132 mice displayed an expansion in the total number of LSK cells and HSCs 
(Figure 1C and Supplemental Figure 2A-C). These cells were additionally more 
proliferative, as measured by the proportion of cells expressing the proliferation marker 
Ki67, compared to LSK cells and HSCs from age-matched WTMG controls (Figure 1D and 
Supplemental Figure 2D). WTmiR-132 HSPCs further demonstrated a down-regulation in 
protein and RNA expression of several negative cell cycle regulators, including p27 and 
p57, although no change in p21 transcript levels was observed (Figure 1E and 
Supplemental Figure 2E). The mRNA expression of p27 remained down-regulated in 
WTmiR-132 HSPCs compared to WTMG HSPCs at 4-months post-reconstitution 
(Supplemental Figure 2F).  
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We next sought to characterize the cellular basis by which WTmiR-132 mice undergo 
depletion in peripheral blood leukocytes at 4 months post-reconstitution. Almost two-thirds 
(29/44) of the WTmiR-132 mice presented with gross pathology characteristic of 
extramedullary hematopoiesis, including enlarged spleens and pale, fibrotic bone marrow 
(Figure 1F and Supplemental Figure 2G). Strikingly, none of the age-matched WTMG mice 
presented such a phenotype. Consistent with the onset of extramedullary hematopoiesis, 
spleens from WTmiR-132 mice had a significant elevation of erythtroid cells (Ter11+) and a 
slight elevation, albeit not statistically significant, of myeloid cells (CD11b+, Gr-1+) when 
compared to WTMG mice (Supplemental Figure 2H). No elevation of myeloid cells was 
found in the peripheral blood of WTmiR-132 mice compared to controls (Supplemental 
Figure 2I). Examination of the bone marrow, however, revealed that WTmiR-132 mice had a 
severe (approximately 3-fold) depletion in the frequency and total number of LSK cells and 
HSCs compared to WTMG controls (Figure 1G and Supplementary Figure 2J,K). A similar, 
though more dramatic, phenotype was observed at 9 months post-reconstitution in WTmiR-
132 mice (Supplemental Figure 3A). This phenotype of rapid proliferation followed by 
depletion of HSCs in the bone marrow compartment is an example of HSC exhaustion.  
 
The depletion of HSCs in WTmiR-132 mice had the expected dramatic effect on the numbers 
of more mature progenitor cells, including multi-potent progenitors (MPPs; LSK CD150- 
CD48+), lymphoid-primed MPPs (LMPPs; LSK Flt3+), and megakaryocyte/erythroid 
progenitors (MEPs; Lineage- Sca1- cKit+ CD34- FcRg-). However, no depletion in 
common myeloid progenitors (CMPs; Lineage- Sca1- cKit+ CD34+ FcRg-) or 
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granulocyte-myeloid progenitors (GMPs; Lineage- Sca1- cKit+ CD34+ FcRg+) was 
observed (Supplemental Figure 3B-F). Importantly, the observed alteration in WTmiR-132 
HSCs was intrinsic to the expression of the miR-132 over-expression vector, because no 
depletion in the proportion of HSCs was evident among the GFP- cells of WTmiR-132 and 
WTMG mice (Supplemental Figure 3H). Furthermore, we found that the observed 
phenotype was specific to the expression of authentic miR-132 because over-expression of 
a miR-132 mutant lacking the correct miR-132 seed sequence resulted in no observable 
phenotype at 9 months post-reconstitution when compared to WTMG controls 
(Supplemental Figure 3H). 
 
We next sought to investigate the role of miR-212 in HSC maintenance. We found that 
enforced expression of miR-212 in the bone marrow compartment of mice didn’t result in a 
significant change in the total number of bone marrow CD45+ cells or LSK cells compared 
to controls (Supplemental Figure 3I,J). However, we found that there was a significant 
depletion of HSCs at 4-months post-reconstitution in these mice (Supplemental Figure 3K), 
thus suggesting a less severe phenotype than enforced miR-132 expression, which is 
consistent with the lower levels of enrichment of miR-212 in HSCs. 
 
The microRNA-212/132 cluster has a physiological role of protecting the aging 
hematopoietic system 
To determine if miR-132 has a physiological role in regulating hematopoietic stem cell 
function, we obtained mice that had a genetic deletion in the entire miR-212/132 cluster 
(herein referred to as miR-212/132-/- mice) (Ucar et al., 2012). We observed no apparent 
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defect in the output of mature hematopoietic cells in the peripheral blood, spleen, and 
bone marrow of 12-week old miR-212/132-/- mice when compared to age-matched wild-
type (WT) controls (Supplemental Figure 4). We noticed, however, an up-regulation of 
miR-132 expression in the bone marrow and LSK compartment of aged (2-year old) WT 
mice compared to young (12-week old) WT mice (Figure 2A), and posited a more 
important role of miR-132 in maintaining the fidelity of aging HSCs. Consistent with this, 
we found that unlike in 12-week old mice (Supplemental Figure 4D), aged (60-week old) 
miR-212/132-/- mice had an elevation in the total number of HSCs (LSK CD150+ CD48- 
and LSK EPCR+) in the bone marrow compartment compared to WT controls (Figure 2B). 
Surprisingly, this was accompanied by a decrease in the total number of bone marrow LSK 
cells, which are mostly downstream products of HSCs (Figure 2B). Aged miR-212/132-/- 
mice further presented with enlarged spleens (Supplemental Figure 5A) and a global 
depletion of all major mature cell types in the bone marrow compartment (Supplemental 
Figure 5B), indicative of a failure of HSCs to maintain normal hematopoietic output and 
the onset of extramedullary hematopoiesis.  
 
To investigate the molecular basis for the role of the miR-212/132 cluster in HSCs, we 
performed gene expression analysis by bulk population RNA-sequencing on WT and miR-
212/132-/- long-term HSCs (LSK CD150+ CD48-), short term HSCs (LSK CD150- CD48-
), and multipotent progenitors (LSK CD150- CD48+). Approximately 14,000 genes were 
expressed in each sample (Supplemental Figure 6A), and clustering based on the number 
differentially expressed genes revealed close similarity between WT short-term and long-
term HSC subsets and miR-212/132-/- short-term and long-term HSC subsets, with both 
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these groups differing significantly from the MPP populations (Figure 2C). Differentially 
expressed genes between the WT and miR-212/132-/- HSC populations were enriched for 
several functional annotations relevant to HSC biology, including regulation of cell-cycle, 
cell differentiation, response to stress, and cell death (Figure 2D).  
 
To investigate if the observed phenotype in miR-212/132-/- mice is intrinsic to the 
hematopoietic system, we transferred bone marrow cells from 12-week old WT or miR-
2121/132-/- mice into irradiated WT recipients. After one year, we found that the 
phenotypes in transplanted mice closely resembled that of aged WT and miR-212/132-/- 
mice, respectively, consistent with a defect intrinsic to the hematopoietic system 
(Supplemental Figure 5C). We next employed an inflammatory model for hematopoietic 
aging (Esplin et al., 2011) to determine if this is sufficient to recreate the observed 
alteration in hematopoiesis. We delivered LPS eight times over one month to 16-week old 
miR-212/132-/- and WT mice. We found that, consistent with the altered hematopoietic 
output we observed in aged mice, miR-212/132-/- mice presented with severely enlarged 
spleens containing an enrichment of splenic HSCs compared to WT mice also injected with 
LPS (Figure 3A and Supplemental Figure 5D). Similar to aged miR-212/132-/- mice, LPS 
treated miR-212/132-/- mice also demonstrated an accumulation of HSCs and a decrease in 
the frequency of LSK cells in the bone marrow compartment compared to LPS treated WT 
controls (Figure 3B). This skewing of hematopoietic progenitor output in miR-212/132-/- 
mice may be characterized by an increase in the total number of long-term HSCs and a 
reduction in total number of short-term HSCs and MPPs in the bone marrow compartment 
(Supplemental Figure 5E). We can therefore mimic the aging-related hematopoietic defect 
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observed in miR-212/132-/- by exposing younger mice to chronic inflammatory stimuli 
via repetitive LPS injections.  
 
Loss of the miR-212/132 cluster reduces HSC cycling and improves engraftment potential 
The cycling characteristics of HSCs are closely related to their ability to self-renew and 
differentiate into committed progenitors (Pietras et al., 2011). Furthermore, increased HSC 
quiescence and an increase in HSC number is characteristic of the aging hematopoietic 
system (Geiger et al., 2013). We thus sought to determine if the accumulation of HSCs and 
decrease in output of more committed progenitors in miR-212/132-/- mice might be a result 
of altered cell cycling. We performed cell-cycling analysis using flow cytometry by 
staining for the proliferation marker Ki67 and utilizing the dsDNA dye Hoescht33342. 
Under steady-state conditions, we observed no major defect in cell cycling in 16-week old 
miR-212/132-/- mice compared to age-matched WT mice (Supplemental Figure 5F). 
However, under conditions of inflammatory stress such as low-grade LPS stimulation, we 
found that miR-212/132-/- HSCs were far less proliferative, with an almost 50% increase in 
the number of cells in the G0 phase of the cell cycle compared to WT HSCs (Figure 3C-E). 
Importantly, we observed a substantial decrease in the number of HSCs in G1 and only a 
small proportion of cells in S/M phases of the cell cycle in miR-212/132-/- mice (Figures 
3C-E). No change in p27 mRNA expression was observed at steady state between miR-
212/132-/- and WT HSCs. However, in mice treated with either LPS or 5-fluorouracil, 
which induce HSC proliferation, the expression of p27 in the bone marrow compartment 
was up-regulated in miR-212/132-/- mice compared to WT mice (Supplemental Figure 
5G,H). It follows that the loss of the miR-212/132 cluster leads to increased HSC 
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quiescence and an accumulation of HSCs, with a concomitant decrease in the number of 
more committed progenitors. 
 
The majority of HSCs in the hematopoietic system remain in a dormant state, and 
disruption of this quiescence can have serious consequences for HSC function (Rossi et al., 
2012). To investigate whether the alteration in cell cycling of aged miR-212/132-/- HSCs 
might be related to altered HSC function, we performed competitive transplant assays. 
Aged (60-weeks) CD45.2 miR-212/132-/- or WT-/- HSCs were transplanted with equal 
numbers of CD45.1 WT HSCs into lethally irradiated CD45.2 recipient mice. The 
peripheral blood of these mice was analyzed 4 months post-reconstitution for repopulation 
of major mature cell types. The cells from aged miR-212/132-/- mice were more effective at 
reconstituting most all immune cells than those from aged WT mice, as evidenced in total 
blood leukocytes (CD45+), B-cells (CD19+), myeloid cells (CD11b+), and granulocytes 
(Gr-1+) in the peripheral blood (Figure 4A). An insignificant difference in the relative 
proportion of T-cells (CD3e+) was observed (Figure 4A). Competitive transplant of young 
(12-weeks) miR-212/132-/- HSCs yielded no observable functional difference compared to 
young WT HSCs except for defective repopulation of T-cells (Figure 4B); however, 
secondary transplantation of young miR-212/132-/- HSCs yielded a similar phenotype to 
that observed with primary transplantation of aged miR-212/132-/- HSCs (Supplemental 
Figure 5I). Consistent with the increased quiescence of aged miR-212/132-/- HSCs 
compared to WT HSCs, miR-212/132-/- cells performed better at long-term repopulation. 
Additionally, HSCs obtained from WTmiR-132 mice, which ectopically over-express miR-
132, were severely defective in long-term reconstitution in competitive transplant assays 
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compared to control HSCs obtained from WTMG mice (Figure 4C). It therefore appears 
that the miR-212/132 cluster is important for tuning the interplay between quiescence and 
functional output of the aging hematopoietic system. 
 
FOXO3 is a target of miR-132 in bone marrow cells 
To understand the molecular mechanism of miR-132 action, we characterized the 
expression of the best computationally predicted targets of miR-132 from TargetScan under 
conditions of miR-132 over-expression (Friedman et al., 2009). RNA was extracted from 
lineage-depleted bone marrow cells of WTmiR-132 and WTMG mice and was subjected to 
quantitative polymerase chain reaction (qPCR) for target genes relevant to HSC function. 
The most significantly down-regulated targets under conditions of ectopic expression of 
miR-132 in WTmiR-132 bone marrow, relative to control WTMG bone marrow, were pursued 
for further analysis. Messenger RNA expression of several genes relevant to hematopoiesis 
was down regulated in WTmiR-132 bone marrow samples, including AchE, FOXO3, Lin28B, 
MMP9, and SOX4 (Figure 5A). We sought to further investigate the role of FOXO3 in 
mediating the effect of miR-132 on HSCs as it contains a perfect 8-mer binding site for 
miR-132 (Figure 5B) and is the most significantly down regulated of these genes. 
Importantly, we also found a global upregulation of miR-132 targets in our RNA-
sequencing analysis of miR-212/132-/- and WT HSCs, and this included an upregulation of 
FOXO3 transcript expression as well as some of its downstream targets (Supplemental 
Figure 6B-D). We validated that miR-132 binds directly to the FOXO3 3’-untranslated 
region (3’UTR) using a luciferase reporter assay in which the FOXO3 3’UTR was 
  
35 
expressed immediately downstream of luciferase. We found that in the presence of miR-
132 the expression of this reporter was significantly lower than from a vector lacking the 
FOXO3 3‘UTR (Figure 5C). This binding was specific to miR-132 because mutating the 
miR-132 binding site on the FOXO3 3’UTR normalized luciferase expression (Figure 5C).  
 
We next quantified FOXO3 protein expression in bone marrow cells from WTmiR-132 and 
WTMG mice. Consistent with FOXO3 being a target of miR-132, we found that protein 
expression was significantly down regulated in WTmiR-132 mice compared to WTMG mice 
(Figure 5D). Expression of FOXO1 and FOXO4, closely related family members of 
FOXO3, remained unchanged in WTmiR-132 bone marrow cells (Supplemental Figure 7A). 
Importantly, we also found that FOXO3 mRNA and protein expression levels were 
elevated in lineage depleted bone marrow cells from miR-212/132-/- mice compared to WT 
controls (Figure 5E,F). Expression of FOXO4 was also slightly elevated in miR-212/132-/- 
cells and expression of FOXO1 was unchanged (Supplemental Figure 7B). We additionally 
performed intracellular staining of FOXO3 and phospho-FOXO3 (p-FOXO3) protein. As 
expected, we found elevated levels of FOXO3 in miR-212/132-/- HSCs compared to WT 
controls. However, we saw only a marginal elevation in p-FOXO3 in miR-212/132-/- HSCs, 
indicating that the majority of extra FOXO3 in these cells is likely in the nucleus in its 
active, un-phosphorylated state (Supplemental Figure 7C,D). Together, the data indicate 
that miR-132 is an important regulator of FOXO3 expression in bone marrow cells. As was 
observed with miR-132 expression, FOXO3 mRNA expression was increased in bone 
marrow cells from aged mice compared to those of young mice (Figure 6A), thus 
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suggesting that miR-132 might serve to maintain FOXO3 protein expression within a 
balanced range for normal hematopoietic function.  
 
miR-132 regulates HSC cycling and function through FOXO3 
To determine if FOXO3 is a key mediator of miR-132 function, we co-expressed FOXO3 
with miR-132 in the bone marrow compartment of WT mice to see if it would rescue the 
phenotype observed with miR-132 expression alone. FOXO3 cDNA lacking a miR-132 
target site was cloned into the MSCV-IRES-eGFP (MIG) vector immediately downstream 
of the MSCV promoter (Figure 6B). As previously described, miR-132 was cloned 
immediately downstream of eGFP. Lethally irradiated mice were reconstituted with bone 
marrow cells transduced with a control vector (WTMIG), or a vector expressing both miR-
132 and FOXO3 (WTFOXO3 + miR-132), miR-132 only (WTmiR-132) or FOXO3 only 
(WTFOXO3). The expression of miR-132 and FOXO3 from these vectors was validated by 
qPCR and Western Blot, respectively (Supplemental Figure 7E-F). We observed the mean 
fluorescence intensity of eGFP in bone marrow cells expressing only FOXO3 to be lower 
than that of the other vectors, suggesting that over-expression of FOXO3 above 
endogenous levels may have a toxic effect on these cells (Supplemental Figure 7G). We 
additionally observed that a larger fraction of bone marrow HSCs from WTFOXO3 mice 
expressed AnnexinV compared to WTMIG controls (Supplemental Figure 7H). This effect 
was not observed when FOXO3 was co-expressed with miR-132, presumably because 
baseline levels of FOXO3 were already down regulated due to miR-132 over-expression.  
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As expected, a reduction in peripheral blood leukocytes was observed in WTmiR-132 mice 
compared to WTMIG mice at 4-months post-reconstitution (Figure 6C). Co-expression of 
FOXO3 with miR-132, however, rescued this defect, as no significant change in peripheral 
blood leukocytes was observed in WTFOXO3 + miR-132 mice compared to WTMIG controls 
(Figure 6C). Examination of the bone marrow compartment of WTFOXO3 + miR-132 mice 
revealed total numbers of HSCs and LSK cells comparable to WTMIG controls, 
demonstrating a rescue of HSC depletion observed with the expression of miR-132 alone 
(Figure 6D,E). In addition, expression of FOXO3 alone resulted in a moderate elevation in 
the total number of bone marrow LSK cells compared to control mice (Figure 6E). HSCs 
from WTFOXO3 + miR-132 mice also showed comparable proportions of Ki67 staining to HSCs 
from WTMIG mice, indicating that these cells were not prone to cycling like WTmiR-132 cells 
(Figure 5F). WTFOXO3 HSCs demonstrated a significant albeit moderate decrease in the 
proportion of cycling HSCs compared to controls (Figure 6F). These experiments suggest 
that co-expression of FOXO3 can rescue the phenotype observed with expression of miR-
132 alone. It seems likely that miR-132 regulates hematopoiesis primarily by directly 
modulating FOXO3 levels, although we cannot rule out that FOXO3 overexpression is able 
to override the miR-132 effect while the true targets of miR-132 in the bone marrow are 
other genes.   
 
Loss of miR-212/132 affects HSC survival through protective autophagy 
FOXO3 is critical for maintaining the hematopoietic stem cell pool by regulating HSC cell-
cycling and resistance to oxidative stress (Miyamoto et al., 2007; Tothova et al., 2007). It is 
also implicated in maintaining the survival of aging HSCs by directing protective 
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autophagy (Warr et al., 2013). To this end, we found that several autophagy-related 
genes were up-regulated in miR-212/132-/- HSCs compared to WT controls upon inspection 
of our RNA-sequencing dataset (Supplemental Figure 6E). Thus, to determine if miR-132 
might play a role in altering survival of HSCs, we sorted HSCs from WT and miR-212/132-
/- mice and cultured them in the presence or absence of survival growth factors and 
cytokines, including mSCF, mIL6, mIL3, TPO, and Flt3L. We used a luciferase-based 
assay to monitor caspase 3 and caspase 7 activities after 12 hours in culture. In the presence 
of survival factors, minimal caspase activity was observed in both WT and miR-212/132-/- 
HSCs. However, under starvation conditions, which induce protective autophagy in aged 
HSCs (Warr et al., 2013), miR-212/132-/- HSCs demonstrated a significant reduction in 
induction of apoptosis compared to WT HSCs (Figure 7A). This is consistent with the 
more rapid induction of a protective autophagy program due to higher levels of FOXO3 in 
miR-212/132-/- HSCs. Importantly, when autophagy was inhibited by Bafilomycin A 
(BafA), a known inhibitor of autophagosome fusion to lysosomes, miR-212/132-/- and WT 
HSCs underwent comparable, higher levels of apoptosis (Figure 7A). As previously 
reported, FOXO3 expression levels had no major effect on autophagy and apoptosis of 
myeloid progenitors (Figure 7B).  
 
To determine if miR-212/132-/- HSCs indeed induce the autophagy machinery more 
potently than WT HSCs, we utilized a fluorescent reporter for autophagosome formation 
that was detectable by flow cytometry. The efficacy of this assay in detecting 
autophagosome formation was validated by comparing signal intensity in WT cells to 
autophagy deficient cells (Supplemental Figure 7I). WT and miR-212/132-/- HSCs were 
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cultured under growth factor rich or starvation conditions as described above and were 
stained for the presence of autophagosomes. Under starvation conditions, miR-212/132-/- 
HSCs demonstrated higher levels of autophagosome formation compared to WT HSCs 
(Figure 7C). In the presence of LY2940002, a PI3-kinase inhibitor and early inhibitor of 
autophagy, autophagosome formation was decreased to comparable levels in miR-212/132-
/- and WT HSCs (Figure 7C). We additionally sought to investigate whether the potent 
induction of autophagy in miR-212/132-/- HSCs may improve survival by altering reactive-
oxygen species (ROS) accumulation. We utilized a fluorescent detection system for ROS 
and found that miR-212/132-/- HSCs had lower levels of ROS accumulation compared to 
WT HSCs under conditions of starvation (Figure 7D). The accumulation of ROS was 
elevated to comparable levels in WT and miR-212/132-/- HSCs when autophagy was 
inhibited with BafA (Figure 7D).  
 
We employed an shRNA knockdown strategy for FOXO3 to determine if it is the key 
mediator of autophagy in miR-212/132-/- HSCs. WT and miR-212/132-/- HSPCs were 
transduced with either a control vector (MB) or a FOXO3 shRNA construct (shFOXO3), 
and were subsequently used to reconstitute lethally irradiated WT mice. At 2 months post-
reconstitution, we sorted HSCs from these mice and subjected them to the aforementioned 
assays for autophagy induction and caspase activation under conditions of growth factor 
starvation. WT HSCs expressing shFOXO3 demonstrated lower autophagy activity and 
higher levels of apoptosis compared to WT HSCs expressing MB (Figure 7E,F). 
Importantly, knockdown of FOXO3 in miR-212/132-/- HSCs resulted in a significant 
reduction in autophagy induction and an increase in caspase activity compared to miR-
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212/132-/- HSCs expressing MB. However, this reduction did not reduce autophagy 
activity completely to that of WT HSCs expressing MB. This may be due to incomplete 
knockdown of FOXO3 in miR-212/132-/- cells or may suggest that factors other than 
FOXO3 might be involved in mediating autophagy induction (Figure 7E,F).  
 
Discussion 
MicroRNAs are key regulators of lineage commitment and function in immune cells 
(Baltimore et al., 2008; Gangaraju and Lin, 2009; O'Connell et al., 2010b). Several 
microRNAs have been implicated in regulating diverse facets of normal HSC maintenance 
and function, such as cell-cycling (Lechman et al., 2012; Song et al., 2013), apoptosis (Guo 
et al., 2010), engraftment potential (O'Connell et al., 2010a; Ooi et al., 2010), and 
resistance to inflammatory stress (Zhao et al., 2013).  While much has been done to 
characterize the functional differences between aged and young HSCs, little is known about 
how microRNAs might contribute to maintaining balanced hematopoietic output as an 
organism ages. Our findings suggest that the miR-212/132 cluster, particularly miR-132, is 
critical in regulating the balance between HSC survival, and proliferation and 
differentiation. We demonstrate that it does this primarily by buffering the expression of 
FOXO3 in the aging hematopoietic system. Deregulation of this cluster, and in turn 
FOXO3, can have negative consequences on the function of HSCs and the output of mature 
hematopoietic cells, leading to extramedullary hematopoiesis.  
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Because the expression of miR-132 was higher in HSCs compared to total bone marrow 
cells, we utilized both gain-of-function and loss-of-function approaches to investigate its 
role in HSC function and survival. Ectopic expression of miR-132 resulted in hyper-
proliferation and depletion of HSCs within the bone marrow compartment. Enforced 
expression of miR-212 produced a similar but less dramatic phenotype. This depletion of 
HSCs with miR-132 over-expression coincided with the onset of extramedullary 
hematopoiesis, including enlarged spleens and fibrotic bone marrow. We observed a drastic 
decrease in protein expression of the miR-132 target FOXO3 within the bone marrow 
compartment of miR-132 over-expressing mice. Consistent with our findings, a genetic 
deletion of FOXO3 in hematopoietic cells leads to increased HSC proliferation and an age-
dependent depletion of the HSC pool with loss of HSC long-term reconstitution potential 
(Miyamoto et al., 2007). This phenotype is exacerbated by the concomitant deletion of the 
FOXO family members FOXO1 and FOXO4 (Tothova et al., 2007). We further found 
several FOXO3 target genes, particularly the negative cell-cycle regulators p21, p57, and 
p27, to be down regulated in miR-132 over-expressing bone marrow. Importantly, 
replenishing levels of FOXO3 during miR-132 over-expression rescued the phenotype we 
observed. 
 
A genetic deletion of the miR-212/132 cluster led to higher basal expression of FOXO3 in 
bone marrow cells. Over time, this led to a dramatic increase in the number of HSCs, a 
decrease in production of more committed progenitors, and a defect in HSC cycling in 
response to environmental stress, such as lipopolysaccharide treatment. Consistent with the 
more quiescent state of miR-212/132-/- HSCs, we found they were marginally better at 
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long-term reconstitution of the hematopoietic system than WT counterparts. FOXO3 is a 
known regulator of apoptosis, and we further demonstrated that ectopic expression of 
FOXO3 from a retroviral vector resulted in a selection for those cells expressing the lowest 
amount of the vector, presumably because higher levels of FOXO3 expression were toxic. 
We have therefore shown that the miR-212/132 cluster is important in regulating 
expression of FOXO3, and that when this target is either up-regulated or down regulated, 
there is a severe alteration in HSC function over time. 
 
The expression of both miR-132 and FOXO3 transcripts is up-regulated with age in murine 
bone marrow cells and early progenitors. The role of FOXO3 as a longevity-associated 
gene remains unknown in the hematopoietic system. FOXO3 may be up-regulated in this 
context due to its vital role in survival through autophagy and in cell cycling. MicroRNAs 
play an important role in buffering perturbations in the expression of their targets in 
response to environmental stress (Ebert and Sharp, 2012; Kim et al., 2013). Such stress 
might include inflammation from repetitive exposure to environmental pathogens and 
hematopoietic aging. Importantly, the abundance of microRNAs in any given cell plays an 
important role in establishing a threshold for target expression (Mukherji et al., 2011); as 
such, up-regulation of the microRNA may require higher target expression to maintain 
important physiological functions. Given that both over-expression and deletion of miR-
132 in bone marrow cells led to inappropriate hematopoiesis, we believe that miR-132 
plays an important role in buffering FOXO3 expression levels within a defined range to 
maintain normal HSC function as an organism ages. The concomitant increase in the 
expression of miR-132 alongside FOXO3 in the aging hematopoietic system may be 
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critical for maintaining an important balance between known FOXO3-regulated 
processes, including cell-cycling and differentiation, and apoptosis of HSCs.  
 
The aging hematopoietic system is characterized by an alteration of the balance between 
self-renewal and differentiation, which leads to the accumulation of less-functional HSCs, 
myeloid-biased differentiation, and a requirement for basal autophagy for survival (Geiger 
et al., 2013; Rossi et al., 2005; Warr et al., 2013). Of note is the fact that the loss of critical 
autophagy factors in the hematopoietic system leads to hyper-proliferation and poor 
survival of HSCs (Mortensen et al., 2011). Recently, it has also been demonstrated that 
FOXO3 plays a critical role in inducing protective autophagy of aging HSCs (Warr et al., 
2013), which is critical for their survival in response to oxidative stress (Eijkelenboom and 
Burgering, 2013). The proposed mechanism of FOXO3 regulation of autophagy is through 
the transcription of glutamine synthase (van der Vos et al., 2012). Consistent with this role 
of FOXO3 in HSC survival, we found that miR-212/132-/- HSCs, when compared to WT 
HSCs, demonstrated increased resistance to growth-factor starvation, as evidenced by the 
decrease in presence of reactive oxygen species, lower levels of apoptosis induction, and an 
increase in accumulation of autophagosomes. We observed an abrogation of this effect 
when we knocked down FOXO3 in miR-212/132-/- HSCs, thus demonstrating that this 
phenotype is mostly due to the up-regulation of FOXO3 in these cells. Importantly, this 
improved survival of miR-212/132-/- cells in response to environmental stress may 
contribute to the age-dependent accumulation of HSCs in miR-212/132-/- mice compared to 
WT mice.  
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Our observations demonstrate that the miR-212/132-/- cluster is an important regulator of 
HSC homeostasis by altering cell cycling, function, and survival. This is one of the first 
clear examples of a microRNA playing a physiological role in maintaining the balance of 
HSC functions during aging. The capacity of this microRNA to buffer expression of 
FOXO3 is critical given the multiple roles FOXO3 plays in regulating HSC biology. Our 
findings open the possibility of utilizing miR-132 mimics or antagonists to alter defects in 
HSC function that might lead to hematopoietic diseases late in life.  
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Experimental Procedures 
DNA constructs 
For in-vivo miR-132 over-expression and FOXO3 shRNA experiments, the mature miR-
132 or FOXO3 shRNA sequence was placed in the microRNA-155 loop-and-arms format 
(O'Connell et al., 2010a) and cloned into the MSCV-eGFP (MG) and MSCV-TagBFP 
(MG) vectors, respectively. For FOXO3 rescue experiments, FOXO3 cDNA was cloned 
into the MSCV-IRES-eGFP (MIG) vector. See supplemental procedures for more details 
about these vectors. FOXO3 shRNA target sequences are given in Table S1. 
 
For luciferase assays, the microRNA-132 expression cassette was sub-cloned into the 
pCDNA3 vector. The 3’untranslated regions of relevant gene targets containing the miR-
132 binding region were cloned immediately downstream of luciferase in the pMiReport 
vector as previously described (Chaudhuri et al., 2012).  
 
Cell culture 
Cells were cultured in a sterile incubator that was maintained at 370C and 5% CO2. 293T 
cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/mL 
penicillin, and 100 U/mL streptomycin. Primary cells were cultured in complete RPMI 
supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, 50uM β-
mercaptoethanol, and appropriate growth cytokines as needed for the experiment (see 
below).  
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Cell sorting for RNA extraction 
For miR-132 expression profiling, bone marrow cells from C57BL/6 mice were depleted of 
RBCs and sorted for the respective cell populations at the Caltech Flow Cytometry Core 
Facility. Detailed procedures are provided in the supplemental procedures. RNA was 
harvested using the miRNAeasy RNA prep kit (Qiagen). For bone marrow samples from 
MG and miR-132 mice, bone marrow was harvested from the respective mice, lysed of red 
blood cells, and spun down. RNA was harvested as described above.  
 
Expression profiling and qPCR 
We performed real time qPCR (RT-qPCR) with a 7300 Real-Time PCR machine (Applied 
Biosystems) as previously described (Chaudhuri et al., 2012). TaqMan qPCR was 
performed for miR-132, miR-212 and snoRNA-202 (control) detection as per 
manufacturers instructions using TaqMan MicroRNA Assays (Life Technologies).  SYBR 
Green-based RT-qPCR was performed for mRNA of mouse FOXO3, FOXO1, p27, p21, 
p57, and relevant miR-132 targets following cDNA synthesis using qScript cDNA 
SuperMix (Quanta) and detection with PerfeCTa qPCR Fastmix with ROX (Quanta) as per 
manufacturers instructions. Gene-specific primers used for qPCR are listed in Table S2. 
RNA-seq library construction and analysis are described in the Supplemental Information. 
 
Target prediction and Luciferase reporter assays 
Relevant targets for miR-132 were investigated using predictions from TargetScan Mouse 
6.2 software (Friedman et al., 2009) and following sorting by probability of conserved 
targeting (PCT). Luciferase assays for miR-132 targets were performed as previously 
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described (Chaudhuri et al., 2012). Briefly, 4 x 105 cells were plated in 12-well plates for 
24 hours and subsequently transfected with either pCDNA or pCDNA-miR-132, a 
pMiReport vector, and a β-gal expression vector. 48 hours later, cells were lysed using 
Reporter Lysis Buffer (Promega) and luciferase and β-gal expression was analyzed, 
respectively, using a Dual Luciferase Kit (Promega) and a chemiluminescent β-gal reporter 
kit (Roche).  
 
Immunoblotting 
Bone marrow samples were prepared as described for RNA preparation. Cell extracts were 
collected using RIPA lysis buffer (Sigma), and were subjected to gel-electrophoresis and 
transfer onto a PVDF membrane. Antibody staining was performed using antibodies for 
FOXO3, p27, and actin. Detailed procedures are given in the supplemental information.  
 
Animals 
The California Institute of Technology Institutional Animal Care and Use Committee 
approved all experiments. C57BL/6 WT and miR-212/132-/- mice were bred and housed in 
the Caltech Office of Laboratory Animal Resources (OLAR) facility. Bone marrow 
reconstitution experiments were performed as previously described (Chaudhuri et al., 2012) 
with the aforementioned vectors and are explained in more detail in the Supplemental 
Procedures. Recipient mice were monitored for health and peripheral blood was analyzed 
for mature blood cell types each month up till the experimental end-point at either 16 or 36 
weeks post-reconstitution. At each end-point, immune organs were harvested for further 
analysis as described. The number of mice for each experimental cohort is described in the 
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figure legends. Each experiment was repeated at least twice, and in many cases three or 
four times.  
 
Competitive transplant experiments 
Bone marrow cells from age and gender-matched WT CD45.2+ C57BL/6 mice, miR-
212/132-/- CD45.2+ C57BL/6 mice, and WT CD45.1+ C57BL/6 mice were harvested and 
depleted of RBCs as described above. A 1:1 ratio of WT CD45.1+ HSCs with either WT or 
miR-212/132-/- CD45.2+ HSCs were subsequently injected into lethally irradiated (1000 
rads) WT CD45.2+ CD57BL/6 mice. Mice were monitored for up to 20 weeks post-
reconstitution and relevant tissues were harvested for further analysis by flow cytometry.  
 
Flow cytometry 
Relevant tissues were harvested and cells were homogenized and subsequently depleted of 
red blood cells as described above. Flurophore-conjugated antibodies were used for the 
indicated markers, and detected using a MACSQuant10 Flow Cytometry machine 
(Miltenyi). Detailed procedures are given in the supplemental information. 
 
Autophagy and reactive-oxygen species assays 
HSCs were sorted as described above from either WT or miR-212/132-/- C57BL/6 mice, or 
from reconstituted mice with donor WT or miR-212/132-/- bone marrow infected with 
either MB or shFOXO3 retroviral constructs. Cells were then cultured with the appropriate 
growth factors and cytokines, or authophagy inhibitors, and processed for caspase activity 
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(Promega), the presence of ROS (Life Technologies), or autophagy activity (Enzo Life 
Sciences). Detailed procedures are given in the supplemental information. 
 
Statistical tests 
All statistical analysis was done in Graphpad Prism software using an unpaired Student’s t 
test. Data was reported as mean ± SEM. Significance measurements were marked as 
follows: * p < 0.05, ** p < 0.01, ** p < 0.001, or ns for not significant.  
 
Data access 
The RNA-seq data used in this study can be accessed from the Gene Expression Omnibus 
under the accession project ID GSE66352. 
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Figure legends 
Figure 1. miR-132 is expressed in hematopoietic stem cells (HSCs) and over-expression 
alters hematopoiesis. (A) miR-132 expression in mature and progenitor hematopoietic 
cells. Cell populations were sorted by FACS directly into RNA lysis buffer and miR-132 
expression was detected using TaqMan RT-qPCR (n=3). (B) – (G) WT C57BL/6 mice 
were lethally irradiated and reconstituted with donor bone marrow cells expressing either a 
control (MG) or a miR-132 over-expressing (miR-132) retroviral vector (n=8-12 mice per 
group). (B) Total numbers of mature leukocytes (CD45+) in the peripheral blood of MG 
and miR-132 mice at the indicated time points post-reconstitution. (C) Total number of 
HSCs (LSK CD150+ CD48-) in the bone marrow of MG and miR-132 mice at 8-weeks 
post-reconstitution. (D) Percentage of Ki-67+ bone marrow HSCs in MG and miR-132 
mice at 8-weeks post-reconstitution. (E) Protein and RNA expression of p27 in the bone 
marrow of MG and miR-132 mice at 8-weeks post-reconstitution (n=3). (F) Representative 
spleen and bone marrow gross pathology of MG and miR-132 mice at 16-weeks post-
reconstitution. (G) Total number of LSK cells and HSCs in the bone marrow of MG and 
miR-132 mice at 16-weeks post-reconstitution. Data represents at least three independent 
experiments and is represented as mean ± SEM. See also Figures S1-S3. * denotes p < 
0.05, ** denotes p < 0.01 and *** denotes p < 0.001 using a Student’s t test. 
 
Figure 2. Genetic deletion of the microRNA-212/132 cluster in mice alters hematopoietic 
output with age. (A) miR-132 expression in total bone marrow and LSK cells from 8-week 
old and 2-year old C57BL/6 WT mice. miR-132 expression was quantified by TaqMan 
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RT-qPCR (n=2). (B) – (D) Mice with a genetic deletion of the miR-212/132 cluster 
(miR-212/132-/-) along with WT mice in the C57BL/6 background were analyzed. (B) Total 
number of HSCs (LSK CD150+ CD48- and LSK EPCR+) and LSK cells in the bone 
marrow compartment of 60-64 week old WT and miR-212/132-/- mice (n=7-12 mice per 
group). (C) Global expression profiling of WT and miR-212/132-/- HSCs, as well as short-
term HSCs and MPPs, from 16-week old mice using RNA-seq. The heat map represents 
the number of differentially expressed genes between the different WT and miR-212/132-/- 
(KO) populations. (D) Enriched gene-ontology terms for differently expressed genes 
between WT and miR-212/132-/- progenitors. Data represents at least two independent 
experiments and is represented as mean ± SEM. See also Figures S4-S6. * denotes p < 
0.05, ** denotes p < 0.01 and *** denotes p < 0.001 using a Student’s t test. 
 
Figure 3. Genetic deletion of miR-212/132 in mice alters hematopoietic output and cycling 
in response to LPS stimulation. (A) – (E) 6-month old WT and miR-212/132-/- mice were 
treated with 9 evenly-spaced low-dose (1mg/kg of body weight) LPS or PBS injections 
over one month. (A) Spleen weights of WT and miR-212/132-/- mice treated with PBS or 
LPS. (B) Proportion of HSCs and LSK cells within the bone marrow compartment of WT 
and miR-212/132-/- mice treated with LPS or PBS. (C) Representative FACS plots for cell 
cycle analysis of HSCs and LSK cells from WT and miR-212/132-/- mice following LPS 
injection. (D) Proportion of bone marrow LSK cells and HSCs in each stage of the cell 
cycle (G0, G1, G2/M) from WT and miR-212/132-/- mice following LPS injection. (E) 
Proportion of bone marrow LSK cells and HSCs expressing Ki67 from WT and miR-
212/132-/- mice following LPS injection. Data represents at least two independent 
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experiments and is represented as mean ± SEM. See also Figures S4-S5. * denotes p < 
0.05, ** denotes p < 0.01 and *** denotes p < 0.001 using a Student’s t test. 
 
Figure 4. The microRNA-212/132 cluster regulates long-term reconstitution potential of 
HSCs with age. (A) and (B) WT or miR-212/132-/- CD45.2+ bone marrow cells, calibrated 
for the total number of phenotypically defined HSCs, were injected in a 1:1 ratio with 
CD45.1+ WT bone marrow cells into irradiated C57BL/6 CD45.2+ recipients. (A) Ratio of 
total CD45.2+ cells to CD45.1+ cells at 16-weeks post-reconstitution for various mature 
immune cell types in the peripheral blood of mice injected with aged WT and miR-
212/132-/- CD45.2+ cells. Data was normalized to proportion of WT CD45.2+ cells. (B) 
Ratio of total CD45.2+ cells to CD45.1+ cells at 16-weeks post-reconstitution for various 
mature immune cell types in the peripheral blood of mice injected with young WT and 
miR-212/132-/- CD45.2+ cells. (C) Control (MG) or miR-132 over-expressing (miR-132) 
bone marrow HSCs, both expressing a retroviral vector containing eGFP, were injected in a 
1:1 ratio with un-infected WT bone marrow HSCs into irradiated C57BL/6 mice. Graphs 
show the ratio of eGFP+ cells to eGFP- cells for various immune cell types in the 
peripheral blood of recipients at 16-weeks post-reconstitution. Data represents at two 
independent experiments and is represented as mean ± SEM. * denotes p < 0.05 using a 
Student’s t test. 
 
Figure 5. FOXO3 is a direct target of miR-132 in bone marrow cells. (A) mRNA 
expression by RT-qPCR of computationally predicted miR-132 targets in control (MG) or 
miR-132 over-expressing (miR-132) bone marrow cells. (B) Schematic of the predicted 
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miR-132 binding site in the FOXO3 3’UTR. (C) Relative luciferase expression in 293T 
cells transfected with a miR-132 over-expression vector and either a vector containing 
luciferase only (control), a vector containing luciferase and the FOXO3 3’UTR 
immediately downstream (FOXO3 3’UTR), or a vector containing luciferase and a FOXO3 
3’UTR with a mutated miR-132 binding site (FOXO3 3’UTR mut). (D) FOXO3 protein 
expression in bone marrow cells from MG and miR-132 mice obtained by Western Blot. 
(E) FOXO3 transcript expression in lineage-depleted bone marrow cells obtained from WT 
or miR-212/132-/- mice. (F) FOXO3 protein expression in lineage-depleted bone marrow 
cells obtained from WT or miR-212/132-/- mice. See also Figure S7A-C. Data represents at 
least two independent experiments (n=2) and is represented as mean ± SEM. * denotes p < 
0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a Student-T test. 
 
Figure 6. Co-expression of FOXO3 with miR-132 rescues the hematopoietic defects 
observed with expression of miR-132 alone. (A) FOXO3 mRNA expression by RT-qPCR 
in total bone marrow cells from 8-week old, 1-year old, and 2-year old C57BL/6 WT mice 
(n=2). (B) Schematic of retroviral vectors constructed for expression of FOXO3 only or for 
co-expression of FOXO3 along with miR-132. (C) – (F) WT C57BL/6 mice were lethally 
irradiated and reconstituted with donor bone marrow cells expressing either a control 
(MG), a miR-132 over-expressing (miR-132), a FOXO3 over-expressing (FOXO3), or a 
FOXO3 and miR-132 over-expressing (FOXO3 and miR-132) retroviral vector (n=10-12 
mice per group). (C) Total peripheral blood CD45+ leukocytes in the respective animals at 
16-weeks post-reconstitution. (D) Total LSK cells in the bone marrow compartment of the 
respective animals at 16-weeks post-reconstitution. (E) Total HSCs in the bone marrow 
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compartment of the respective animals at 16-weeks post-reconstitution. (F) Proportion of 
bone marrow HSCs expressing Ki-67 in the respective animals at 16-weeks post-
reconstitution. Data represents at least two independent experiments and is represented as 
mean ± SEM. See also Figure S7E-H. * denotes p < 0.05, ** denotes p < 0.01, and *** 
denotes p < 0.001 using a Student’s t test. 
 
Figure 7. Genetic deletion of the miR-212/132-/- cluster results in a FOXO3 dependent 
alteration in autophagy and survival of HSCs. (A) and (B) Cells obtained from WT and 
miR-212/132-/- mice were cultured with or without growth cytokines (mIL3, mIL6, mSCF, 
TPO, Flt3L, and G-CSF) or BafA. Caspase activation was measured using a luciferase 
based assay (n=6). (A) Caspase activation observed in HSCs from WT and miR-212/132-/- 
mice with or without growth factor starvation and BafA treatment. (B) Caspase activation 
observed in myeloid progenitors from WT and miR-212/132-/- mice with or without growth 
factor starvation and BafA treatment. (C) Autophagy activity in WT and miR-212/132-/- 
HSCs with or without growth factor starvation and LY294002 treatment. Autophagy was 
measured using a dye that fluorescently labels autophagosomes (cyto-ID autophagy assay) 
(n=5). (D) ROS accumulation in WT and miR-212/132-/- HSCs with or without growth 
factor starvation and BafA treatment measured using a fluorescence-based ROS detection 
system (CellROX assay) (n=5). (E) and (F) WT C57BL/6 mice were lethally irradiated and 
reconstituted with WT or miR-212/132-/- donor bone marrow cells expressing either a 
control or FOXO3 shRNA knockdown vector. At 8-weeks post-reconstitution HSCs were 
sorted from bone marrow and assays were performed. (E) Autophagy activity measured in 
HSCs from the respective mice in response to growth factor starvation (n=6). (F) Caspase 
  
55 
activation measured in HSCs from the respective mice in response to growth factor 
starvation (n=6). Data represents two independent experiments and is represented as mean 
± SEM. See also Figure S7I. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 
0.001 using a Student’s t test. 
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Supplemental Figure Legends 
Figure S1, related to Figure 1: Validation of microRNA-132 over-expression in bone 
marrow cells expressing control (MG) or a miR-132 over-expressing (miR-132) vector. (A) 
miR-212 expression in total bone marrow and HSCs. (B) Schematic of the retroviral 
construct used to over-express miR-132 and reconstitution efficiency of mice transplanted 
with MG or miR-132 donor bone marrow. Peripheral blood was analyzed at 8-weeks post-
reconstitution for the proportion of eGFP+ CD45+ leukocytes. (C) Representative FACS 
plots and gating strategies used for sorting MG and miR-132 expressing bone marrow cells 
prior to transplantation into irradiated recipients. (D) Expression of miR-132 in bone 
marrow cells obtained from MG and miR-132 mice. Data is represented as mean ± SEM. 
 
Figure S2, related to Figure 1: Ectopic expression of microRNA-132 leads to dregulated 
hematopoiesis. (A) – (K) WT C57BL/6 mice were lethally irradiated and reconstituted with 
donor bone marrow cells expressing either a control (MG) or a miR-132 over-expressing 
(miR-132) retroviral vector (n=8-12 mice per group). (A) Total number of LSK cells in the 
bone marrow of MG and miR-132 mice at 8-weeks post-reconstitution. (B) Frequency of 
HSCs in the bone marrow of MG and miR-132 mice at 8-weeks post-reconstitution. (C) 
Frequency of LSK cells in the bone marrow of MG and miR-132 mice at 8-weeks post-
reconstitution. (D) Percentage of Ki-67+ cells within the bone marrow LSK compartment 
of MG and miR-132 mice at 8-weeks post-reconstitution. (E) p27, p57, and p21 transcript 
expression in the bone marrow compartment of MG and miR-132 mice at 2-months post-
reconstitution obtained by RT-qPCR. (F) p27 transcript expression in the bone marrow 
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compartment of MG and miR-132 mice at 4-months post-reconstitution. (G) Spleen 
weights for MG and miR-132 mice at 16-weeks post-reconstitution. (H) Percentage of 
Ter119+, CD11b+, and Gr-1+ cells in the spleen of MG and miR-132 mice at 16-weeks 
post-reconstitution. (I) Percentage of CD11b+ and Gr-1+ cells in the peripheral blood of 
MG and miR-132 mice at 16-weeks post-reconstitution. (J) Representative FACS plot and 
gating for HSCs (Lineage- Sca1+ cKit+ CD150+ CD48-) in the bone marrow compartment 
of MG and miR-132 mice at 16-weeks post-reconstitution. (K) Percentage of LSK cells and 
HSCs in the bone marrow of MG and miR-132 mice at 16-weeks post-reconstitution. Data 
represents at least three independent experiments and is represented as mean ± SEM. * 
denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a Student’s t test. 
 
Figure S3, related to Figure 1: Ectopic expression of miR-132 and miR-212 leads to 
deficits in several early and late hematopoietic progenitor populations. (A) – (G) WT 
C57BL/6 mice were lethally irradiated and reconstituted with donor bone marrow cells 
expressing either a control (MG) or a miR-132 over-expressing (miR-132) retroviral vector 
(n=8-12 mice per group). Data represents at least three independent experiments. (A) Total 
number of LSK cells and HSCs in the bone marrow compartment of MG and miR-132 
mice at 9-months post-reconstitution. (B) Total number of multipotent progenitors (MPPs) 
in the bone marrow compartment of MG and miR-132 mice at 16-weeks post-
reconstitution. (C) Total number of lymphoid primed MPPs (LMPPs) in the bone marrow 
compartment of MG and miR-132 mice at 16-weeks post-reconstitution. (D) Total number 
of granulocyte-monocyte progenitors (GMPs) in the bone marrow compartment of MG and 
miR-132 mice at 16-weeks post-reconstitution. (E) Total number of common myeloid 
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progenitors (CMPs) in the bone marrow compartment of MG and miR-132 mice at 16-
weeks post-reconstitution. (F) Total number of myeloid-erythroid progenitors (MEPs) in 
the bone marrow compartment of MG and miR-132 mice at 16-weeks post-reconstitution. 
(G) Percentage of HSCs in the bone marrow within the eGFP- population of bone marrow 
cells in MG and miR-132 mice at 16-weeks post-reconstitution. (H) WT C57BL/6 mice 
were lethally irradiated and reconstituted with donor bone marrow cells expressing either a 
control (MG) or a miR-132-mutant over-expressing (miR-132-mutant) retroviral vector in 
which the miR-132 seed sequence was mutated (n=5 mice per group). Graphs shows total 
peripheral blood CD45+ leukccytes and CD11b+ cells at 9-months post-reconstitution. (I) – 
(K) WT C57BL/6 mice were lethally irradiated and reconstituted with donor bone marrow 
cells expressing either a control (MG) or a miR-212 over-expressing (miR-212) retroviral 
vector (n=4 mice per group). (I) Total bone marrow CD45+ cells in MG and miR-212 
mice. (J) Frequency and total number of LSK cells in the bone marrow of MG and miR-
212 mice. (K) Frequency and total number of HSCs in the bone marrow of MG and miR-
212 mice. Data represents two independent experiments and is represented as mean ± 
SEM. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a Student’s 
t test. 
 
Figure S4, related to Figure 2 and 3: Genetic deletion of the microRNA-212/132 cluster 
has no observable effect on hematopoiesis in young mice. (A) – (C) Mice with a genetic 
deletion of the miR-212/132 cluster (miR-212/132-/-) along with WT mice in the C57BL/6 
background were analyzed to understand the physiological contribution of the miR-
212/132 cluster on hematopoietic output (n=7-8 mice per group). (A) Total number of 
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peripheral blood CD45+, CD19+, and CD11b+ cells in WT and miR-212/132-/- mice at 
12-weeks of age. (B) Total number of splenic CD45+, CD19+, and CD11b+ cells in WT 
and miR-212/132-/- mice at 12-weeks of age. (C) Total number of bone marrow CD45+, 
CD19+, and CD11b+ cells in WT and miR-212/132-/- mice at 12-weeks of age. (D) Total 
number of HSCs in the bone marrow compartment of 12-week old WT and miR-212/132-/- 
mice. Data represents two independent experiments and is represented as mean ± SEM. 
 
Figure S5, related to Figures 2, 3 and 4: Genetic deletion of the microRNA-212/132 
cluster in mice leads to deregulated hematopoiesis with age. (A) – (E) Mice with a genetic 
deletion of the miR-212/132 cluster (miR-212/132-/-) along with WT mice in the C57BL/6 
background were analyzed to understand the physiological contribution of the miR-
212/132 cluster on hematopoietic output (n=7-12 mice per group). (A) Representative 
spleen gross pathology, spleen weight, and percentage of CD11b+, CD19+, and CD3e+ 
cells in the spleen of WT and miR-212/132-/- mice at 60-64 weeks of age. (B) Total number 
of CD45+, CD11b+, CD19+, and CD3e+ cells in the bone marrow of WT and miR-
212/132-/- mice at 60-64 weeks of age. (C) WT or miR-212/132-/- (KO) bone marrow cells 
were transplanted into lethally irradiated C57BL/6 mice. The relative ratio (KO/WT) of 
total numbers of various cell populations in the bone marrow of these mice at 60-weeks 
post-reconstitution is shown. (D) – (F) 6-month old WT and miR-212/132-/- were treated 
with 9 evenly-spaced low-dose (1mg/kg of body weight) LPS or PBS injections over one 
month. (D) Total number of HSCs in the spleen of WT and miR-212/132-/- mice treated 
with PBS or LPS. (E) Summary of relative proportions of early progenitors in the bone 
marrow of WT and miR-212/132-/- mice treated with LPS. (F) Proportion of bone marrow 
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LSK cells and HSCs in each stage of the cell cycle (G0, G1, G2/M) from WT and miR-
212/132-/- mice following PPS injection. (G) Expression of p27 in the bone marrow 
compartment of mice treated with LPS as described above. (H) Expression of p27 in the 
bone marrow compartment of mice 5-days after a single treatment of 5-fluorouracil. (I) WT 
or miR-212/132-/- CD45.2+ bone marrow cells from primary transplant experiments, 
calibrated for the total number of phenotypically defined HSCs, were injected in a 1:1 ratio 
with CD45.1+ WT bone marrow cells into irradiated C57BL/6 CD45.2+ recipients. The 
graph represents the relative ratio of mature cells in the peripheral blood of these secondary 
transplant mice at 16-weeks post-reconstitution. Data represents at least two independent 
experiments and is represented as mean ± SEM. * denotes p < 0.05, ** denotes p < 0.01, 
and *** denotes p < 0.001 using a Student-T test. 
 
Figure S6, related to Figure 2. Summary of RNA-sequencing analysis of WT and miR-
212/132-/- HSCs from 16-week old mice. (A) Summary of the number of detected protein 
coding genes and FPKM values for sequenced samples. LT-HSC: long-term HSCs, LSK 
CD150+ CD48-. SH-HSCs: short-term HSCs, LSK CD150- CD48-. MPPs: multipotent 
progenitors, LSK CD150- CD48+. WT: wildtype sample. KO: miR-212/132-/- sample. (B) 
Box-plot showing enrichment of miR-132 targets in miR-212/132-/- HSCs compared to WT 
HSCs. (C) Fold-change of several miR-132 targets in miR-212/132-/- HSCs compared to 
WT HSCs. (D) Fold-change in several FOXO3 regulated genes in miR-212/132-/- HSCs 
compared to WT HSCs. (E) Fold-change in several autophagy related genes in miR-
212/132-/- HSCs compared to WT HSCs. Data represents two replicate experiments.  
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Figure S7, related to Figures 6 and 7: Validation of microRNA-132 and FOXO3 over-
expression in FOXO3 rescue experiment. (A) FOXO1 and FOXO4 expression in total bone 
marrow cells from WTMG and WTmiR-132 mice. (B) FOXO1 and FOXO4 expression in 
lineage-depleted bone marrow cells from WT and miR-212/132-/- mice. RNA was obtained 
from the respective cell populations and FOXO1 and FOXO4 expression was quantified by 
RT-qPCR (n=2-3 biological replicates). (C) Intracellular staining analyzed by FACS for 
FOXO3 protein expression in bone marrow HSCs obtained from WT and miR-212/132-/- 
mice and starved for 12 hours in-vitro. (D) Intracellular staining analyzed by FACS for 
phosphorylated FOXO3 (p-FOXO3) protein expression in bone marrow HSCs obtained 
from WT and miR-212/132-/- mice and starved for 12 hours in-vitro. (E) – (F) Bone 
marrow expressing either a control (MIG), a miR-132 over-expressing (MIG-miR-132), a 
FOXO3 over-expressing (MIG-FOXO3), or a FOXO3 and miR-132 over-expressing 
(MIG-FOXO3-miR-132) retroviral vector were analyzed using Taqman RT-qPCR for 
miR-132 expression or Western Blot for FOXO3 protein expression. (E) FOXO3 protein 
expression in bone marrow cells transduced with the indicated retroviral vectors. (F) 
Mature miR-132 expression in in bone marrow cells transduced with the indicated 
retroviral vectors. (G) eGFP expression in the bone marrow compartment of mice 
reconstitution with bone marrow cells transduced with the indicated retroviral vector. (H) 
AnnexinV staining performed on bone marrow HSCs from MIG and MIG-FOXO3 mice 
(n=3). (I) Detection of autophagy activity using the Cyto-ID autophagy detection assay in 
bone-marrow-derived dendritic cells treated with Rapamycin and obtained from WT and 
Atg16 deficient (Atg16 KO) mice. Data represents at least two independent experiments 
and is represented as mean ± SEM.  
  
67 
Supplemental Experimental Procedures 
DNA Constructs 
The miR-132 over-expression construct was cloned into the MSCV-eGFP (MG) vector. In 
this modified vector, MG-miR-132, containing an MSCV promoter, the eGFP is placed 
immediately downstream of the 5’ LTR, and the miR-132 expression cassette is placed 
immediately downstream of the eGFP stop codon. A miR-132-mutant vector was similar 
constructed with a mutated miR-132 seed sequence. For FOXO3 rescue experiments, 
FOXO3 cDNA was cloned into the MSCV-IRES-eGFP (MIG) vector, immediately 
downstream of the 5’ LTR and upstream of the IRES. miR-132 was cloned downstream of 
eGFP as described above. For FOXO3 knockdown experiments, TagBFP was first 
subcloned into the MG vector, creating MSCV-TagBFP (MB). Several FOXO3 shRNA 
sequences were designed using the Invitrogen Block-iT RNAi Designer and cloned in the 
microRNA-155 loop-and-arms format immediately downstream of TagBFP in the MB 
vector.  
 
Cell sorting for RNA extraction 
Bone marrow cells were harvested from WT C57BL/6 mice and depleted of red blood cells 
(RBCs) using RBC lysis buffer (BioLegend). Cells were then spun down, resuspended in 
MACS separating buffer (Phosphate buffered saline, pH7.2, with 0.5% BSA and 2mM 
EDTA), and filtered through a 70uM cell-strainer. These cells were then blocked with 
FcBlock (Becton Dickinson) and depleted of mature cells on a magnetic column using 
biotin-conjugated mouse antibodies for CD3e, CD8, CD4, CD19, B220, CD11b, Gr-1, IL-
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7Ra, and Ter119 (BioLegend) and streptavidin magnetic beads (Miltenyi), as suggested 
by the manufacturer (Miltenyi). Cells were subsequently stained with fluorophore-
conjugated antibodies for lineage markers (CD3, CD19, CD11b, Gr-1, Ter119, Nk1.1), 
cKit, Sca1, CD150, CD48, and with 7-AAD, and several populations were sorted for 
analysis including HSCs (Lineage- cKit+ Sca1+ CD150+ CD48-), LSK cells (Lineage- 
cKit+ Sca1+), and other progenitor subsets as detailed in the text. Cells were sorted on a 
FACSAria IIu cell sorter (Becton Dickinson) at the Caltech Flow Cytometry Core Facility. 
Mature cell populations were sorted using a magnetic column as described above using 
positive-selection for the respective surface marker (Gr-1, CD11b, CD19). All cells were 
lysed using Qiazol lysis buffer (Qiagen) and processed using the miRNAeasy RNA prep kit 
(Qiagen). RNA was then subjected to qPCR.  
 
Sample preparation for RNA-sequencing 
LT-HSCs (LSK CD150+ CD48-), ST-HSCs (LSK CD150- CD48-) and MPPs (LSK 
CD150- CD48+) from WT and miR-212/132-/- were sorted as described above. Cells were 
sorted directly into cell lysis buffer and processed using an RNAeasy kit (Qiagen) with 
DNAseI digestion (Qiagen) as per manufacturer’s protocol. Libraries were prepared using 
the SMART-seq2 protocol (Picelli et al., 2013) modified to use Maxima H Minus enzyme 
for reverse transcription (Thermo Scientific). Amplified cDNA products were purified 
using AMPure XP SPRI beads (Beckman Coulter) and eluted in TE buffer (Teknova). 
Cleaned-up amplified cDNA was used for library construction using the Nextera XT DNA 
Sample Preparation Kit and Nextera XT Index Kit (Illumina). Libraries were then pooled 
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and cleaned-up using AMPure XP SPRI beads (Beckman Coulter Genomics). Final 
library quality and quantity were assessed using a DNA High Sensitivity chip (Agilent).  
 
RNA-seq data generation and analysis 
Libraries were sequenced on the Illumina HiSeq 2500. Paired-end 2x25bp reads were 
generated. The reads were filtered for rRNA contamination by aligning against mouse 
ribosomal sequences using Bowtie (version 0.12.7) (Langmead et al., 2009) and retaining 
unaligned read pairs. The refSeq annotation for the mm9 version of the mouse genome was 
used to create a transcriptome Bowtie index, to which read pairs were aligned with the 
following settings: “-v 2 -a -X 1000”. Gene expression levels were estimated using eXpress 
(version 1.5.1) (Roberts and Pachter, 2013), and the effective count values were used as 
input to DESeq (Anders and Huber, 2010) for evaluating differential expression. The 
targets of miR-132 were obtained from TargetScan (mouse release 6.2) (Friedman et al., 
2009). 
 
Immunoblotting 
Pelleted cells were resuspended in RIPA lysis buffer (Sigma) containing protease inhibitors 
for 20 minutes on ice. Samples were spun down at max speed at 4oC for 10 minutes and the 
supernatant was processed immediately or flash-frozen on dry ice for analysis in the future. 
Total cell extracts were fractionated by gel-electrophoresis on a mini-PROTEAN TGX 
gradient (4-15%) gel (Bio-Rad) and electroblotted onto a PVDF membrane using a wet 
transfer apparatus (Bio-Rad). Protein detection was subsequently performed with the 
following antibodies: FoxO3a (75D8) (Cell Signaling Technologies), p27-HRP (sc-538) 
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(Santa Cruz Biotechnology), actin-HRP (sc-1616) (Santa Cruz Biotechnology), and goat 
anti-rabbit-IgG-HRP (sc-2030) (Santa Cruz Biotechnology).  
 
Mice 
All mice used in this study are of the C57BL/6 background. The miR-212/132-/- mice were 
generated previously and are described elsewhere (Ucar et al., 2012). Briefly, these mice 
were generated by homologous recombination targeting the genomic cluster containing 
both microRNA-212 and microRNA-132. Mice obtained were backcrossed to the C57BL/6 
background for at least 20 generations prior to the initiation of the reported studies.  
 
Bone marrow reconstitution 
WT C57BL/6 or miR-212/132-/- mice were treated with 5-fluorouracil (10ug; Sigma) for 5 
days to enrich for hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. 
After 5 days, bone marrow cells were harvested, red blood cells (RBCs) were lysed with 
RBC lysis buffer (BioLegend), and cells were plated in HSPC media, which was composed 
of complete RPMI with mouse SCF (50 ng/mL), IL-3 (20 ng/mL), and IL-6 (50 ng/mL). 
Cells were then cultured in 24-wel plates for 24 hours and spin-infected with PCL-
ecotropic pseudotyped gamma-retrovirus expressing the construct of interest, which was 
either a microRNA, shRNA, or a gene, as described in under the DNA Constructs and 
Primers section of the main text. Spin-infections were performed by removing supernatant 
carefully from cell culture plates and adding virus with 8 ug/mL Polybrene (Santa Cruz 
Biotechnology). Plates were then placed in a centrifuge for 2 hours at 300C and 2500RPM. 
Immediately following infection, virus supernatant was removed and replaced with HSPC 
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media. 24 hours later a second identical spin infection was performed. After another 24 
hours, recipient mice were lethally irradiated (1000 rads from Cs137 source) and 250,000 
to a million virus-infected HSPCs were retro-orbitally delivered to reconstitute the immune 
system. Recipients were maintained on Septra and in autoclaved cages for at least one 
month post-reconstitution.  
 
Virus production 
To generate retrovirus for HSPC infection, 10 million HEK293T cells were first plated in a 
15cm plate. 24 hours later, cells were transfected with both the pCL-Eco vector and either 
the pMG vector or the relevant variant described above for gene delivery. For transfection, 
we used BioT (Bioland Scientific) as per the manufacturers protocol. 36 hours after 
transfection, virus was collected, filtered through a 45uM syringe filter, and used for 
infection of HSPCs. 
 
Flow cytometry 
Cells were stained with fluorophore-conjugated antibodies (all from BioLegend unless 
indicated) for CD45.1, CD45.2, CD11b, Gr-1, CD19, B220, CD3e, Nk1.1, Ter119, cKit, 
Sca1, CD150, CD48, EPCR (Ebioscience), CD34, Flt3, FcRg or IL-7Ra in various 
combinations to characterize relevant hematopoietic cell populations. Intracellular staining 
was performed by first performing surface staining of cells, followed by fixation and 
permeabilization (Cytofix/Cytoperm kit; BD Biosciences) and subsequent staining with 
either Ki67 (BioLegend) and Hoescht33342 (Life Technologies) for cell-cycling analysis, 
or an anti-FoxO3a (75D8) (Cell Signaling Technologies) or anti-FoxO3a (phosphor S253) 
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(Abcam) primary antibody followed by an anti-Rabit-IgG secondary antibody 
conjugated to Alexafuor488 (Cell Signaling Technologies). Samples were analyzed on a 
MACSQuant10 Flow Cytometry machine (Miltenyi). Gating and analysis was performed 
using FlowJo software. 
 
Autophagy and reactive-oxygen species assays 
HSCs were sorted as described above from either WT or miR-212/132-/- C57BL/6 mice, or 
from reconstituted mice with donor WT or miR-212/132-/- bone marrow infected with 
either MB or shFOXO3 retroviral constructs. For all in-vitro experiments, cells were sorted 
directly in a 96-wel plate containing cell culture media with the appropriate growth factors 
and cytokines (all from Ebioscience). For caspase activation assays and reactive oxygen 
species detection, 5000 cells were cultured with or without Bafilomycin A (5nM; Sigma) 
and with either no growth factors or cytokines, or with mSCF (50 ng/mL), IL-3 (20 
ng/mL), IL-6 (50 ng/mL), Flt3L (25 ng/mL), TPO (25 ng/mL), and GM-CSF (10ng/mL). 
Cells were cultured for 12 hours and subsequently processed. Caspase activity was detected 
using the luciferase-based Caspase Glo 3/7 assay system as per manufactures instructions 
(Promega). Reactive-oxygen species were detected by flow cytometry using the CellROX 
Deep Red reagent (Life Technologies). For authophagy detection assays, 5000-8000 cells 
were cultured with or without LY294002 (20uM; Cell Signaling Technologies) and with or 
without aforementioned growth factors or cytokines. Autophagy activity was determined 
by flow cytometry using the CytoID autophagy detection kit as per manufacturers 
instructions (Enzo Life Sciences).  
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Supplemental Tables 
Table S1: sequences for FOXO3 shRNA constructs. 
FOXO3 shRNA sequence (in miR-155-arms-and-loop-format) 
mmu-FOXO3 shRNA #1 gaaggctgtaTGCTGCCATCATTCAGATTCATGGTGGTTTTGGCCACTGACTGACCACCATGACTGAATGATGGcaggacacaaggcctg 
mmu-FOXO3 shRNA #2 gaaggctgtaTGCTGAACACGGTACTGTTGAAGGAGGTTTTGGCCACTGACTGACCTCCTTCAAGTACCGTGTTcaggacacaaggcctg 
mmu-FOXO3 shRNA #3 gaaggctgtaTGCTGAAGAGAAGGTGGCTGGTCTGTGTTTTGGCCACTGACTGACACAGACCACACCTTCTCTTcaggacacaaggcctg 
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Table S2: primer sequences used for qPCR. 
Primer sequences 
AchE F CTCCCTGGTATCCCCTGCATA 
AchE R GGATGCCCAGAAAAGCTGAGA 
BTG2 F ATGAGCCACGGGAAGAGAAC 
BTG2 R GCCCTACTGAAAACCTTGAGTC 
FOXO1 F CCCAGGCCGGAGTTTAACC 
FOXO1 R GTTGCTCATAAAGTCGGTGCT 
FOXO3 F CTGGGGGAACCTGTCCTATG 
FOXO3 R TCATTCTGAACGCGCATGAAG 
HMGA2 F GAGCCCTCTCCTAAGAGACCC 
HMGA2 R TTGGCCGTTTTTCTCCAATGG 
JARID1A F CACAGACCCGCTGAGTTTTAT 
JARID1A R CTTCACAGGCAAATGGAGGTT 
Lin28b F AGAATGCAGTCTACCTCCTCAG 
Lin28b R CCTCCCACTTCTCTTGGTGC 
MAPK1 F GGTTGTTCCCAAATGCTGACT 
MAPK1 R CAACTTCAATCCTCTTGTGAGGG 
MMP9 F CTGGACAGCCAGACACTAAAG 
MMP9 R CTCGCGGCAAGTCTTCAGAG 
p21 F CCGCTGGAGGGCAACTTCGT  
p21 R TTTCGGCCCTGAGATGTTCC 
p27 F  TCTCAGGCAAACTCTGAGGAC  
p27 R TTCGGAGCTGTTTACGTCTGG 
p300 F CTCGCACTTGCCCTTACCTTT 
p300 R GGTCGCAGTGGCTGGAGA 
p57 F TGATGAGCTGGGAACTGAGCC 
p57 R ACGTCGTTCGACGCCTTGTTC 
PTBP2 F GGATCTGACGAGCTACTCTCA 
PTBP2 R TTCTTACTATCGTTACCGTTGGC 
RB1 F TGCATCTTTATCGCAGCAGTT 
RB1 R GTTCACACGTCCGTTCTAATTTG 
SOX4 F GACAGCGACAAGATTCCGTTC 
SOX4 R GTTGCCCGACTTCACCTTC 
SOX5 F CCCGTGATCCAGAGCACTTAC 
SOX5 R CCGCAATGTGGTTTTCGCT 
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Figure'2:'Gene;c'dele;on'of'the'microRNA0212/132'cluster'in'mice'
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Figure'5:'.'FOXO3'is'a'direct'target'of'microRNA0132'in'bone'marrow'cells.''
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Figure'S1:'Valida;on'of'microRNA0132'over0expression'in'bone'marrow'cells'
expressing'control'(MG)'or'a'miR0132'over0expressing'(miR0132)'vector.''
B"
MSCV GFP 
 
miR-132 
antisense-9,10 mir-132 sequence 
155 loop 
155-5      155-3  
MG
mi
R-
13
2
0
20
40
60
80
100
eG
FP
+ 
(%
)
NS
B"
   
 F
S
C
"
BSC"
co
un
t"
eGFP"
MG"
50.11%"
   
 F
S
C
"
BSC"
miR(132"
co
un
t"
eGFP"
47.09%"
MG
mm
u-m
iR-
13
2
0
100
200
300
R
el
at
iv
e 
m
iR
-1
32
 e
xp
re
ss
io
nD"
A"
H
SC
To
ta
l B
M
0.0
0.5
1.0
1.5
2.0 *
R
el
at
iv
e 
m
ic
ro
R
N
A-
21
2 
ex
pr
es
si
on
  
84 
 
 
 
 
 
I"
K"
MG
mi
R-
13
2
0.00
0.05
0.10
0.15
0.20
p = 0.0962
Sp
le
en
 w
ei
gh
t (
g)
MG
mi
R-
13
2
0
5
10
15
20
%
 T
er
11
9+
 c
el
ls
 (o
f t
ot
al
)
*H"
MG
mi
R-
13
2
0
200000
400000
600000
800000
NS
To
ta
l C
D
45
+ 
C
D
11
b+
 c
el
ls
  (
ce
lls
/m
L)
MG
mi
R-
13
2
0
200000
400000
600000
800000
NS
To
ta
l C
D
45
+ 
G
r-1
+ 
ce
lls
 (c
el
ls
/m
L)
MG
mi
R-
13
2
0
5
10
15
20
25
NS
%
 C
D
11
b+
 c
el
ls
 (o
f t
ot
al
)
MG
mi
R-
13
2
0
10
20
30
%
 G
r-1
+ 
ce
lls
 (o
f t
ot
al
)
p = 0.0594
MG" miR(132"
   
 c
-K
it"
   Sca1"
   
 C
D
48
"
   CD150"
J"
MG
mi
R-
13
2
0.0
0.2
0.4
0.6
0.8
%
 L
in
- c
Ki
t+
 S
ca
1+
 (o
f t
ot
al
)
**
MG
mi
R-
13
2
0.00
0.01
0.02
0.03
%
 L
SK
 C
D
15
0+
 C
D
48
- c
el
ls
 (o
f t
ot
al
)
***
MG
mI
R-
13
2
0
10
20
30
40
50
**
%
 K
i-6
7+
 (o
f t
ot
al
 L
SK
 c
el
ls
)
MG
mi
R-
13
2
0
20000
40000
60000
80000
*
To
ta
l L
in
- c
Ki
t+
 S
ca
1+
 c
el
ls
A" D"
E"
Figure'S2:'Ectopic'expression'of'
microRNA0132'leads'to'dregulated'
hematopoiesis.'
MG
mi
R-
13
2
0.0
0.5
1.0
1.5
R
el
at
iv
e 
p2
7 
m
R
N
A 
ex
pr
es
si
on
*
MG
mi
R-
13
2
0.0
0.5
1.0
1.5
R
el
at
iv
e 
p5
7 
m
R
N
A 
ex
pr
es
si
on
*
MG
mi
R-
13
2
0.0
0.5
1.0
1.5
NS
R
el
at
iv
e 
p2
1 
m
R
N
A 
ex
pr
es
si
on F"
MG
mi
R-
13
2
0.0
0.5
1.0
1.5
R
el
at
iv
e 
p2
7 
m
R
N
A 
ex
pr
es
si
on
*
G"
MG
mi
R-
13
2
0.0
0.2
0.4
0.6
0.8
1.0 p = 0.0623
%
 L
in
- c
Ki
t+
 S
ca
1+
 (o
f t
ot
al
)
MG
mi
R-
13
2
0.00
0.02
0.04
0.06
0.08
*
%
 L
SK
 C
D
15
0+
 C
D
48
- c
el
ls
 (o
f t
ot
al
)B" C"
  
85 
 
 
 
 
 
MG
mi
R-
13
2
0.000
0.005
0.010
0.015
0.020
NS
%
 L
SK
 C
D
15
0+
 C
D
48
- c
el
ls
 (o
f t
ot
al
 e
G
FP
- )
MG
mi
R-
13
2
0
10000
20000
30000
40000
50000
**
To
ta
l L
in
- c
Ki
t+
 S
ca
1-
 C
D
34
- F
cR
g-
 c
el
ls
MG
mi
R-
13
2
0
10000
20000
30000
40000
NS
To
ta
l L
in
- c
Ki
t+
 S
ca
1-
 C
D
34
+ 
Fc
R
g-
 c
el
ls
Figure'S3:'Ectopic'expression'of'miR0132'leads'to'deficits'in'several'early'and'
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Figure'S4:'Gene;c'dele;on'of'the'microRNA0212/132'cluster'has'no'
observable'effect'on'hematopoiesis'in'young'mice.''
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Abstract 
MicroRNAs have emerged as key regulators of B cell fate decisions and immune function. 
Deregulation of several microRNAs in B cells leads to the development of autoimmune 
disease and cancer in mice. We demonstrate that the microRNA-212/132 cluster (miR-
212/132) is induced in B cells in response to B cell receptor signaling. Enforced expression 
of miR-132 results in a block in early B cell development at the pre-pro-B cell to pro-B cell 
transition and induces apoptosis in primary bone marrow B cells. Importantly, loss of miR-
212/132 results in increased B cell output under non-homeostatic conditions. We find that 
miR-212/132 regulates B lymphopoiesis by targeting the transcription factor Sox4. Co-
expression of SOX4 with miR-132 rescues the defect in B cell development from over-
expression of miR-132 alone. In addition, we show that the expression of miR-132 can 
inhibit cancer development in cells that are prone to spontaneous B cell cancers, such as B 
cells expressing the c-Myc oncogene. We have thus uncovered a novel regulator of B cell 
lineage specification that may potentially have applications in B cell cancer therapy.  
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Introduction 
Recently, the microRNA-212/132 cluster (miR-212/132) has emerged as an important 
regulator of anti-viral immunity (Lagos et al., 2010), as well as macrophage and TH17 T 
cell immune function (Nahid et al., 2013; Nakahama et al., 2013; Shaked et al., 2009; 
Taganov et al., 2006). In addition, it has been shown that miR-132 plays a role in the 
proliferation and invasion of certain solid tumors (Jiang et al., 2015; Zhang et al., 2014), as 
well as in pathological angiogenesis (Anand et al., 2010), thus making it a potential 
candidate for cancer therapeutics. Recently, several groups have also identified miR-
212/132 as deregulated in certain B cell cancers (Lawrie et al., 2008; Pede et al., 2013; 
Tavolaro et al., 2015). In this study, we uncover a novel role for miR-212/132 as a 
regulator of early B cell development by targeting the transcription factor Sox4. In 
addition, we find that miR-132 induces apoptosis in B cells and that this may be leveraged 
to inhibit the progression of B cell cancers, such as spontaneous B cell lymphomas in mice 
expressing the c-Myc oncogene driven by the IgH enhancer (Langdon et al., 1986). 
 
Results 
The microRNA-212/132 cluster is induced in B cells in response to B cell receptor 
activation 
To investigate the role of the microRNA-212/132 cluster (miR-212/132) in B cells we first 
examined the expression of miR-212/132 in various sorted splenic and bone marrow cell 
populations obtained from wild-type (WT) C57BL/6 mice. RNA was extracted from these 
cells and we performed TaqMan qPCR to profile microRNA expression. We initially found 
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that miR-212/132 was not significantly enriched in either the splenic or bone marrow 
CD19+ B cell population (Fig. S1A). However, we found a significant upregulation of 
miR-132 in these cells in response to stimulation with mouse anti-IgM, which binds to and 
activates the B cell receptor (BCR) (Fig. 1A and S1B). This induction peaked at 24 hours, 
and was specific to BCR signaling through an NF-κB independent pathway, since it could 
be replicated by stimulation with PMA and ionomycin, but not with activation of NF-κB 
through TLR ligands or anti-CD40 (Fig. 1A and S1C). The level of miR-132 induction 
demonstrated a strong dependence on the concentration of anti-IgM used for stimulation 
(Fig. S1D).  Importantly, we found that B cells from mice with a genetic deletion of miR-
212/132 (miR-212/132-/-) demonstrated no detectable expression of miR-132 at steady state 
and after anti-IgM stimulation (Fig. S1E). 
 
Enforced expression of microRNA-132 inhibits B cell development 
We next examined the result of miR-132 over-expression on B cell development. We chose 
to over-express miR-132 since it was the most strongly induced of the two microRNAs. 
Bone marrow from WT C57BL/6 mice that was enriched for hematopoietic stem and 
progenitor cells (HSPCs) was retrovirally transduced with control vector (WTMG) or a miR-
132 over-expression vector (WTmiR-132). These cells were then used to reconstitute the 
immune system of lethally irradiated C57BL/6 WT recipients, and we subsequently tracked 
the development of B cells. We found that WTmiR-132 mice had a significant depletion in the 
frequency and total number of peripheral blood B cells compared to WTMG controls at 3-4 
months post-reconstitution (Fig. 1B,C). This was accompanied by a decrease in the total 
number of leukocytes (CD45+), B cells (CD19+), and plasma cells (CD138+) in the spleen 
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of WTmiR-132 mice (Fig. 1D,E). The loss of B-cells was dramatically mirrored in the bone 
marrow compartment (Fig. 1F), where a minor increase in myeloid cells was also observed 
(Fig. 1G). A similar depletion in total leukocytes, B cells, and T cells was observed in the 
spleen of mice at 9-months post-reconstitution (Fig. S2A). The bone marrow compartment 
of these mice also demonstrated a loss in B cells and T cells, but no change in myeloid cells 
was apparent (Fig. S2B). Enforced expression of miR-212 alone resulted in slight decrease 
in B cells in the bone marrow compartment at 4 months post-reconstitution; however, no 
changes in the frequency of bone marrow B cell progenitors or splenic B cells was 
observed compared to controls (Fig. S3).  
 
We next sought to better understand the underlying cellular mechanism for this defect in B 
cell development in WTmiR-132 mice. To begin to address this question, we performed RNA-
seq on immature B cells obtained from WT and miR-212/132-/- mice under steady state 
conditions, and after 8-hours or 20-hours of anti-IgM stimulation. We found a number of 
differentially expressed genes between samples (Fig. S4A). These were enriched for genes 
related to cell death, calcium ion transport, B cell receptor signaling, and cytokine 
production when comparing anti-IgM stimulated cells to unstimulated cells (Fig. S4B). 
Clustering analysis of differentially expressed genes revealed that WT and miR-212/132-/- 
cells from the same time-points were more closely related to each other than to any other 
sample (Fig. 2A). Importantly, among the genes that were differentially regulated between 
WT and miR-212/132-/- cells at the same time-point, there was enrichment for genes related 
to B cell apoptosis and precursor-B (pre-B) cell differentiation (Fig. 2B).  
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To better understand the influence of miR-212/132 in early B cell commitment, we 
profiled the expression of miR-132 in B cell progenitors. We found a slight enrichment in 
miR-132 in progenitor B (pro-B) cells and precursor B (pre-B) cells compared to total bone 
marrow cells and common lymphoid progenitors (CLPs) (Fig. 2C). Consistent with this 
finding, we found that the bone marrow of WTmiR-132 mice had a comparable frequency of 
CLPs (Lineage-cKit+Sca1+Flt3+IL7Ra+) and a slight, but not statistically significant, 
decrease in the frequency precursor-progenitor B (pre-pro-B) cells compared to WTMG 
mice (Fig. 2D,E). However, we found a significant decrease in the frequency of both pre-B 
cells and pro-B cells in the bone marrow of WTmiR-132 mice (Fig. 2F,G), which is indicative 
of a developmental block somewhere between the pre-pro-B cell to pro-B cell transition.   
 
The microRNA-212/132 cluster regulates B cell survival 
We next sought to investigate whether miR-132 may influence B cell development by 
altering the survival or proliferation of B cells.  We found that primary splenic B cells in 
WTmiR-132 at 2 months post-reconstitution demonstrated increased cell death compared to 
WTMG controls, as measured by AnnexinV staining (Fig. 3A). This indicates that  
overexpression of miR-132 results in apoptosis in B cells of these mice. We next cultured 
primary splenic B cells from miR-212/132-/- and WT mice with or without anti-IgM, and 
found in both conditions that miR-212/132-/- B cells were more resistant to apoptosis (Fig. 
3B and S5), as is consistent with the potential role of miR-212/132 in regulating cell death. 
Importantly, we found no difference in proliferation of splenic B cells from miR-212/132-/- 
or WT mice in unstimulated conditions or in the presence of TLR ligands (Fig. 3C).  
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Loss of the microRNA-212/132 cluster enhances B cell development under non-
homeostatic conditions 
A close examination of the peripheral blood, spleen, and bone marrow of miR-212/132-/- 
and WT mice at 16-weeks of age revealed no significant difference in the frequency of B 
cells present in these compartments, though a marginal elevation in CD19+ B cells in the 
peripheral blood was observed (Fig. S6A-C). We next challenged WT and miR-212/132-/- 
mice with an anti-CD20 antibody to deplete all mature B cells (Sarikonda et al., 2013). We 
observed a rapid depletion of peripheral blood B cells in all mice treated with anti-CD20 
compared to control mice treated with phosphate buffered saline (PBS) (Fig. 4). Within 3 
days, the total number of B cells in both anti-CD20 treated cohorts was less than 1% of the 
total number of peripheral blood leukocytes. Interestingly, under these conditions, miR-
212/132-/- mice demonstrated a more rapid rebound in the frequency of peripheral blood B 
cells compared to WT mice about 21 days after anti-CD20 treatment (Fig. 4). This 
indicates a unique advantage of miR-212/132-/- B cell progenitors to replenish the B cell 
pool under conditions of stress. We further corroborated this result by treating miR-
212/132-/- and WT mice with serial LPS injections to mimic aging under conditions of 
inflammatory stress. Consistent with the aforementioned result, we found that miR-
212/132-/- mice showed a large accumulation B cells in the spleen compared to WT mice 
(Fig. S6D). 
 
Sox4 is a direct target of microRNA-132 in B cells and rescues defective B cell 
development with enforced expression of microRNA-132 
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We have previously shown that Sox4 mRNA expression levels are decreased in the bone 
marrow of WTmiR-132 mice compared to WTMG controls. Sox4 is a known regulator of B 
cell development (Laurenti et al., 2013; Mallampati et al., 2014; Sun et al., 2013) and has a 
conserved, computationally predicted 7mer-m8 binding site for miR-132 (Fig. 5A).  We 
thus validated that it is a direct target of miR-132 and explored the possibility that miR-132 
may regulate B cell development through So4. We transfected HEK293T cells with a 
construct that over-expressed miR-132 in the presence of a luciferase reporter immediately 
upstream of either the 3’-untranslated region (3’UTR) of Sox4, the 3’UTR of Sox4 with a 
mutated miR-132 binding site, or an irrelevant 3’UTR (control). We found decreased 
expression of luciferase when expressing the construct with an intact Sox4 3’UTR when 
compared to the control vector; however, this luciferase expression was restored upon 
mutating the miR-132 binding site (Fig. 5B). Examination of Sox4 protein expression in 
whole bone marrow lysates from WTmiR-132 and WTMG mice by Western Blot did not reveal 
significant differences (Fig. S7A). However, we found a significant decrease in Sox4 
mRNA and protein expression levels in purified bone marrow B cells from WTmiR-132 mice 
when compared to WTMG controls (Fig. 5C,D). We further validated that enforced 
expression of miR-132 down-regulated Sox4 protein expression in the 70Z/3 B cell line 
(Fig. S7B). We also found a marginal decrease in Rag1 expression levels in purified bone 
marrow B cells from WTmIR-132 when compared to WTMG cells, but observed no changes in 
the expression levels of other genes critical for B cell development, including PU.1, Ikxf1, 
Ebf11, E2A, and Pax5 (Fig. S7C).  
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While it is known that a complete loss of Sox4 has dramatic consequences on B cell 
development, we explored whether a partial decrease in Sox4 protein levels, as might be 
expected by upregulation of a microRNA, may alter B cell fate. To do this, we 
reconstituted lethally irradiated C57BL/6 mice with HSPC enriched bone marrow cells 
transduced with either a control vector (WTMG) or a vector expressing an shRNA 
knockdown for Sox4 (WTshSOX4) using a strategy previously described (Chaudhuri et al., 
2012). WTshSOX4 mice, when compared to WTMG controls, demonstrated a significant 
depletion in the frequency of B cells in the spleen (Fig. 5E) and bone marrow compartment 
(Fig. 5F) at 4 months post-reconstitution. We observed no change in the frequency of pre-
pro B cells (Fig. 5G); however, there was a significant decrease in the frequency of pro-B 
cells (Fig. 5H) and pre-B cells (Fig. 5I) in the bone marrow of WTshSOX4 mice.  
 
To determine if Sox4 is the key target of miR-132 responsible for regulating B cell 
development, we attempted to rescue the defect in B cell development observed with 
enforced expression of miR-132 by co-expressing Sox4 in the same cells. To do this we 
reconstituted mice with HSPCs expressing an empty vector (WTMIG), or with a vector 
expressing either miR-132 only (WTmiR-132), Sox4 only (WTSOX4), or miR-132 and Sox4 
together (WTmiR-132-SOX4) using a strategy previously described (Rao et al., 2010). We 
validated the expression of Sox4 and miR-132 in the respective samples by qPCR (Fig. 
6A,B). Analysis of the peripheral blood of these mice at three months post-reconstitution 
revealed that co-expression of Sox4 partially rescues the loss of B cells observed with 
expression of miR-132 alone (Fig. 6C), thus suggesting that miR-132 regulates B cell 
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development in part by altering the expression of Sox4. Importantly, we also found that 
WTSOX4 mice had enhanced output of B cells compared to WTMG controls (Fig. 6C).  
 
MicroRNA-132 protects Eµ-myc mice from spontaneous B cell leukemia development 
Several groups have uncovered that the microRNA-212/132 cluster is deregulated in 
certain leukemia’s of B cell origin (Pede et al., 2013; Tavolaro et al., 2015). Given our 
observation that miR-212/132 inhibits B cell development and induces B cell apoptosis, we 
investigated whether it may play a role in inhibiting B cell leukemias or lymphomas. To 
this end, we over-expressed miR-132 in 70Z/3 cells, a pre-B cell lymphoblast tumor line, 
and found increased AnnV+ staining in cells expressing miR-132 compared to a control 
vector (Fig. 7A). We next investigated whether delivering miR-132 to bone marrow cells 
from mice with a c-Myc transgene driven by an IgH enhancer (Eµ-myc mice) (Langdon et 
al., 1986) could prevent the spontaneous occurrence of B cell cancers. To do this, we 
reconstituted lethally irradiated WT C57BL/6 mice with HSPC enriched bone marrow cells 
from WT or Eµ-myc mice that were transduced with either a control vector or a miR-132 
expressing vector. Over 4 months, none of the mice reconstituted with WT cells developed 
cancer and almost all of them survived. However, a significant majority of the mice that 
received cells from Eµ-myc donors expressing the control vector developed spontaneous B 
cell lymphomas or leukemias, and quickly passed away (Fig. 7B). While approximately 
50% of the mice receiving Eµ-myc donor cells transduced with a miR-132 expression 
vector succumbed to cancer, there was a significant improvement in survival compared to 
mice receiving Eµ-myc cells with the control vector (Fig. 7B). Importantly, surviving mice 
that received Eµ-myc donor cells expressing miR-132 demonstrated a rescue in the 
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frequency of CD19+ B cells, CD11b+ myeloid cells and pre-B cells in the bone marrow 
compartment compared to mice that received Eµ-myc donor cells with the control vector 
(Fig. 7C-E). Thus, the expression of miR-132 had a protective effect on cancer occurrence 
in mice that were given Eµ-myc cells predisposed to forming B cell cancers.  
 
Discussion 
A handful of microRNAs have been implicated in regulating hematopoietic cell fate 
decisions, including B cell linage commitment (O'Connell et al., 2010b; Rao et al., 2010; 
Xiao et al., 2007). As post-transcriptional regulators of gene expression, these microRNAs 
primarily serve to fine-tune the expression of their targets, and in turn confer robustness to 
biological processes (Ebert and Sharp, 2012). When deregulated, however, microRNAs can 
tip the balance between normal and pathologic function of a cell. In this study, we have 
uncovered a novel role for miR-212/132 in regulating the differentiation of pre-pro-B cells 
to pro-B cells by targeting the transcription factor Sox4. We found that deregulating miR-
132 in vivo can affect survival of B cells, and this may be utilized for therapeutic purposes 
in combating B cell cancers.  
 
We observed that miR-212/132 is highly induced in B cells in response to B cell receptor 
activation, but not to activation of TLR receptors or CD40, which result in a strong NF-κB 
response. This highlights a potentially unique regulation of miR-212/132 in B cells, 
independent of what has been observed in macrophages, where a significant but less 
dramatic induction of miR-212/132 has been observed with TLR4 stimulation (Shaked et 
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al., 2009; Taganov et al., 2006). Importantly, this induction was replicated by 
stimulation with PMA, a DAG analog, but not with ionomycin, which mimics Ca2+ influx 
into a cell, thus suggesting that miR-212/132 may be regulated by CREB or a host of other 
factors in B cells, as has been observed in neurons (Klein et al., 2007; Wen et al., 2010). 
Importantly, we found that enforced expression of miR-132 blocks the development of pro-
B cells, which express the pre-BCR. Thus, it remains to be seen whether miR-212/132 may 
be induced by pre-BCR signaling and what role this may play in the developmental 
process. We may hypothesize that high levels of miR-212/132 induction from strong pre-
BCR induction may serve as a safety check to buffer aberrant B cell development and 
induce apoptosis in highly reactive cells.  
 
A genetic deletion in miR-212/132 resulted in B cells that were more resistant to apoptosis. 
In addition, miR-212/132-/- mice had an increased output of B cells compared to WT mice 
under non-homeostatic conditions, such as when B cells were depleted with a mouse anti-
CD20 antibody. Aging these mice did not reveal the occurrence of B cell cancers; however, 
it may be possible that deregulation of miR-212/132 may aid in the progression of cancers 
once they have been established. In fact, it has been demonstrated that miR-212/132 is 
deregulated in cancers of various forms, including B cell leukemias, and that upregulation 
of miR-212/132 in lung cancers inhibits proliferation and progression of the disease (Jiang 
et al., 2015; Pede et al., 2013; Tavolaro et al., 2015; Zhang et al., 2014). We found that 
enforced expression of miR-132 in donor cells from Eµ-myc mice, which are prone to 
develop spontaneous B cell lymphomas, had a strong protective effect on cancer 
development. Importantly, as was observed in primary B cells, the delivery of miR-132 to 
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70Z/3 cells, a B cell cancer line, induced apoptosis in these cells. We note, however, 
that this contrasts the role of miR-132 promoting pathological angiogenesis (Anand et al., 
2010), thus requiring targeted delivery of miR-132 specifically to the tumor cells only and 
complicating treatment of solid tumors.  
 
Our work also led to the discovery of Sox4 as a novel target for miR-132. We demonstrated 
that Sox4 is a key player in mediating the B cell development defect observed with miR-
132 over-expression. A genetic deletion of Sox4 in mice has been shown to completely 
abolish the development of pro-B cells (Sun et al., 2013). Consistent with this, we found a 
dramatic loss of pro-B cells with miR-132 over-expression and a concomitant increase in B 
cell apoptosis. Importantly, we demonstrated that sub-threshold levels of Sox4, either by 
miR-132 over-expression or by shRNA knockdown of Sox4, are sufficient to recreate the 
defect in pro-B cell development. We found that over-expression of miR-132 also affected 
downstream targets of Sox4 (Mallampati et al., 2014), particularly Rag1.  
 
We have thus identified miR-212/132 as a novel player in regulating B cell development. 
While much remains to be understood about the role of miR-212/132 in pro-B cell 
differentiation, we have identified a novel target for miR-212/132 in Sox4, and together 
these findings provide unique insight into the post-transcriptional mechanisms that govern 
B cell fate. Furthermore, our current work also suggests a potential role for miR-212/132 in 
combating cancers of B cell origin. 
 
  
103 
Experimental Procedures 
DNA constructs 
For in-vivo miR-132 expression and Sox4 shRNA experiments, we cloned either the 
mature miR-132 or Sox4 shRNA sequence in the microRNA-155 loop-and-arms format 
(O'Connell et al., 2010a) and into the MSCV-eGFP (MG) vector. For Sox4 rescue 
experiments, Sox4 lacking its 3’UTR was cloned into the MSCV-IRES-eGFP (MIG) 
vector using a strategy previously described (Rao et al., 2010). Sox4 shRNA target 
sequences are given in Table S1. 
 
For luciferase assays, the microRNA-132 expression cassette was sub-cloned into the 
pCDNA3 vector. The 3’UTR of Sox4 containing either the intact or mutated miR-132 
binding site was cloned immediately downstream of luciferase in the pMiReport vector as 
previously described (Chaudhuri et al., 2012).  
 
Cell culture 
Cells were cultured in a sterile incubator that was maintained at 370C and 5% CO2. 
HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 
U/mL penicillin, and 100 U/mL streptomycin. Primary splenic B cells were cultured in 
complete RPMI supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL 
streptomycin, 50uM β-mercaptoethanol, and the indicated stimulants.  All stimulants, 
including anti-IgM (goat F(ab’)2 anti-mouse IgM; Southern Biotech), lipopolysaccharide 
(055:B5; Sigma Aldrich), CpG (ODN 1826; Invivogen), mouse IL-4 (Biolegend), mouse 
  
104 
CD40 ligand (eBioscience), phorbol-12-myristate-13-acetate (PMA; Calbiochem), and 
ionomycin (Calbiochem) were prepared as per manufacturers instructions and used at the 
indicated concentration in the text. 
 
Cell sorting for RNA extraction 
For miR-132 expression studies, we sorted cells either using MACS columns (Miltenyi) or 
by FACS. To isolate B cells, RBC depleted bone marrow or spleen samples were sorted on 
MACS columns (Miltenyi). Briefly, bone marrow or spleen cells were incubated first with 
biotin-conjugated CD19 (positive-selection) or CD43 (negative selection) antibodies 
(BioLegend) in MACS sorting buffer (Miltenyi), followed by incubation with streptavidin-
conjugated magnetic beads (Miltenyi) as per manufacturers protocol, before being 
separated on the columns. For profiling studies on B cell progenitors, cells were sorted on a 
FACSAria IIu cell sorter (Becton Dickinson) at the Caltech Flow Cytometry Core Facility 
after surface staining with fluorescent antibodies for B220, CD19, CD43, CD24, IgM, 
CD11b, CD3e, Gr-1, Ter119, Nk1.1, Sca1, cKit, Flt3, and IL7Ra (BioLegend). RNA was 
then harvested from these cells using the miRNAeasy RNA prep kit (Qiagen). 
 
Expression profiling and qPCR 
RNA harvested from the respective cell populations was analyzed as previously described 
(Chaudhuri et al., 2012) by real time qPCR (RT-qPCR) with a 7300 Real-Time PCR 
machine (Applied Biosystems). We used TaqMan MicroRNA Assays (Life Technologies) 
for miR-132, miR-212 and snoRNA-202 (control) to perform TaqMan qPCR as per 
manufacturers instructions.  We performed SYBR Green-based RT-qPCR for mRNA 
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expression of mouse Sox4, Ikzf1, Ebf1, E2A, Pax5, PU.1, and Rag1 following cDNA 
synthesis using qScript cDNA SuperMix (Quanta) and detection with PerfeCTa qPCR 
Fastmix with ROX (Quanta) as per manufacturers instructions. Table S2 lists primers used 
for qPCR. 
 
Luciferase reporter assays 
We performed luciferase assays for the SOX4 3’UTR as has been previously described 
(Rao et al., 2010). 4 x 105 cells HEK293T cells, plated for 24 hours, were transfected with 
either pCDNA or pCDNA-miR-132, a β-gal expression vector, and a pMiReport vector 
containing either no 3’UTR, the Sox4 3’UTR, or a Sox4 3’UTR with a mutant miR-132 
binding site. 48 hours later, cells were lysed using Reporter Lysis Buffer (Promega) and 
luciferase and β-gal expression was analyzed, respectively, using a Dual Luciferase Kit 
(Promega) and a chemiluminescent β-gal reporter kit (Roche), respectively.  
 
Immunoblotting 
Whole bone marrow samples and bone marrow B cells were sorted using the procedure 
described for RNA preparation using MACS columns (Miltenyi). Whole protein lysates 
were collected using RIPA lysis buffer (Sigma), and were subjected to gel-electrophoresis 
on a mini-PROTEAN TGX gradient (4-15%) gel (Bio-Rad), and then transfered onto a 
PVDF membrane. Proteins were detected using the following antibodies: anti-Sox4 
(154C4a) (Abcam), actin-HRP (sc-1616) (Santa Cruz Biotechnology), and goat anti-
mouse-IgG-HRP (sc-2005) (Santa Cruz Biotechnology).  
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Flow cytometry 
Respective tissue samples were collected from the appropriate mice as indicated in the text, 
RBC lysed (BioLegend), and processed as previously described (Chaudhuri et al., 2012). 
They were subsequently stained with a combination of flurophore-conjugated antibodies 
(all from BioLegend), such as CD45, B220, CD19, CD43, CD24, IgM, CD11b, CD3e, Gr-
1, Ter119, Nk1.1, Sca1, cKit, Flt3, and IL7Ra. Surface markers were detected and analyzed 
using a MACSQuant10 Flow Cytometry machine (Miltenyi). Gating and analysis was 
performed using FlowJo software. 
 
Animals 
All experiments were approved by the California Institute of Technology Institutional 
Animal Care and Use Committee (IACUC). C57BL/6 WT and miR-212/132-/- mice were 
bred and housed in the Caltech Office of Laboratory Animal Resources (OLAR) facility. 
Bone marrow reconstitution experiments were performed as previously described 
(Chaudhuri et al., 2012) using donor cells from C57BL/6 WT mice or Eµ-myc mice, and 
with the appropriate retroviral vectors as described in the text. In vivo B cell depletion 
studies were performed by intraperitoneal delivery of 50µg of mouse anti-CD20 (5D2) 
(Genentech) in 250uL of phosphate buffered saline (PBS). Treated mice were subsequently 
bled at the indicated time points and cell populations in the peripheral blood were analyzed 
using FACS as described above.  
 
RNA-seq data generation and analysis 
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RNA-seq libraries were prepared from polyA+ selected RNA using the TruSeq RNA 
Sample Preparation Kit at the Millard and Muriel Jacobs Genetics and Genomics 
Laboratory at Caltech. Libraries were sequenced on the Illumina HiSeq 2500 generating 
single-end 50bp reads. The refSeq annotation for the mm9 version of the mouse genome 
was used to create a transcriptome Bowtie (version 0.12.7) (Langmead et al., 2009) index, 
to which reads were aligned with the following settings: “-v 3 -a”. Gene expression levels 
were estimated using eXpress (version 1.2.2) (Roberts and Pachter, 2013), and the effective 
count values were used as input to DESeq (Anders and Huber, 2010) for evaluating 
differential expression.  
 
Statistical tests 
All statistical analysis was done in Graphpad Prism software using an unpaired Student’s t 
test. Data was reported as mean ± SEM. Significance measurements were marked as 
follows: * p < 0.05, ** p < 0.01, ** p < 0.001, or NS for not significant.  
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Figure Legends 
Figure 1. miR-132 is induced in B cells and over-expression of miR-132 in mice alters B-
cell development. (A) Relative miR-132 expression in primary splenic B cells stimulated 
with anti-IgM (5µg/mL), LPS (20µg/mL), CD40L (2µg/mL), IL-4 (10ng/mL), or CpG 
(0.5µM) for the indicated durations. miR-132 expression was detected using Taqman RT-
qPCR (n=3). (B)-(G) WT C57BL/6 mice were lethally irradiated and reconstituted with 
donor HPSCs expressing either a control (MG) or a miR-132 over-expressing (miR-132) 
vector. Mice were analyzed at 4 months post-reconstitution (n>10 mice per group). (B) 
Frequency of peripheral blood B cells (B220+) in MG and miR-132 mice. (C) Total 
number of peripheral blood B cells (B220+) in MG and miR-132 mice. (D) Total number 
of leukocytes (CD45+) and B cells (CD19+) in the spleen of MG and miR-132 mice. (E) 
Total number of plasma cells (CD138+) in the spleen of MG and miR-132 mice. (F) Total 
number of B cells (CD19+) in the bone marrow of MG and mIR-132 mice. (G) Total 
number of myeloid cells (CD11b+) and granulocytes (Gr-1+) in the bone marrow of MG 
and miR-132 mice. Data represent at least three independent experiments. The mean ± 
SEM is shown. * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 using a 
Student’s t test.  
 
Figure 2. miR-132 causes a block in early B cell development. (A)-(B) B cells were 
purified from miR-212/132-/- and WT mice and subsequently either left unstimulated, or 
stimulated for 8 hours or 20 hours with anti-IgM (5µg/mL). RNA was harvested from the 
cells and RNA-seq libraries were generated and sequenced. (A) Heat map and clustering 
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indicating the number of differentially expressed genes between each sample. (B) 
Enriched functional annotations for genes differentially expressed between miR-212/132-/- 
and WT B cells at any of the time points. (C) miR-132 expression in various bone marrow 
B cell progenitor populations. Cells were sorted by FACS directly into RNA lysis buffer 
and miR-132 expression was detected using Taqman RT-qPCR (n=2). (D)-(G) Analysis of 
MG and miR-132 mice at 4 months post-reconstitution (n>10 mice per group). (D) 
Frequency of CLPs (Lineage-cKit+Sca1+Flt3+IL7Ra+) in the bone marrow MG and miR-
132 mice. (E) Frequency of pre-pro-B cells (B220+IgM-CD43+CD24-) in the bone 
marrow of MG and miR-132 mice. (F) Frequency of pro-B cells (B220+IgM-
CD43+CD24+) in the bone marrow of MG and miR-132 mice. (G) Frequency of pre-B 
cells (B220+IgM-CD43-) in the bone marrow of MG and miR-132 mice. Data represent at 
least three independent experiments. The mean ± SEM is shown. * denotes p < 0.05, ** 
denotes p < 0.01, and *** denotes p < 0.001 using a Student’s t test.  
 
Figure 3. miR-212/132 regulates B cell apoptosis. (A) Frequency of bone marrow B cells 
(CD19+) and myeloid cells (CD11b+) from MG and miR-132 mice that demonstrated 
positive staining for AnnexinV and 7-AAD. (B) miR-212/132-/- and WT splenic B cells 
were isolated and cultured in vitro for the indicated durations. Graph demonstrates the 
frequency of AnnV+ cells at each time point. (C) miR-212/132-/- or WT splenic B cells 
were cultured in the presence of no stimulation, or with LPS (20µg/mL) or CpG (0.5µM). 
Proliferation of these cells was measured at the indicated time points using the WST-1 cell 
proliferation assay (see methods). Data represent two independent experiments. The mean 
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± SEM is shown. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 
using a Student’s t test.  
 
Figure 4. Loss of miR-212/132 alters B cell development under non-homeostatic 
conditions. 16-week old miR-212/132-/- (KO) and WT mice were treated with either an 
anti-CD20 antibody (30µg/mouse) or phosphate buffered saline (PBS) (n=3-4 mice per 
group). Graph indicates the frequency of B cells (B220+) in the peripheral blood at each of 
the indicated time points after anti-CD20 antibody treatment. Data represent two 
independent experiments. The mean ± SEM is shown. * denotes p < 0.05 using a Student’s 
t test.  
 
Figure 5. SOX4 is a direct target of miR-132 and is a key regulator of B cell development. 
(A) Schematic of the predicted miR-132 binding site in the Sox4 3’ UTR. (B) Relative 
luciferase expression in HEK293T cells transfected with a miR-132 over-expression vector 
and either a vector containing luciferase only (control), luciferase and the Sox4 3’ UTR 
immediately downstream (Sox4 3’ UTR), or a vector containing luciferase and a Sox4 3’ 
UTR with a mutated miR-132 binding site (Sox4 3’ UTR mut). (C) Sox4 transcript 
expression level, obtained by RT-qPCR, in B cells purified from the bone marrow of MG 
and mIR-132 mice. (D) Sox4 protein expression levels, obtained by Western Blot, in B 
cells purified from the bone marrow of MG and mIR-132 mice. (E)-(I) WT C57BL/6 mice 
were lethally irradiated and reconstituted with donor bone marrow cells transduced with 
either a control (MG) or Sox4 shRNA expressing (shSOX4) retroviral vector. Mice were 
analyzed at 4 months post-reconstitution. (E) Frequency of B cells (CD19+) in the spleen 
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of MG and shSOX4 mice. (F) Frequency of B cells (B220+) in the bone marrow of MG 
and shSOX4 mice. (G) Frequency of pre-pro-B cells in the bone marrow of MG and 
shSOX4 mice. (H) Frequency of pro-B cells in the bone marrow of MG and shSOX4 mice. 
(I) Frequency of pre-B cells in the bone marrow of MG and shSOX4 mice. Data represent 
two independent experiments. The mean ± SEM is shown. * denotes p < 0.05, ** denotes p 
< 0.01, and *** denotes p < 0.001 using a Student’s t test.  
 
Figure 6. Co-expression of Sox4 rescues the defect in B cell development with expression 
of miR-132 alone. WT C57BL/6 mice were lethally irradiated and reconstituted with donor 
bone marrow cells expressing either a control (MIG), a miR-132 over-expressing (MIG-
miR-132), a SOX4 over-expressing (MIG-SOX4), or a SOX4 and miR-132 over-
expressing (MIG-SOX4-miR-132) retroviral vector (n=5 mice per group). (A) Validation 
of miR-132 over-expression in donor HSPCs transduced with the labeled constructs. (B) 
Validation of Sox4 expression in donor HSPCs transduced with the labeled constructs. (C) 
Frequency of B cells in the peripheral blood of MIG, MIG-miR-132, MIG-SOX4, and 
MIG-SOX4-miR-132 mice at 3 months post-reconstitution. Data represent the combination 
of two independent experiments. The mean ± SEM is shown. * denotes p < 0.05, ** 
denotes p < 0.01, and *** denotes p < 0.001 using a Student’s t test.  
 
Figure 7. Enforced expression of miR-132 inhibits the development of spontaneous B cell 
cancers in cells with the Eµ-myc transgene. (A) Cells from a pre-B cell lymphoblastic 
leukemia line, 70Z/3, were transduced with a control vector (MGP) or a miR-132 over-
expressing vector (miR-132) and cultured for 48 hours with or without LPS (20µg/mL). 
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The frequency of cells expressing AnnV was then measured by FACS. (B)-(E) 
C57BL/6 mice were reconstituted with donor HSPCs from WT or Eµ-myc mice that were 
either transduced with a control vector (MG) or miR-132 over-expressing vector (miR-
132). These mice were followed for 4 months and harvested for analysis at this time point 
(n=8-10 mice). (B) Survival curve for all experimental cohorts. Frequency of (C) bone 
marrow B cells (CD19+), (D) myeloid cells (CD11b+), and (E) pre-B cells (B220+IgM-
CD43-) in all cohorts. Data represent two independent experiments. The mean ± SEM is 
shown. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a 
Student’s t test.  
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Supplemental Figure Legends 
Figure S1, refers to Figure 1. miR-212/132 is induced in B cells by activation of the B 
cell receptor (BCR). (A) miR-132 expression in various splenic and bone marrow cell 
populations. RNA was harvested from the indicated cell populations and miR-132 
expression was detected using Taqman RT-qPCR (n=3). (B)-(E) Splenic B cells were 
purified from C57BL/6 mice and cultured in the presence of the indicated stimulants for the 
indicated duration of time. The expression of miR-132 and miR-212 was detected using 
Taqman RT-qPCR (n=3). (B) Relative expression of miR-212 in splenic B cells stimulated 
with LPS (20µg/mL) or anti-IgM (aIgM; 5µg/mL) for the indicated times. (C) Relative 
expression of miR-132 in splenic B cells stimulated for 8 hours with a combination of 
PMA (15ng/mL), ionomycin (0.5µg/mL), and anti-IgM (5µg/mL) as indicated. (D) 
Relative expression of miR-132 in splenic B cells stimulated for 8 hours with varying 
concentrations of anti-IgM as indicated. (E) Relative expression of miR-132 in splenic B 
cells obtained from miR-212/132-/- or WT mice and stimulated with LPS (20µg/mL) or 
anti-IgM (5µg/mL) for the indicated time points. Data represents two independent 
experiments and is represented as mean ± SEM. 
 
Figure S2, refers to Figure 1 and 2. Enforced expression of miR-132 alters B cell output 
in mice up to 9 months post-reconstitution. WT C57BL/6 mice were lethally irradiated and 
reconstituted with donor HPSCs expressing either a control (MG) or a miR-132 over-
expressing (miR-132) vector. Mice were analyzed at 9 months post-reconstitution (n>6 
mice per group). (A) Total number of leukocytes (CD45+), B cells (CD19+) and T cells 
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(CD3e+) in the spleen of MG and miR-132 mice. (B) Total number of myeloid cells 
(CD11b+), B cells (CD19+), and T cells (CD3e+) in the bone marrow of MG and miR-132 
mice. Data represents at least three independent experiments and is represented as mean ± 
SEM. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a Student’s 
t test.  
 
Figure S3, refers to Figures 1 and 2. Enforced expression of miR-212 has a marginal 
effect on B cell output. WT C57BL/6 mice were lethally irradiated and reconstituted with 
donor HPSCs expressing either a control (MG) or a miR-212 over-expressing (miR-212) 
vector. Mice were analyzed at 4 months post-reconstitution (n=4-5 mice per group). (A) 
Frequency of B cells (CD19+) in the spleen of MG and miR-212 mice. (B) Frequency of B 
cells (B220+) in the bone marrow of MG and miR-212 mice. (C) Frequency of pre-pro-B 
cells (B220+IgM-CD43+CD24-) in the bone marrow of MG and miR-212 mice. (D) 
Frequency of pro-B cells (B220+IgM-CD43+CD24+) in the bone marrow of MG and miR-
212 mice. (E) Frequency of pro-B cells (B220+IgM-CD43-) in the bone marrow of MG 
and miR-212 mice. Data represents at least three independent experiments and is 
represented as mean ± SEM. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 
0.001 using a Student’s t test.  
 
Figure S4, refers to Figure 2. Stimulation of B cells through the B cell receptor (BCR) 
results in dramatic gene expression changes. B cells were purified from miR-212/132-/- and 
WT mice and subsequently either left unstimulated, or stimulated for 8 hours or 20 hours 
with anti-IgM (5µg/mL). RNA was harvested from the cells and processed for RNA-
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sequencing. (A) Summary of differential gene expression analysis between samples. 
Table shows the number of upregulated genes in the described row sample compared to the 
described column sample. (B) Functional annotations for differentially expressed genes 
between WT stimulated B cells (8 hours or 20 hours with anti-IgM) compared to WT 
unstimulated B cells.  
 
Figure S5, refers to Figure 3. miR-212/132 regulates B cell apoptosis. miR-212/132-/- and 
WT splenic B cells were isolated and cultured in vitro with anti-IgM stimulation (5ug/mL) 
for the indicated durations. Graph demonstrates the frequency of AnnV+ cells at each time 
point. Data represents two independent experiments and is represented as mean ± SEM. * 
denotes p < 0.05 using a Student’s t test.  
 
Figure S6, refers to Figure 4. miR-212/132-/- mice demonstrate no observable defect in B 
cell output under steady state conditions. (A)-(C) miR-212/132-/- and WT mice were 
analyzed at 12-16 weeks of age to understand the physiological contribution of miR-
212/132 on B cell output (n=7-10 mice per group). (A) Frequency of B cells (CD19+) in 
the peripheral blood of miR-212/132-/- and WT mice. (B) Frequency of B cells (CD19+) in 
the spleen of miR-212/132-/- and WT mice. (C) Frequency of B cells (CD19+) in the bone 
marrow of miR-212/132-/- and WT mice. (D) 6-month old miR-212/132-/- and WT mice 
were treated with 9 evenly-spaced LPS (1mg/kg of body weight) or PBS injections over 
one month. Graphs shows the total number of B cells (CD19+) in the spleen after the last 
injection. * denotes p < 0.05 using a Student’s t test.  
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Figure S7, refers to Figure 5. miR-212/132 targets Sox4 in B cells. (A) Sox4 protein 
expression by Western Blot in whole bone marrow lysate from MG and miR-132 mice. (B) 
Sox4 protein expression by Western Blot in 70Z/3 cells transduced with a control vector 
(MG) or a miR-132 over-expression vector (miR-132). (C) Transcript expression levels of 
PU.1, Ikzf1, Ebf1, E2A, Pax5, and Rag1 obtained by RT-qPCR from B cells purified from 
the bone marrow of MG and miR-132 mice. Data represents two independent experiments 
and is represented as mean ± SEM.  
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Supplemental Tables 
Table S1: sequences for SOX4 shRNA constructs. 
SOX4 shRNA sequence (in miR-155-arms-and-loop-format) 
mmu-FOXO3 shRNA #1 gaaggctgtaTGCTGTTGAGCAGCTTCCAGCGTTTGGTTTTGGCCACTGACTGACCAAACGCTAAGCTGCTCAAcaggacacaaggcctg 
mmu-FOXO3 shRNA #2 gaaggctgtaTGCTGTTCACTTTCTTGTCGGCAGGGGTTTTGGCCACTGACTGACCCCTGCCGAAGAAAGTGAAcaggacacaaggcctg 
mmu-FOXO3 shRNA #3 gaaggctgtaTGCTGTTTAGAAGCTTTGCTTGGCTTGTTTTGGCCACTGACTGACAAGCCAAGAAGCTTCTAAAcaggacacaaggcctg 
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Table S2: primer sequences used for qPCR. 
Primer sequences 
SOX4 F GACAGCGACAAGATTCCGTTC 
SOX4 R GTTGCCCGACTTCACCTTC 
EBF1 F GCATCCAACGGAGTGGAAG 
EBF1 R GATTTCCGCAGGTTAGAAGGC 
E2A F GGGTGCCAGCGAGATCAAG 
E2A R ATGAGCAGTTTGGTCTGCGG 
PAX5 F CCATCAGGACAGGACATGGAG 
PAX5 R GGCAAGTTCCACTATCCTTTGG 
PU.1 F ATGTTACAGGCGTGCAAAATGG 
PU.1 R TGATCGCTATGGCTTTCTCCA 
IL-7R F GCGGACGATCACTCCTTCTG 
IL-7R R AGCCCCACATATTTGAAATTCCA 
Rag1 F ACCCGATGAAATTCAACACCC 
Rag1 R CTGGAACTACTGGAGACTGTTCT 
Ikzf1 F ATGTCCCAAGTTTCAGGAAAGG 
Ikzf11 R GCACGCCCATTCTCTTCATC 
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Figure'4.'Loss'of'miR,212/132'alters'B'cell'development'under'
non,homeosta=c'condi=ons.''
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SOX4 is regulated by miR-132 
SOX4 CDS 3’ UTR 
miR-132 7mer-m8 
Human 3’ UTR:  5’ ---UUAAAGAUUUCUGUAUAAGACUGUUGAGCAGUUUUUA--- 3’ 
Rat 3’ UTR:   5’ ---UUGAAGAUUUCUGUAUAAGACUGUUGAGCAUUUUUUA--- 3’ 
Mouse 3’ UTR:  5’ ---UUGAAGAUUUCUGUAUAAGACUGUUGAGCAGUUUUUA--- 3’ 
 
microRNA-132:     3’ GCUGGUACCGACAUCUGACAAU 5’ 
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Figure'S1.'miR,212/132'is'induced'in'B'cells'by'ac=va=on'of'the'B'
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Figure'S3.'Enforced'expression'of'miR,212'has'a'marginal'effect'
on'B'cell'output.''
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Figure'S4.'S=mula=on'of'B'cells'through'the'B'cell'receptor'(BCR)'
results'in'drama=c'gene'expression'changes.''
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Figure'S5.'miR,212/132'regulates'B'cell'apoptosis.''
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Figure'S6.'miR,212/132,/,'mice'demonstrate'no'observable'defect'
in'B'cell'output'under'steady'state'condi=ons.'
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Figure'S7.'miR,212/132'targets'SOX4'in'B'cells.''
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C h a p t e r  4  
Chapter 4: microRNA-125b regulates hematopoiesis by 
targeting Lin28A 
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Abstract  
MicroRNA-125b is upregulated in patients with leukemia. Overexpression of miR-125b 
alone in mice causes a very aggressive, transplantable myeloid leukemia. Prior to leukemia, 
these mice do not display elevation of white blood cells in the spleen or bone marrow; 
rather, the hematopoietic compartment shows lineage-skewing with myeloid cell numbers 
dramatically increased and B cell numbers severely diminished. MiR-125b exerts this 
effect by upregulating the number of common myeloid progenitors while inhibiting 
development of pre-B cells. We applied a miR-125b ‘sponge’ loss-of-function system in 
vivo to show that miR-125b physiologically regulates hematopoietic development. 
Investigating the mechanism by which miR-125b regulates hematopoiesis, we found that 
among a panel of candidate targets, the mRNA for Lin28A, an induced pluripotent stem 
cell (IPSC) gene, was most repressed by miR-125b in mouse hematopoietic stem and 
progenitor cells. Overexpressing Lin28A in the mouse hematopoietic system mimicked the 
phenotype observed upon inhibiting miR-125b function, leading to a decrease in 
hematopoietic development. Relevant to the miR- 125b overexpression phenotype, we also 
found that knockdown of Lin28A led to hematopoietic lineage-skewing, with increased 
myeloid and decreased B cell numbers. Thus, the miR-125b target Lin28A is an important 
regulator of hematopoiesis and a primary target of miR-125b in the hematopoietic system.  
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Introduction  
Lin28A is an important regulator in early embryogenesis in mice and humans 
(Viswanathan and Daley, 2010). The levels of Lin28A are enriched in embryonic stem 
(ES) cells and decrease as these cells differentiate (Viswanathan and Daley, 2010). Ectopic 
expression of Lin28A along with three other genes (Oct4, Sox2, and Nanog) causes de-
differentiation of mature human cells into induced pluripotent stem (IPS) cells (Yu et al., 
2007). This demonstrates the power of Lin28A to endow cells with pluripotent qualities. 
Still, it remains to be seen whether Lin28A also plays developmental roles in biological 
systems arising from adult stem cells, such as hematopoiesis.  
In this study, we examine the role of miR-125b in inducing cancer and show that 
overexpression of this microRNA induces a pre-leukemic state before the aggressive frank 
leukemia is evident. This pre-leukemic state is characterized by overproduction of myeloid 
cells and their precursors as well as inhibition of B cell development. We then show that 
the most affected target gene of miR-125b is Lin28A and that Lin28A downregulation can 
mimic the pre-leukemic state induced by miR-125b. Furthermore, downregulation of miR-
125b has profound effects on normal hematopoiesis and Lin28A overexpression mimics 
those effects.  
Results  
MiR-125b ectopic expression favors myeloid differentiation and causes a highly invasive 
myeloid leukemia  
Previously, we showed that over-expression of miR-125b in bone marrow transplanted 
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recipient mice causes a myeloid leukemia 4-6 months after bone marrow reconstitution 
(O'Connell et al., 2010). Here, we found that the neoplastic myeloid cells infiltrate non- 
hematopoietic organs, including the brain, and overwhelm the periphery (Fig 1, Fig S1). 
Also, mice over-expressing miR-125a developed an aggressive leukemia, as demonstrated 
by enlarged spleen and infiltration into the liver and kidneys (Fig S2). These mice died by 
six months post-reconstitution. Thus, dysregulated expression of miR-125b or its paralogue 
leads to an aggressive leukemia that efficiently invades non- hematopoietic organs.  
To understand the initial events that precede the frank leukemia, we examined the spleen 
and bone marrow at seven weeks after reconstitution, a time well before the onset of 
cancer, as indicated by similar white blood cell counts in the spleen and bone marrow of 
MG and MG-125b animals (Fig 2A, Fig S3, Fig S4A-B). At this time, MG- 125b animals 
showed dramatic increases in all myeloid lineages, including granulocytes, macrophages, 
and dendritic cells with T cell numbers being similar to those in the MG mice (Fig 2A, 
S4C-E). However, B cell numbers were significantly decreased in these miR-125b over-
expressing animals (Fig 2A, S4F). Whether miR- 125b physiologically regulates B cell 
development will require further studies. Thus, miR-125b over-expression at the pre-
cancerous stage causes a lineage-skewing of the hematopoietic compartment with myeloid 
cell numbers elevated and B cells diminished.  
To investigate the developmental stage at which miR-125b over-expression promotes 
myelopoiesis and compromises B cell development, we analyzed hematopoietic stem and 
progenitor cell (HSPC) numbers in the bone marrow at 7 weeks following bone marrow 
transplantation. In these mice, the numbers of hematopoietic stem cell (HSC) numbers 
  
142 
were similar in MG-125b animals compared to MG controls (Fig S4G, H). Progenitors 
directly downstream of HSCs, however, including multipotent progenitors (MPPs), 
common myeloid progenitors and granulocyte macrophage progenitors (CMP/GMPs), 
myeloid-erythroid progenitors (MEPs), and common lymphoid progenitors (CLPs), were 
all significantly increased however (Fig 2B). Of these, CMP/GMPs were the most 
drastically augmented, being up 8.4-fold in MG-125b animals compared to controls (Fig 
2B). Notably, pre-B cell numbers were severely decreased (Fig 2B), providing a 
developmental basis for the decreased B cell numbers we observed in MG- 125b animals. 
This also indicates that miR-125b overexpression causes a developmental block between 
the CLP and pre-B cell stages. In summary, we show here that prior to the onset of 
leukemic disease, miR-125b skews hematopoietic differentiation towards the myeloid 
lineage, likely by increasing CMP/GMP and blocking B cell development.  
Physiological regulation of hematopoiesis by miR-125b  
While over-expression studies are relevant to the role of miR-125b role as an oncomiR, we 
developed a loss-of-function system to assess the potential physiological role of miR-125b 
in hematopoiesis. We generated a ‘sponge’ decoy to competitively inhibit miR-125b 
binding to its natural targets (Fig 5SA) (Ebert et al., 2007; Ebert and Sharp, 2010; 
Starczynowski et al., 2010; Wang et al., 2011). Of note is that the ‘sponge’ does not 
decrease miR-125b expression but rather serves as a decoy to compete miR- 125b away 
from endogenous targets. Indeed, the sponge decoy (MG-sponge) was capable of 
significantly de-repressing a luciferase reporter vector containing an artificial 3’ UTR with 
two perfect miR-125b complementary sequences (Fig S5B). Demonstrating the 
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effectiveness of this approach, a UTR-less reporter vector was not de-repressed by the 
sponge (Fig S5C). To determine the hematopoietic effect of miR-125b loss-of- function, 
recipient mice were reconstituted with equal numbers of sorted GFP
+ 
MG and MG-sponge 
transduced bone marrow cells (Fig S5D). The MG-sponge mice at one month post-
reconstitution had significantly fewer white blood cells (CD45
+
), myeloid cells (CD45
+ 
CD11b
+
), pre-erythrocytes (CD45
+ 
Ter119
+
), and granulocytes (CD45
+ 
Gr1
+
) and 
compared to the MG controls (Fig 3). The blood was also noticeably thinner in the sponge 
mice compared to controls, indicating that mature erythrocytes were decreased as well. The 
sponge data indicates an important physiological role for miR- 125b in hematopoietic 
development, while the overexpression data shows that excess levels lead to cancer.  
Lin28A is a primary target of miR-125b in the hematopoietic system  
To identify miR-125b targets that might regulate hematopoietic development, we 
performed a nonbiased screen using Targetscan (Friedman et al., 2009; Grimson et al., 
2007; Lewis et al., 2005) to isolate putative miR-125b targets with PConserved Targeting > 
0.8 (P < 0.2 that the putative microRNA site is evolutionarily maintained due to selective 
microRNA targeting rather than chance) (Friedman et al., 2009). Application of this screen 
yielded 192 genes. Gene ontology analyses indicate that these genes are functionally 
enriched for biological processes that include transcriptional regulation, vasculature 
development, proteolysis, and apoptosis (David Functional Annotation Bioinformatics, P < 
0.05). We focused on those that were pro- apoptotic or involved with stem cell regulation 
as these processes have been correlated with leukemic development. This yielded four 
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candidate genes, Bak1, Trp53inp1, BMF and Lin28A, which independently have been 
previously validated as miR-125b targets by other groups (Enomoto et al., 2011; Shi et al., 
2007; Wu and Belasco, 2005; Xia et al., 2009). We examined and confirmed by qPCR that 
miR-125b represses these genes, including Lin28A, in 5-FU treated bone marrow 
hematopoietic cells enriched for HSPCs (Fig 4A). As evidence of these genes being miR-
125b direct targets, we found that the 3’ UTR luciferase reporter of all of these genes, but 
not the negative control Picalm, were significantly repressed by miR-125b over-expression 
(Fig 4B). Notably, endogenous expression of Lin28A, Trp53inp1, and BMF were de- 
repressed by the miR-125b sponge decoy in HSPC-enriched bone marrow (Fig S6A). The 
miR-125b sponge decoy also de-repressed 5-fold a luciferase reporter containing the mouse 
Lin28A 3’ UTR (Fig 4C), which contains a 9 nucleotide miR-125b seed sequence (Fig 
S6B). Demonstrating that the miR-125b:Lin28A interaction exhibits species conservation 
between mouse and human hematopoietic cells, human myeloid K562 cells transduced 
with either MGP, MGP-125b-1, MGP-125b-2, or a seed mutant of miR-125b exhibited 
seed-dependent repression of Lin28A by both miR-125b species at both the RNA and 
protein level (Fig 4D, Fig S6C-E). Of note, the expression of Lin28B isoform was not 
repressed by miR-125b (Fig S6F, G). In summary, miR-125b directly represses Lin28A in 
hematopoietic cells, an interaction conserved between mouse and human. Previously, up-
regulation of Lin28A and Lin28B has been associated with cancer development. Thus, we 
examined the expression of these genes in leukemic samples over-expressing miR-125b but 
found that Lin28A and Lin28B expression was similar in the cancer samples and control 
cells (Fig S7).  
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Lin28A regulates aspects of hematopoiesis that mirror those controlled by miR- 125b  
The regulation of Lin28A by miR-125b is highly conserved across species. The C. elegans 
homologue of miR-125b Lin-4 also represses the RNA-binding protein Lin28A. The Lin-
4:Lin28A cascade has been shown to be critical for proper worm development. However, a 
potential critical developmental function of miR-125b:Lin28A signaling in mammals has 
not yet been explored. In addition, Lin28A is known to be involved in maintaining 
pluripotency of embryonic stem cells, but its role in other biological events, such as 
hematopoiesis, has not been fully characterized. Thus, we were interested in determining 
whether miR-125b-mediated repression of Lin28A has a role in the hematopoietic system. 
We bypassed the repressive effect exerted by endogenous miR-125b by over-expressing 
Lin28A lacking its 3’UTR. We utilized the MSCV-IRES-GFP (MIG) vector system 
(Bousquet et al., 2008), which allowed the co-expression of Lin28A and GFP from the 
same vector. A Western blot was performed to confirm expression of Lin28A from the 
MIG-Lin28A vector in transfected 293T cells (Fig S8A). Next we performed bone marrow 
transplant experiments with HSPC-enriched bone marrow cells transduced with either MIG 
or MIG-Lin28A. We achieved over 80% transduction efficiency as measure by GFP-
positive cells (Fig S8B). Similar to mice reconstituted with the miR-125b sponge decoy 
(Fig 3), animals with Lin28A over-expression had significant decreases in total white blood 
cells (CD45
+
), total myeloid cells (CD45
+ 
CD11b
+
), granulocytes (CD45
+ 
Gr1
+
), and 
erythrocytes (Ter119
+ 
CD11b
-
) (Fig 5A-D). Also similar to the sponge mice, the blood 
was noticeably thinner from MIG-Lin28A animals compared to MIG controls, likely due to 
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the diminished erythrocyte numbers we observed. Of importance, whereas all the 
controls remained healthy, the Lin28A over- expressing mice with the thinnest blood (2 out 
of 15) died at five weeks post-reconstitution, likely as a consequence of impaired 
hematopoietic development. Thus, over-expressing Lin28A in the hematopoietic system 
mirrored the phenotypes observed upon miR-125b inhibition (Fig 3).  
Next, we used Lin28A loss-of-function studies to examine whether Lin28A physiologically 
regulates hematopoiesis. Also, loss-of-function assays allowed us to determine whether 
inhibiting Lin28A function would mimic specific aspects of hematopoietic development 
observed upon over-expressing miR-125b. Thus we transduced HSPC-enriched bone 
marrow with Lin28A shRNA and achieved ~70% transduction with a 2-fold knockdown of 
Lin28A as assessed by qPCR (Fig 6A-B), less than the level of repression exerted by miR-
125b over-expression (Fig 4A). Strikingly, mice reconstituted with shLin28A exhibited 
similar but less dramatic features of hematopoietic development to those caused by over-
expression of miR-125b at the pre- cancerous stage: expansion of myeloid cells 
(CD45
+
CD11b
+
, CD45
+
Gr1
+
) and a decrease of B cells (CD19
+
CD11b
-
) (Fig 6C-E). The 
Lin28A knockdown mimicked the alteration of the hematopoietic system that we observed 
in miR-125b over-expressers (Fig 2A), namely increased myeloid cells and decreased B 
cells (Fig 6C-E). Thus, we show that Lin28A is a primary target of miR-125b in 
hematopoiesis and that its levels influence development of the hematopoietic system.  
Discussion  
We demonstrate here that 1) miR-125b over-expression causes a highly invasive myeloid 
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leukemia; 2) in the pre-leukemic stage of disease, miR-125b induces a skewing of the 
hematopoietic system favoring myeloid development; 3) before terminal leukemia 
development, miR-125b drastically increases CMP/GMP numbers; 4) In addition to the 
pathological role of miR-125b, it also physiologically regulates hematopoiesis as shown by 
downregulating it with a ‘sponge’ construct; 5) Lin28A is a bona fide primary target of 
miR-125b in hematopoietic cells; and 6) Lin28A over-expression and knockdown mimic 
important aspects of miR-125b loss-of-function and gain-of-function, respectively. We 
conclude that miR-125b physiologically regulates hematopoiesis, and that constitutive 
over- expression of miR-125b in our experimental system leads to uncontrolled generation 
of myeloid progenitors and mature myeloid cells that subsequently causes a myeloid 
leukemia. We also conclude that the miR-125b primary target Lin28A is an important 
regulator of hematopoietic development.  
In this study, we observed that miR-125b over-expression induces an aggressive myeloid 
leukemia that is highly invasive. Of note, two mice out of the fourteen analyzed in two 
cohorts exhibited significantly increased lymphoid cells as well, supporting studies by 
Bousquet et al., Ooi et al., and Enomoto et al. that miR-125b is capable of causing 
leukemias involving lymphoid cell types (Bousquet et al., 2010; Enomoto et al., 2011; Ooi 
et al., 2010). Interestingly, Enomoto et al. confirms the remarkable potency of miR-125b as 
an oncomiR by showing that B-cell restricted ectopic expression of miR-125b can drive 
lymphoid leukemia (Enomoto et al., 2011). In our system, miR-125b and GFP is expressed 
from the same transcript. Interestingly, the GFP intensity in the CD11b
+ 
myeloid cells of 
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the MG-125b mice was much higher than that of CD19
+ 
B cells (geometric mean 
fluorescence of 85.2±7.3 versus 15.7±0.8, respectively), suggesting that miR-125b is 
expressed more highly in the former lineages. This might explain the predominance of 
myeloid leukemia observed in our system. Of importance, miR-125b has been found to be 
over-expressed in a variety of human leukemias, including AML (Bousquet et al., 2010; 
Enomoto et al., 2011), CML (Enomoto et al., 2011), AmkL (Gefen et al., 2010), and ALL 
(Enomoto et al., 2011; Gefen et al., 2010), suggesting that deregulated miR-125b 
expression in different contexts can lead to distinct types of cancer.  
Interestingly, Ooi et al. showed that recipient mice reconstituted with miR-125b over-
expression display elevated HSC numbers (Ooi et al., 2010). Although we did not observe 
an increase in HSC number, our study does not exclude that miR-125b regulates HSC 
development; the discrepancy likely reflects differences in experimental models used 
between the two studies. Ooi et al. overexpressed miR-125b in purified HSCs using a 
lentiviral system, whereas we ectopically expressed the microRNAs in unsorted progenitor-
enriched bone marrow hematopoietic cells using a retroviral system. It is possible that our 
retroviral system may not adequately over-express miR-125b in HSCs to observe a 
phenotype in these cells. Nonetheless, we show here that miR-125b over- expression is 
capable of inducing an aggressive myeloid leukemia and increases levels of MPP, 
CMP/GMP, MEP, and CLPs independent of HSC numbers. In the future, it will be 
interesting to investigate whether miR-125b overexpression drives tumorigenesis in 
myeloid progenitors and/or the mature myeloid cells.  
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We show here that miR-125b is an important regulator of hematopoiesis both 
physiologically and pathologically. Searching for a mechanism by which miR-125b exerts 
its effects on the hematopoietic system, we found that miR-125b’s direct target Lin28A is 
also a regulator of hematopoiesis. The miR-125b seed sequence within 3’UTR of Lin28A 
has been previously identified and shown to be functionally important for miR-125b 
repression (Wu and Belasco, 2005). In our study, manipulating Lin28A expression levels in 
mice mimicked the hematopoietic phenotypes of those with modulated miR-125b levels. 
Of note, shRNA-mediated knockdown of Lin28A was less effective than miR-125b 
mediated knockdown, indicating that a better specific knockdown of Lin28A might more 
precisely mimic the miR-125b overexpression phenotype. Although we demonstrate 
Lin28A as a miR-125b target important for hematopoiesis, we do not exclude that other 
miR-125b targets might play a role as well. Indeed, Le et al. have recently demonstrated 
that miR-125b regulates a panel of genes in the p53 pathway (Le et al., 2011). Potentially, 
Lin28A knockdown by miR-125b may help setting the stage for myeloid leukemia. We did 
not, however, observe obvious signs of leukemia in the shLin28A mice after three months 
following bone marrow transplantation, suggesting that either cancer will occur later or that 
repression of other targets such as the pro-apoptotic genes Bak1, Trp53inp1, and BMF, 
may collaborate with Lin28A inhibition during miR- 125b mediated cancer.  
In summary, this work links two molecules shown in different contexts to be important in 
development, miR-125b and Lin28A, and indicates that their interaction serves as a 
fundamental regulator of hematopoietic physiology and pathology. Indeed, the interplay 
between miR-125b and Lin28A is one that might be toggled therapeutically to ameliorate 
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hematopoietic disorders such as leukemia and bone marrow failure.  
Experimental Procedures 
Cell Culture. 293T cells were cultured in complete DMEM with 10% FBS, 100 units/ml 
penicillin, and 100 units/ml streptomycin. K562 cells and splenocytes from mice were 
cultured in complete RPMI with 10% FBS, 100 units/ml penicillin, 100 units/ml 
streptomycin and 50 µM 2-Mercaptoethanol.  
DNA Constructs. The retroviral vectors MG, MGP, MGP-125b-1 and MGP-125b-2 have 
been described previously (O'Connell et al., 2009; O'Connell et al., 2010; O'Connell et al., 
2008; Rao et al., 2010). Both Lin28A shRNA and MGP-125b-Mutant were cloned using a 
miR-155 arms-and-loop format, which has been previously described (O'Connell et al., 
2009; O'Connell et al., 2010; O'Connell et al., 2008; Rao et al., 2010). The Lin28A shRNA 
sequence was predicted using the Invitrogen BlockiT RNAi Designer. The 3’ UTRs for 
mouse Lin28A, Trp53inp1, Bak1, and BMF as well as the antisense 2mer were cloned 
downstream of luciferase in the pMIR-REPORT vector (Ambion). For the Lin28A 
overexpression vector, the mouse Lin28A coding sequence (Open Biosystems) was cloned 
downstream of the LTR and preceding the IRES-GFP of the MSCV Ires GFP (MIG) vector 
(Cherry et al., 2000). All primers are listed in Table S1.  
Retroviral Transduction and Bone Marrow Reconstitution Experiments. C57Bl/6 mice 
were bred and housed in the Caltech Office of Laboratory Animal Resources (OLAR) 
facility. The Caltech Institutional Animal Care and Use Committee (IACUC) approved all 
experiments related to mice. Virus production and reconstitution experiments were 
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performed as previously described (O'Connell et al., 2009; O'Connell et al., 2010; 
O'Connell et al., 2008; Rao et al., 2010). K562 cells were transduced with VSV-G 
pseudotyped MGP, MGP-125b-1, MGP-125b-2, and MGP-125b- Mut as described 
previously (O'Connell et al., 2010).  
Cell Counting and Flow Cytometry. Cells were counted using a Coulter Counter (Beckman 
Coulter) or a MACSQuant flow cytometer (Miltenyi Biosciences). Absolute cell counts in 
the blood were obtained by FACS-staining equivalent volumes of blood, resuspending the 
stained samples in equivalent volumes of FACS buffer, and running equal volumes of each 
sample using the MACSQuant. For flow cytometry, cells were harvested, homogenized, 
and red blood cells were lysed. Cells were stained with the following fluorophore-
conjugated antibodies that were purchased from Biolegend, Ebioscience, or BD 
Pharmingen and assayed using MACSQuant (Miltenyi Biosciences) or a FACSCalibur 
(Becton Dickinson). Al data was analyzed with FlowJo software (Treestar). Specific gating 
strategies are available upon request.  
Cell Sorting for Sponge Reconstitution. 5-FU enriched bone marrow was transduced with 
retroviral vectors as previously described (O'Connell et al., 2009; O'Connell et al., 2010; 
O'Connell et al., 2008; Rao et al., 2010). Prior to IV injection into mice, GFP-positive MG, 
and MG-Sponge transduced samples were sorted using an iCyt cell sorter. Equal numbers 
of cells were then injected into lethally irradiated recipient animals.  
Target Analysis. Predicted miR-125b targets in H. Sapien were downloaded from 
Targetscan and rank-ordered by their Probability of Conserved Targeting (PCT) scores. 
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Repeated target genes were removed from this list using a PERL script (available upon 
request). Literature search was performed on the resulting list in order to identify candidate 
target genes. For one target, Lin28A, the 3’ UTR for the mouse version of the gene was 
obtained and aligned with miR-125b using TargetScan.  
Luciferase Reporter Assays. Reporter assays to measure microRNA-based repression of 
target 3’ UTRs were performed as previously described (O'Connell et al., 2009; O'Connell 
et al., 2010; O'Connell et al., 2008). For de- repression assays with the sponge construct, 
we added MG (empty vector) or MG- Sponge to the transfection mix. After 24 hours, cells 
were lysed with Passive Lysis Buffer (Promega) and luciferase assays were performed as 
previously described (O'Connell et al., 2009; O'Connell et al., 2010; O'Connell et al., 
2008).  
RNA Preparation and Quantitation. RNA was isolated with TRIzol (Invitrogen) as per the 
manufacturer’s instructions. We performed SYBR Green (Quanta Biosciences) based 
quantitative real-time PCR (qPCR) with a 7300 Real-Time PCR machine (Applied 
Biosystems) to assay mRNA levels. A Taqman approach was used to quantify miR- 125b 
and snoRNA-202 expression (Applied Biosystems). All mRNA levels were normalized to 
L32 whereas microRNA-125b levels were normalized to snoRNA-202. Sequence specific 
primers are listed in Table S1.  
Immunoblotting. Total cell extracts were fractionated by electrophoresis on a 12% SDS 
polyacrylamide gel and electroblotted onto a Trans-Blot nitrocellulose membrane with a 
semidry transfer apparatus. Protein detection was performed using the following 
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antibodies: Lin28A (A177) (Cell Signaling), β-Actin (A1978) (Sigma), anti-rabbit 
HRP- conjugated secondary antibody (Santa Cruz Biotechnology), and anti-mouse HRP- 
conjugated secondary antibody (Santa Cruz Biotechnology).  
Statistical Tests. Statistical tests were performed using Graphpad PRISM software or 
Microsoft Excel. The two-tailed student’s T test was used to determine P values.  
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Figure Legends  
Figure 1: MiR-125b over-expression causes an aggressive invasive myeloid leukemia. A) 
Infiltration of GFP
+ 
CD45
+ 
and GFP
+ 
CD11b
+ 
cells into the brain. (Top) Representative 
flow cytometric plots are shown. (Bottom) Average percent GFP
+ 
CD45
+ 
and GFP
+ 
CD11b
+ 
in the brain are shown from three MG and two MG-125b mice. B) Leukemic cell 
infiltration into non-hematopoietic organs. Sections from the kidney, lung, and liver were 
stained with hematoxylin and eosin. The normal structures of the MG- 125b mouse kidney, 
lung and liver are effaced by a dramatic infiltrate of leukemic cells. A representative image 
for each tissue is shown. The brain, kidney, lung, and liver were harvested from animals 
five months after bone marrow reconstitution. During the time of harvest, the average 
%GFP
+ 
cell in the spleen of MG and MG-125b mice were 49±9.7 and 91±2.9 %, 
respectively. All plots shown depict the mean with standard error of the mean (SEM). All 
data is representative of two independent experiments. Abbreviations: Inf, Infiltrate; G, 
Glomerulus; A, alveolar space; CV, central vein.  
Figure 2: MiR-125b over-expression causes a skewing of the hematopoietic system at 
seven weeks post-bone marrow reconstitution. A) Flow cytometric analyses of the spleens 
were used to quantify the percent of granulocytes (GR-1
+ 
CD19
-
), macrophages (F4/80
+ 
CD68
+
), dendritic cells (CD11b
+ 
CD11c
+
), T cells (CD3ε
+ 
CD19
-
), and B cells (CD19
+ 
GR-1
-
). The total leukocyte counts in the spleen were similar between MG and MG-125b 
mice. B) The percent of MPPs and total numbers of CMP/GMPs, MEP, CLP, and pre-B 
  
155 
cells in the bone marrow were measured by flow cytometry. Horizontal lines represent 
the mean and each dot represents an individual mouse. Data is representative of 2-3 
independent experiments with 4-5 mice per group.  
Figure 3: Inhibiting miR-125b function decreases hematopoietic output. Equal numbers of 
sorted GFP
+ 
MG and MG-Sponge transduced progenitor-enriched BMCs were injected 
into recipient animals. A) Total numbers of white blood cells, B) myeloid cells, C) 
granulocytes, and erythroid cells (Ter119
+
) were measured by flow cytometry. Data 
represent Mean number of cells / ml of blood (SEM shown). P values were calculated using 
unpaired Student’s T test. All results are representative of two independent experiments 
with 9-10 animals per group.  
Figure 4: MiR-125b represses Lin28A expression in mouse and human hematopoietic 
cells. A) Relative expression of miR-125b candidate targets in miR-125b over- expressing 
progenitor-enriched BMCs compared to MG control. Bone marrow cells from 5-FU treated 
mice were infected with miR-125b over-expressing vector and RNA was subsequently 
harvested for expression level analysis. The relative expression level was measured by 
qPCR. B) 3’UTR reporter analyses. The 3’UTR of the indicated genes were cloned into a 
luciferase reporter and co-transfected with a miR-125b expression vector. Relative 
luminescence of the luciferase reporters was measured and normalized to an empty vector 
control. The Picalm 3’ UTR, which contains no miR-125b putative binding sites, is shown. 
The 2mer positive control, which consists of two adjacent miR-125b antisense sites, is also 
shown. C) Relative luminescence of the Lin28A 3’ UTR reporter co-transfected with either 
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MG or miR-125b sponge decoy vector into 293T cells. D) Protein expression of 
Lin28A transduced with either MGP empty vector or MGP expressing miR-125b-1, miR-
125b-2, or a miR-125b seed mutant in K562 cells. Protein levels were obtained by Western 
blot and β-actin was included as a loading control. All data shown represent mean with 
SEM. * indicates p < 0.02; ** indicates p < 0.01.  
Figure 5: Lin28A over-expression inhibits hematopoiesis. Recipients were transplanted 
with progenitor-enriched BMCs transduced with MIG-Lin28A or MIG. Five weeks post- 
reconstitution, the number of A) white blood cells, B) myeloid cells, C) granulocytes, and 
D) erythrocytes per ml in the blood were measured by flow cytometry. We did not observe 
an increase in B-cells in the MIG-Lin28A animals. Data is pooled from two independent 
groups of MIG-Lin28A animals, each with 7-8 animals and compared to MIG (6 animals). 
Data shown graphically represents the mean and SEM.  
Figure 6: Inhibition of Lin28A increases the number of myeloid cells but decreases B cells. 
A) Flow cytometry of progenitor-enriched bone marrow transduced with MG- Lin28A 
shRNA or MG control vector was performed and the percent GFP
+ 
cells is indicated. B) 
Lin28A mRNA expression was obtained by qPCR on the samples shown in A, and the 
results were normalized to L32. Representative of two independent experiments with 4 
samples per group. C) Total myeloid, D) granulocytes, and E) B cells were measured from 
blood five weeks post-bone marrow reconstitution with 7-8 animals per group. Data shown 
represents mean and SEM. P values are indicated.  
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Supplemental Figure Legends  
Figure S1: MiR-125b overexpressing animals exhibit myeloid infiltration into peripheral 
organs five months post-reconstitution. Moribund MG-125b animals were sacrificed and 
their organs harvested. Flow cytometry on GFP
+ 
CD45
+ 
and GFP
+ 
CD11b
+ 
populations 
were performed for the A) kidney, C) lung, and E) liver. A representative FACS plot is 
shown for each organ. Gross pathology comparing MG and MG-125b B) kidney and D) 
lung are also shown. F) A representative MG-125b liver is shown. G) Blood smear. Wright 
stain was performed when miR-125b overexpressing mice were moribund. All data is 
representative of 8 MG animals and 5 MG-125b animals.  
Figure S2: MiR-125a overexpression causes an aggressive leukemia six months post-
reconstitution. Mice overexpressing miR-125a became moribund six months post-
reconstitution, at which point they were euthanized. Gross pathology from A) spleen, B) 
liver, and C) kidneys are shown. Arrows show the infiltration of cancer cells into the 
kidneys in the miR-125a mice. Representative of two animals. Note: Pictures for MG and 
miR-125a overexpressing mice were obtained on separate days and the colors are thus not 
to be used for direct comparison.  
Figure S3: MiR-125b overexpression increases leukocyte count five months post-
reconstitution. Spleens from MG and MG-125b animals were harvested, RBC-lysed, and 
the relative leukocyte count was determined by flow cytometry. Each dot represents a 
mouse; the Mean and SEM are also indicated. Data is from four MG and five MG-125b 
animals and is representative of two independent experiments.  
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Figure S4: Bone marrow and peripheral blood from MG-125b animals early post- 
reconstitution display hematopoietic reconfiguration. At seven weeks post- reconstitution, 
A) total white blood cell counts and B) total GFP
+ 
white blood cells were measured in MG 
and MG-125b mouse bone marrow. Total number of C) GFP
+ 
granulocytes (GFP
+ 
Gr1
+ 
Ter119
-
), D) dendritic cells (GFP
+ 
CD11b
+ 
CD11c
+
), E) macrophages (GFP
+ 
F480
+
), F) 
B cells (GFP
+ 
CD19
+ 
CD11c
-
), G), GFP
+ 
long term HSCs (LT HSC, Lin
- 
Sca1
+ 
cKit
+ 
CD48
- 
CD150
+
), and H) short term HSCs (ST HSC, Lin
- 
Sca1
+ 
cKit
+ 
CD48
- 
CD150
-
) 
were also measured in MG and MG-125b mouse bone marrow at this time point. Each dot 
represents an individual mouse and a horizontal line indicates the mean. P values are also 
shown. Data is representative of two independent experiments.  
Figure S5: Inhibiting miR-125b function decreases hematopoietic output. A) Design and 
testing of the miR-125b ‘sponge’ decoy system. MiR-125b sponge decoy was constructed 
by placing four miR-125b complementary sites downstream of GFP in the MG vector with 
a 4-6 nt spacer between each site. A 3 nt mismatch region was placed in each miRNA 
binding site, since it has been shown to increase the effectiveness of sponge decoys (11-
14). B) Sponge de-represses a miR-125b reporter vector comprised of 2 perfect antisense 
sites placed downstream of luciferase in 293T cells. C) Sponge does not de-repress the 
pMiR-Report negative control vector in 293T cells. Luciferase values were measured and 
normalized to the loading control β-gal. Assays were performed with three samples per 
group; Mean and SEM are plotted. Results are representative of three independent 
experiments. Abbreviations: nt, nucleotide; miRNA, microRNA. Note: The sponge de-
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represses the 2mer reporter by 30%. D) GFP
+ 
cells were isolated from MG and MG-
Sponge transduced progenitor- enriched bone marrow by fluorescent activated cell sorting 
(FACS). Equal numbers of GFP
+ 
cells were injected into recipient animals. (Left) Oval 
indicates gating on the primary population of cells based on forward (FSC) and side scatter 
(BSC). (Right) GFP
+ 
cells within the primary population were sorted as indicated by the 
blue arrow.  
Figure S6: MiR-125b represses Lin28 expression in mouse and human hematopoietic 
cells. A) Relative expression of Lin28, Trp53inp1, and BMF expression in miR-125b 
sponge-transduced progenitor-enriched bone marrow, normalized to MG transduced 
controls. The percent expression relative to MG is shown. Broken line demarcates 100%. 
B) MiR-125b seed sequence in the 3’UTR of Lin28 is shown. Depiction is not drawn to 
scale. C) MiR-125b mutant vector expresses a seed mutant version of miR-125b. MGP-
125b-Mutant vector was designed to express a seed mutant version of miR-125b by 
utilizing a miR- 155 arms-and-loop format (top). Sequences expressed by wild type miR-
125b and the mutant are shown below. D) Quantitative PCR shows relative expression of 
the mutant version of miR-125b (normalized to L32) in K562 cells transduced with MGP-
125b-Mutant or MGP control. E) RNA expression of Lin28 transduced with either MGP 
empty vector or MGP expressing miR-125b-1, miR-125b-2, or a miR-125b seed mutant in 
K562 cells. F) Immunoblot of Lin28B transduced with either MGP empty vector or MGP 
expressing miR-125b-1 or miR-125b-2 in K562 cells. G) qPCR of Lin28B after 
transduction with either MG empty vector or MG- miR-125b in bone marrow cells 
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harvested from 5-FU injected mice.  
Figure S7: Lin28A and Lin28B expression in miR-125b over-expressing leukemic 
samples. RNA from peripheral blood mononuclear (PBMC) of cancer mice, which was 
transplanted with miR-125b over-expressing leukemic cells, was harvested. Equal amounts 
of RNA were used for RT-qPCR analyses. The control samples were PBMC from 
recipients of MG mice that did not develop cancer. The relative expressions of Lin28A, 
Lin28B, and the control Rpl19 gene are displayed. Each dot represents an individual 
animal. Student T-test was for statistical analyses.  
Figure S8: Lin28 over-expression inhibits hematopoiesis. A) Lin28 over- expression was 
confirmed by western blot with B-actin as loading control. Note: We confirmed by qPCR 
that Lin28 is over-expressed using this vector system in mouse primary bone marrow cells. 
B) Recipients were transplanted with progenitor-enriched BMCs that were transduced 
MIG-Lin28 or MIG with similar efficiency.  
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Figures 
 
Figure 1: MiR-125b over-expression causes an aggressive invasive myeloid leukemia. 
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Figure 2: MiR-125b over-expression causes a skewing of the hematopoietic system at 
seven weeks post-bone marrow reconstitution. 
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Figure 3: Inhibiting miR-125b function decreases hematopoietic output. 
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 Figure 4: MiR-125b represses Lin28A expression in mouse and human hematopoietic 
cells. 
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Figure 5: Lin28A over-expression inhibits hematopoiesis. 
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 Figure 6: Inhibition of Lin28A increases the number of myeloid cells but decreases B 
cells. 
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Figure S1: MiR-125b overexpressing animals exhibit myeloid infiltration into 
peripheral organs five months post-reconstitution. 
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Figure S2: MiR-125a overexpression causes an aggressive leukemia six months post-
reconstitution. 
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Figure S3: MiR-125b overexpression increases leukocyte count five months post-
reconstitution. 
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Figure S4: Bone marrow and peripheral blood from MG-125b animals early post- 
reconstitution display hematopoietic reconfiguration. 
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Figure S5: Inhibiting miR-125b function decreases hematopoietic output. 
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Figure S6: MiR-125b represses Lin28 expression in mouse and human hematopoietic 
cells. 
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Figure S7: Lin28A and Lin28B expression in miR-125b over-expressing leukemic 
samples. 
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Figure S8: Lin28 over-expression inhibits hematopoiesis. 
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C h a p t e r  5  
Chapter 5: Conclusions and Future Directions 
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A putative role of miR-132 in maintaining HSC function 
with age 
 
In this thesis I have uncovered a novel role of miR-132 in HSC and B cell function. We 
observed that miR-132 buffers the expression of the transcription factor FOXO3 in order to 
maintain balanced hematopoietic output of aging HSCs. Deregulation of miR-132 results in 
altered HSC cell cycling, function, and survival through protective autophagy. Several 
open questions remain about the role of miR-132 in HSCs: 
 
1) What regulates the expression of miR-132 in HSCs? And why is it up regulated 
with age? 
2) What is the molecular mechanism by which a loss in protective autophagy leads 
to decreased HSC survival? What cellular and molecular changes in HSCs result 
in survival through autophagy becoming more important with age? 
3) What are the other critical targets of miR-132 that regulate HSC function with 
age? 
4) Can we alter age-related functional decline of HSCs? Can we use this to prevent 
age-associated hematopoietic disease? 
 
Uncovering potential roles of miR-132 in normal and 
malignant B cell development 
 
We have additionally shown that miR-132 regulates B cell development by targeting the 
transcription factor Sox4. We found that delivery of miR-132 can also inhibit B cancer 
progression in mice. Several open questions remain about the role of miR-132 in B cell 
  
180 
development. Our current efforts seek to understand the following: 
 
1) How is miR-132 induced in early B cell progenitors? Can we induce miR-132 
with pre-BCR signaling? What regulates this induction? 
2) What roles does Sox4 play in altering pro-B cell fate? What is the molecular 
mechanism by which Sox4 regulates B cell fate decisions? How does Sox4 alter B 
cell apoptosis? 
3) Finally, we observed in our studies that the induction of miR-132 is 3-fold higher 
than that of miR-212. Thus, an open question remains as to how miR-132 and 
miR-212, expressed in a cluster, are differentially regulated in B cells.  
 
A proposal to better understand HSC aging with age at 
single-cell resolution 
 
 To better understand how molecular changes in aging HSCs may lead to age-associated 
hematopoietic disease, we are currently investigating the molecular characteristics of 
hematopoietic progenitors using single-cell protomic and transcriptomic experiments. 
Below is a proposal for future work in this area. 
 
Significance  
Aging is a progressive degenerative process, tightly integrated with chronic inflammation. 
However, the molecular link between chronic inflammation and aging is still poorly 
understood. This proposed study aims to make fundamental advances in defining the key 
molecular regulators of hematopoietic aging and their relationship to chronic inflammation. 
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Using single cell analysis, we will determine the molecular signature of specific 
subpopulations within the hematopoietic stem and progenitor cells (HSPC) pool from 
young and aged mice, and chronically inflamed mouse models. We will further 
characterize the relative contribution of these molecular factors to the aging process.  
 
Our combined study of chronic inflammation models and the molecular signature of aging 
will enable us elucidate the molecular pathways responsible for immune aging and 
understand the relationship between chronic inflammation and aging. This proposed study 
might also reveal potential therapeutic approaches for treating immune-aging related 
malignancies, such as cancer, autoimmunity, and anemia.  
 
Innovation  
To date, cellular and molecular properties are largely investigated by utilizing bulk 
methods that measure the average values for population of cells. Bulk analysis of these 
cells masks an understanding of the way each individual cell behaves, and is often 
insufficient for characterizing the biological processes in which cellular heterogeneity plays 
a key role. The hematopoietic stem and progenitor cell compartment is heterogeneous by 
nature, enabling many cell fate decisions for each cell. In this proposed study, we will 
determine the molecular signature of specific subpopulations within the HSPC pool by 
using single cell cytokine secretion and transcriptome analysis. This methodology will 
enable us to determine the key molecular regulators of hematopoietic aging and chronic 
inflammation. This approach will also allow us further characterize the contribution of 
these molecular pathways to immune aging, inflammation, and homeostasis.  
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Approach  
Aim 1: Define the molecular signature of the hematopoietic stem and progenitor cell 
compartment in young and aged mice in response to inflammatory signals. 
Background: Aging alters the cellular composition of the hematopoietic system, leading to 
more myeloid-biased hematopoietic stem and progenitor cells (HSPCs), pro-inflammatory 
macrophages, and T cells, as well as expansion of memory B cells. These alterations 
contribute to the increased susceptibility to infectious diseases, autoimmunity, vaccine 
failure, and cancers such as leukemia (Morrison et al., 1996). Similarly, changes observed 
during chronic inflammation are reminiscent of hematopoietic stem cell (HSC) aging, 
including alterations in HSC cycling, impairment in the capacity of HSCs to repopulate and 
self-renew in transplanted animals, and skewing of differentiation towards myeloid cell 
types (Morrison et al., 1996; Rossi et al., 2005). We hypothesize that a molecular signature 
exists within HSPCs that reflects the aging-dependent response of the hematopoietic 
system to chronic or acute challenges. We further hypothesize that by characterizing the 
proteome and transcriptome of single hematopoietic cells, we will resolve the molecular 
networks that are associated with how aging influences the hematopoietic system.  
The goal of this aim is to discover key regulators of hematopoietic aging and their 
relationship to diseases of age; as such, we are using a global, unbiased approach to 
studying the gene and protein expression networks of hematopoietic cells. We recently 
demonstrated the remarkable ability of HSPCs to produce cytokines, especially in response 
to direct inflammatory stimulation (Zhao et al., 2014). Of note is that the types and 
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abundance of cytokines produced by HSPCs varied significantly, with some producing 
myeloid-biased cytokine profiles and others lymphoid-biased profiles. This, in turn, is 
reflective of the inherent heterogeneity of hematopoietic progenitors. In this Aim, we 
propose to elaborate on these measurements in context of the aging hematopoietic system 
at steady state and after exposure to inflammatory stimuli. In doing so, we will build a 
resource tool of molecular pathways that reflect the aging process at the single cell level.  
Subaim 1.1. Define a molecular signature of hematopoietic progenitors that reflects the 
altered response to danger signals during the process of aging. 
We seek to define a molecular signature of the hematopoietic system that reflects the 
process of aging and how aging influences the capacity of the hematopoietic system to deal 
with chronic or acute inflammation. Our preliminary results indicate that early progenitors 
demonstrate a robust response to the bacterial components lipopolysaccharide (LPS) + 
Pam3csk4, ligands for toll-like receptor 4 (TLR4) and toll-like receptor 2 (TLR2), 
respectively (Figure 1A,B). However, it remains unclear whether this response is analogous 
to that of more mature immune cell types and how this response is altered with age. We 
first seek to investigate the molecular pathways that are altered in bulk populations of 
young and aged HSPCs in response to critical danger signals, such as bacterial components.  
Approach: In order to investigate the molecular pathways that are critical for HSPC 
response to danger signals, we will perform RNA-sequencing on bulk populations of 
various hematopoietic progenitors from young and aged mice over a comprehensive time-
course. Long-term HSCs (Lineage- cKit+ Sca1+ CD150+ CD48-), short-term HSCs 
(Lineage- cKit+ Sca1+ CD150- CD48-), MPPs (Lineage- cKit+ Sca1+ CD150- CD48+), 
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and more committed hematopoietic progenitors will be sorted from young (12 weeks) and 
aged (> 22 months) mice by fluorescence activated cell sorting (FACS). These cells will 
subsequently be cultured without stimulants, or stimulated with LPS + Pam3csk4 for 30 
minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours. Samples will then be 
processed for bulk RNA-sequencing as shown in the preliminary data (Figure 1A,B). 
Briefly, RNA will be harvested using a commercially available kit (Qiagen), and processed 
for cDNA double-strand synthesis, whole-transcriptome amplification, and library 
preparation (Shalek et al., 2014). Samples will be sequenced at the Caltech’s Milliard and 
Muriel Jacobs Genetics and Genomics Core Facility on a HiSeq2500 machine (Illumina), 
using 50 base-pair paired-end sequencing. Sequencing reads will be aligned using TopHat 
and quantified using Cufflinks (Trapnell et al., 2010). Reads will then be analyzed in 
several ways, including analysis for differentially expressed genes between time points, 
enrichment of gene-ontology terms, and for expression of co-expressed gene networks in 
order to characterize the differences between cells with different durations of stimulation, 
and cells from young and aged mice. In this way, we seek to understand the transcriptional 
response of hematopoietic progenitors to acute inflammatory stimuli, and to elucidate the 
differences between how young and aged HSPCs respond to bacterial infections. 
Preliminary results from young progenitors suggest a clear and unique cell type 
transcriptional response to LPS + Pam3csk4, with differential changes in proliferation, 
differentiation, and inflammatory related genes (Figure 1 A, B).  
Anticipated results: We expect a strong transcriptional response from aged and young 
progenitors alike, and a robust upregulation of several NF-κB activated genes, since both 
LPS + Pam3csk4 are potent activators of the NF-κB pathway. Importantly, we expect that 
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aged mice will show a strong predisposition to the production of myeloid-biased 
transcripts, including major cytokines such as IL-6 and TNF-α, which would be consistent 
with their well-established bias towards myeloid cell differentiation.  
Potential pitfalls and solutions: We might find that there are few transcriptional differences 
between young and aged progenitor cells in response to TLR stimulation, in which case we 
will still have learned a significant amount about how these cells respond to acute 
inflammatory stimuli, and how this response changes with age. In addition, TLR2 and 
TLR4 ligands might not be the best acute inflammatory stimulants for early progenitors, in 
which case we will explore the expression of other TLR receptors, as well as cytokine and 
growth factor receptors on these cells and stimulate with their respective ligands for further 
analysis of the response of these progenitors to an inflammatory environment.  
Figure 1. Transcriptomic analysis of bulk hematopoietic progenitors. Comparison between selected 
expressed genes in (A) ST-HSCs (LSK CD150
−
CD48
−
) and (B) LT-HSCs (LSK CD150
+
CD48
−
) in 
response to LPS + Pam3csk4 stimulation. Each cell type show a robust up-regulation of several known 
inflammatory genes, including cytokines such as IL-6, IL-1β and TNF-α. Blue coloring indicates genes 
that are downregulated after stimulation, and red coloring indicates genes that are uprgeulated after 
stimulation, compared to no stimulation. Color bar represent fold change from no stimulation.  
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Subaim 1.2. Investigate the differences in gene expression and cytokine secretion between 
young and aged HSPCs in response to danger signals at the single-cell level. 
Bulk analysis of HSPCs, while useful, masks an understanding of the way each individual 
cell behaves in an ageing hematopoietic system. By studying single cells, we are able to 
examine whether there is a transcriptionally-primed, clonally expanded subset of myeloid 
biased cells in an aged mouse, or if in fact all cells have similar molecular signatures, and 
specific environmental cues influence the differentiation potential of the cell.  
Our preliminary work has demonstrated that young HSPCs are inherently heterogeneous in 
their secretion of inflammatory cytokines in response to LPS + Pam3csk4 stimulation 
(Figure 2A,B (Zhao et al., 2014)). Looking at multipotent progenitors (MPPs), we find that 
aged MPPs are less potent cytokine producers and secrete fewer cytokines per cell 
compared to young MPPs (Figure 2C). Importantly, aged cells secrete myeloid-biased 
cytokines, and do so in a much more homogenous manner than their young counterparts 
(Figure 2D). While these differences might reflect the lineage potential of these cells, this 
remains largely unexplored, especially in the context of aging. To better understand the 
molecular characteristics of the response of HSPCs, especially earlier progenitors like LT-
HSCs and ST-HSCs, to danger signals, we will perform single-cell proteomic analysis of 
secreted cytokines, with concomitant single-cell transcriptome analysis using RNA-
sequencing and single-molecule RNA fluorescent in situ hybridization (FISH) (Figure 
2E,F).  
Approach: To understand the process of aging at the single cell level we will apply a two-
pronged approach for both young and aged hematopoietic progenitors: 1) we will 
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determine the relevant functional secreted and intracellular proteins from each individual 
cell using a single-cell barcode chip (SCBC) (Figure 2A) (Ma et al., 2011; Zhao et al., 
2014) and 2) we will determine the transcriptional landscape of these same cells using 
parallel single-cell RNA-sequencing and single-molecule RNA FISH (in collaboration with 
Dr. Long Cai, Caltech) (Figure 2E,F). Cells from bone marrow, spleen, peripheral blood, 
and thymus will be collected from young (12 weeks) and aged (18-24months) mice. 
Hematopoietic cell populations will be characterized by FACS. We will then use the SCBC 
to analyze the secretion profile of up to 15 cytokines important in hematopoietic 
differentiation and immune cell function from long-term hematopoietic stem cells 
(Lineage-Sca1+cKit+CD150+CD48-), short-term hematopoietic stem cells (Lineage-
Sca1+cKit+CD150-CD48-), multipotent progenitors (Lineage-Sca1+cKit+CD150-
CD48+), as well as more committed progenitors such as lymphoid-primed multipotent 
progenitor (LMPPs), common myeloid progenitors (CMPs), granulocyte-macrophage 
progenitors (GMPs), common lymphoid progenitor cells (CLPs), and megakaryocyte–
erythroid progenitor cell (MEPs). Cytokines of interest include but are not limited to GM-
CSF, M-CSF, TGF-b, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-12, and IFN-g. Single cells are 
then indexed, picked, and processed for single-cell massive parallel RNA-sequencing (in 
collaboration with Dr. Aviv Regev. Broad Institute of MIT and Harvard) (Shalek et al., 
2013; Yosef et al., 2013). This methodology allows us the unique ability to obtain 
proteomic and transcriptional information for the same single hematopoietic cell. This in 
turn can be used to determine the relationship between the transcriptional landscape of 
young and aged hematopoietic stem cells and their functional output, in terms of cytokine 
secretion. We have demonstrated the detection of both transcripts and proteins from the 
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same single cells (Figure 2C-F). Comprehensive transcriptomics will allow us to elucidate 
unique molecular events that govern hematopoietic cell fate decisions in old and young 
mice. Once gene networks have been identified, we will use single-molecule RNA FISH to 
validate our results and do absolute quantitation of genes of interest. Single-molecule RNA 
FISH enables us to analyze vast number of cells in different conditions and get absolute 
counts of RNA abundance for each gene within a cell (Singer et al., 2014). This allows us 
to obtain extremely high-resolution data that, along with RNA-sequencing, will help define 
the entire transcriptional landscape of young and aged progenitors. By utilizing single-
molecule RNA FISH, we can focus our efforts on specific signaling pathways in a high-
throughput manner that allows us to test many cells and experimental conditions. 
Anticipated results: We anticipate, as our proteomic data already suggests (Figure 2), that 
aged hematopoietic stem cells have a myeloid biased gene expression signature, reflected 
in an expansion of single hematopoietic stem cells with biased myeloid differentiation 
potential. Importantly, we anticipate that several pathways implicated in ageing of the 
hematopoietic system, including TGF-signaling and cell-cycling, will be deregulated in 
aged hematopoietic stem cells.Potential pitfalls and solutions: It is possible that culturing 
cells for 12 hours to perform proteomic studies might severely alter the transcriptome of 
these cells; this in turn, might not be reflective of the transcriptome of hematopoietic stem 
cells in vivo. If we find that this is the case, we will significantly shorten the incubation 
time to 3-6 hours, as required. If necessary, we will also perform single-cell RNA-
sequencing on cells directly sorted into RNA lysis buffer. While we won’t get proteomic 
and transcriptome information from the same cell in this case, we will still learn a  
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Figure 2. Transcriptomic and proteomic analysis of hematopoietic progenitors (A) Single-cell barcode chip 
(SCBC) analysis of hematopoietic progenitors. The SCBC contains >6000 microchambers, each designed 
with a central well in which a cell is localized. The microchip surface is coated with a cocktail of magnetic 
beads conjugated to anti-mouse-CD34, anti-mouse-cKit, or anti-mouse-Sca1 antibodies to hold the cells in 
place over a magnet. Unbound cells are washed off and the chip is sealed and incubated at 37oC in 5% CO2 
for 12 hrs. During incubation, secreted proteins are captured on a miniature 12-element antibody array, 
which is later developed using sandwich ELISA to record those secreted protein levels. Single cells are 
indexed by location and cytokine production, and may then be processed for RNA-sequencing. (B) Data 
from SCBC analysis. The six cell groups analyzed are BM (total BM cells), LSK cells, LMPPs (LSK 
CD34+Flt3hi), MPPs (LSK CD34+Flt3int), ST-HSCs (LSK CD34+Flt3−), and LT-HSCs (LSK CD34−Flt3−), 
all under LPS + Pam3CSK4 stimulation for 12 hrs. (C) Proportion of young and aged MPPs secreting 
certain numbers of cytokines. (D) Principal component analysis of young and aged MPPs: each data point 
represents a single cell and principal component 1 (PC1) explains the highest variation in cytokine 
secretion in the data set. Young MPPs are highly heterogeneous and aged MPPs are more uniform in their 
cytokine secretion profile. (E) Single-molecule RNA FISH performed on LT-HSCs for various cytokines 
before stimulation or after 1 hr of LPS + Pam3csk4 stimulation. (F) Single-cell RNA-sequencing traces 
from HSPCs processed as described in the text. 
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Figure 2. Single-Cell Analysis of Cytokine Production by Various HSPC Subsets in Response to TLR Stimulation
(A–E) Data from single-cell cytokine chip analysis. The six cell groups analyzed are BM (total BM cells), LSK cells, LMPPs (LSK CD34+Flt3hi), MPPs (LSK
CD34+Flt3int), ST-HSCs (LSK CD34+Flt3!), and LT-HSCs (LSK CD34!Flt3!), all under LPS and Pam3CSK4 stimulation for 12 hr.
(A) Polyfunctionality and population-level statistics of the cell types analyzed. The percentage of cells secreting different number of cytokines is shown for each
cell type studied. Different colors represent cells producing different number of cytokines from 1 to 12 (labeled with different colors); the number on top of each
cell type represents the total percentage of cells secreting detectable amount of any of the 12 cytokines.
(B) Comparison of HSPC subsets by individual cytokines. Four out of 12 cytokines are shown here, and the rest are shown in Figure S4B. Each plot is composed
of several thousand individual dots from several thousand single cells. The six cell groups arranged from left to right are total BM, LSK cells, LMPPs, MPPs,
ST-HSCs, and LT-HSCs under LPS and Pam3CSK4 stimulation. The numbers on top represent the percentage of cytokine-producing cells identified by the gate
(the dotted line), and the bars represent the mean intensity of only the cytokine-producing cells (average intensity of the cells above the dotted line).
(C) A summary heat map showing the percentage of the six groups of cells that secrete any individual cytokine under different stimulations.
(D and E) Principal component analysis of all six cell groups that reduce a 12-dimensional cytokine data set from six different cell groups into two principal
components (PC1 and PC2).
(D) PC1 represents the overall cytokine production capacity of a cell and is positively correlated to the overall intensity of all 12 cytokines (see Figure S4C). After all
12 cytokine intensities of each cell are converted into a single PC1 value, the relative frequency of cells with each PC1 value is calculated for all six cell subsets.
Graphs show the relative freque cy of cells (y axis) of the six cell groups against PC1 (x axis). Each c ll type is represented by a different color.
(E) PC2 represents the level of biased cytokine production profile and is positively correlated to the lymphoid group of cytokines, including IL-2, IL-17a, IL-4, IL-12,
IL-1b, and IFN-g, but is negatively correlated to the myeloid group of cytokines, including TNF-a, IL-6, and GM-CSF (see Figures S4D and S4E). Graphs show the
relative frequency of cells (y axis) of the six cell groups against PC2 (x axis). Each cell type is represented by a different color.
See also Figure S4.
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tremendous amount about the heterogeneous responses of aged and young HSPCs to 
danger signals. 
 
Subaim 1.3. Elucidate the functional and lineage potential of young vs. old as well as acute 
and chronically inflamed HSPCs.  
Our basic premise is that the hematopoietic stem cell pool changes its composition during 
mammalian aging: a change from a balanced HSC pool in young animals to a myeloid-
biased pool in older animals.  This change in HSC composition is one of the direct factors 
leading to a pro-inflammatory milieu in aging organisms. 
 
It is uncertain, however, how each cell from the HSC pool contributes to this myeloid bias. 
We seek to determine if all old HSCs are programmed to be myeloid biased, or if a fraction 
of “youthful” cells within that population that behave like young HSCs exists. In this 
Subaim, we will further examine the change of the HSC pool at the proteomic and 
transcriptomic level during aging, as done in Subaim 1.2. We will use this information to 
define a precise cytokine production signature of different HSC subsets in young and aged 
mice. Once we are able to define different HSC subsets, we will isolate them for lineage 
and functional analysis in transplant studies in vivo. This methodology enables us to 
determine the differentiation potential of single cells with a known molecular signature, 
and has the potential to reveal new, un-described subpopulations within the HSC 
compartment.  
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Approach: We will isolate various subsets of hematopoietic stem and progenitor cells from 
young and old WT mice, define their cytokine secretion signature and examine their 
lineage potential and functional properties. From Subaim 1.2, we will have obtained the 
cytokine and transcriptomic signature of individual HSPCs and will be able to correlate 
different cytokine production profiles with transcriptomic signatures. To further understand 
the functional significance of HSPCs with different cytokine production profiles and 
transcriptomic signatures, we will recover individual cells based on their cytokine profile 
for measurement of their lineage potential and functional properties in vivo. We will use 
competitive repopulation assays, where we inject distinguishable cell mixtures (HSPCs 
with a known signature together with control young or old HSPCs) into irradiated 
recipients and measure the percentage of differentiated cells produced by each cell type. 
Blood will be collected from mice every month after injection, and analyzed for mature 
immune cell populations (such as with the surface markers CD11b, CD19, CD3ε, and 
CD45) by flow cytometry. After 12 weeks, mice will be sacrificed and the homing and 
repopulation potential of HSPCs will be analyzed by quantifying long-term hematopoietic 
stem cells (Lineage-Sca1+cKit+CD150+CD48-), short-term hematopoietic stem cells 
(Lineage-Sca1+cKit+CD150-CD48-), and multipotent progenitors (Lineage-
Sca1+cKit+CD150-CD48+), as well as more committed progenitors (such as LMPPs, 
CMPs, GMPs, CLPs, and MEPs). We will then determine whether HSPCs with different 
cytokine profiles display different functions and lineage potential in competitive 
repopulation studies carried out with acute as well as chronic inflammation environments. 
To this end, cells will be challenged in vitro prior to being transplanted into WT mice, to 
mimic challenge with an acute inflammatory stimulus, or be transplanted into recipient 
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mice in an established chronic inflammatory state. In particular, we will utilize recipient 
mice that have a genetic deletion in the interleukin-10 gene or the microRNA-146a gene, 
both of which have higher basal inflammatory state in most of their tissues (see Aim 2).  
 
Anticipated Results: We expect to find disparate differentiation potential for HSPCs with 
the same membrane markers but different molecular signatures. We believe our approach 
will discover many different subpopulations with different functional properties and 
differentiation potential within each HSPCs population examined. 
 
Potential pitfalls and solution: Single cell repopulation assays have low success rate and 
high rate of false negatives. If this will be the case, we will be able to inject up to 100 cells 
with similar cytokine signatures to each mouse. In addition, we will perform in vitro 
methycellulose differentiation assays for cells of similar cytokine signatures. Also, we note 
that LPS + Pam3csk4 stimulation may change the repopulation capacity of HSCs. If this 
becomes a major obstacle, we will utilize cells that have not been stimulated but express 
differing levels of basal cytokine secretion. Unstimulated cells tend to express fewer 
cytokines at much lower abundance; however, we will still be able to identify subsets of 
secreting cells by screening a much larger number of them.  
 
Subaim 1.4. Characterize the cardinal molecular components associated with HSPCs 
aging. 
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Using the approaches described in Subaims 1.1 and 1.2, we will establish a comprehensive 
database of the molecular pathways important for the aging process of different HSPCs, in 
both normal and inflamed environments. We then plan to further understand the relevant 
contribution of selected pathways and genes to aging using genetic and pharmacologic 
manipulations. Using this approach, we will build an integrated model to capture the 
molecular basis of the aging process and might find potential pathways that can be used as 
targets for drug development. 
 
Approach: We will first apply one of several approaches to identifying pathways important 
in regulating HSPC behavior with age. We will begin by studying differentially expressed 
genes using TopHat for sequence alignment, and Cufflinks for quantitation of genes 
(Trapnell et al., 2012). Of the genes that are differentially expressed, we will perform gene-
onotolgy and gene-set enrichment analysis to identify pathways particularly affected by age 
and inflammatory status (Huang da et al., 2009; Subramanian et al., 2005). We will further 
identify modules of co-expression networks (working closely with Aviv Regev, MIT) as 
potential targets for perturbation (Novershtern et al., 2011). We will then apply loss and 
gain of function studies using a retroviral delivery system on the most differentially 
expressed molecular pathways and targets between young and aged mice identified from 
Subaims 1.1 and 1.2. Bone marrow cells from donor mice will be infected with retroviruses 
expressing the examined genes of interest for gain of function, or shRNA knockdown 
constructs for loss of function studies. The cells will then be injected into lethally irradiated 
mice. We will then determine whether genetic manipulation at these nodes may attenuate 
the detrimental effects of aging mice by repopulation assays as described in Subaim 1.3. 
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We will also test pharmacologic interventions that can act along these nodes as effective 
and safe anti-inflammatory drugs in aged mice, and compare their HSPC molecular 
signature to non-treated mice. During both genetic and pharmacologic interventions, we 
will study both the positive and negative effects of blocking inflammation on aging by 
regulating key inflammatory pathways. Importantly, we will investigate the effects of these 
perturbations in preventing age-related onset of immune diseases, such as autoimmunity 
and blood cancers, by using mouse models of chronic inflammation, as described in 
Subaim 2.1 and 2.2. Mice with a genetic deletion in the interleukin-10 gene or the 
microRNA-146a gene both have a predisposition to develop autoimmune disease, and in 
the case of microRNA-146a deletion, these mice develop myeloproliferative disorder and 
myeloid leukemias.  
 
Anticipated results: We expect to reveal that genetic manipulation of a few discovered 
genetic nodes will lead to a phenotypic attenuation of the aging process both in WT and 
chronically inflamed mice. 
 
Potential pitfalls and solution: It is reasonable to believe that some of the pathways 
discovered in this Subaim will also have a crucial role in the normal immune response, 
making them unsuitable for drug design. Nonetheless, understanding of the contribution of 
these pathways to HSPC function and aging is of great importance, and will lead us and 
others to further characterize the relevance of each gene in this process to HSPC aging.  
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During an infection, the body increases the output
of mature immune cells in order to fight off the path-
ogen. Despite convincing evidence that hemato-
poietic stem and progenitor cells (HSPCs) can sense
pathogens directly, how this contributes to hemato-
poietic cell output remains unknown. Here, we have
combined mouse models with a single-cell prote-
omics platform to show that, in response to Toll-
like receptor stimulation, short-term HSCs and
multipotent progenitor cells produce copious
amounts of diverse cytokines through nuclear factor
kB (NF-kB) signaling. Interestingly, the cytokine pro-
duction ability of HSPCs trumps mature immune
cells in both magnitude and breadth. Among cyto-
kines produced by HSPCs, IL-6 is a particularly
important regulator of myeloid differentiation and
HSPC proliferation in a paracrine manner and in
mediating rapid myeloid cell recovery during neutro-
penia. This study has uncovered an important prop-
erty of HSPCs that enables them to convert danger
signals into versatile cytokine signals for the regula-
tion of stress hematopoiesis.
INTRODUCTION
Immune cells of the myeloid lineage are often considered the
first responders of host defense against bacterial infection;
meanwhile, hematopoietic stem and progenitor cells (HSPCs)
may respond in a delayed fashion to ensure sufficient production
of myeloid cells consumed during an infection. The response by
HSPCs was originally thought to be of a passive response to the
depletion of downstream immune cells, but more recent evi-
dence suggests that HSPCs may participate directly by sensing
systemically elevated cytokines through cytokine receptors and
bacterial and viral components through Toll-like receptors (TLRs)
(King and Goodell, 2011; Nagai et al., 2006).It is well known that immune cells are potent cytokine pro-
ducers upon encountering bacteria and viruses. When cytokines
produced by immune cells and nonhematopoietic tissues accu-
mulate to sufficient quantity, they circulate back to the bone
marrow (BM) niche via blood circulation to activate HSPCs.
Numerous cytokines, including IL-6, TNF-a, IFN-a, IFN-g, TGF-
b, and M-CSF, with the ability to regulate proliferation and differ-
entiation of HSPCs have been identified (Baldridge et al., 2010,
2011; Challen et al., 2010; Essers et al., 2009; Maeda et al.,
2009; Mossadegh-Keller et al., 2013; Pronk et al., 2011). On
the other hand, it is clear now that HSPCs can also respond
to TLR stimulation directly, leading to accelerated myeloid cell
production in vitro (Nagai et al., 2006) and most likely in vivo as
well (Megı´as et al., 2012). However, it remains unclear how direct
pathogen sensing by HSPCs translates into signals directing
myeloid differentiation under the stressed conditions. Conven-
tional wisdom would suggest that TLR signaling activates line-
age-specific transcriptional factors that can directly regulate
differentiation within HSPCs. Currently, little is known about
what transcription factors downstream of TLR activation might
mediate this process. An alternative, but not mutually exclusive,
hypothesis is that TLR stimulation activates a general proinflam-
matory program within HSPCs in order to induce cytokine pro-
duction, which can act in an autocrine or paracrine manner to
regulate differentiation.
In this study, we have combined extensive mouse genetics
and a microfluidic single-cell proteomics platform to show that
HSPCs can directly respond to bacterial components via the
TLR/necrosis nuclear factor kB (NF-kB) axis, and, in response,
HSPCs, specifically short-term HSCs (ST-HSCs) and multipo-
tent progenitor cells (MPPs), produce copious amounts of cyto-
kines. In addition, single-cell analysis shows that HSPCs contain
heterogeneous subsets based on their different cytokine pro-
duction profiles. The cytokine production ability of HSPCs is
shown to be regulated byNF-kBactivity, given that p50-deficient
HSPCs have significantly attenuated cytokine production,
whereas miR-146a-deficient HSPCs display significantly
enhanced cytokine production. Interestingly, HSPCs are signifi-
cantly more potent cytokine producers in both breadth and
quantity than the conventional known cytokine producers of
the immune system, such as myeloid cells and lymphocytes.Cell Stem Cell 14, 1–15, April 3, 2014 ª2014 Elsevier Inc. 1
(legend on next page)
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tional NF-kB signaling, and cytokine receptors—an entire
cascade of molecules necessary for translating danger signals
into cytokine signals. Lastly, we have demonstrated the func-
tional significance of HSPC-produced cytokines, especially IL-
6, in promoting myelopoiesis in vitro and in vivo in neutropenic
mice after chemotherapeutic treatment or BM transplant. We
believe that this represents a previously underappreciated
mechanism by which HSPCs convert danger signals encoun-
tered during an infection into a range of versatile cytokine signals
in order to ensure efficient stress-induced hematopoiesis. This
circumvents both the delay associated with having to wait for
systemic cytokine accumulation and the need to ‘‘reinvent’’ the
molecular circuitry within HSPCs in order to convert TLR activa-
tion into specific differentiation signals.
RESULTS
Heterogeneity in Cytokine Production Profile among
Purified HSPCs
To test whether any of the HSPC populations have the capability
of cytokine production, we adapted a high-throughput, micro-
fluidic-based technology to quantify a panel of up to 15 secreted
proteins at the single-cell level (Ma et al., 2011). HSPCs are rare
cells in BM, with LSK cells (defined as LinSca1+cKit+), a mixed
population of long-term HSCs (LT-HSCs), ST-HSCs, MPPs, and
lymphoid-biased MPPs (LMPPs) accounting for less than 1%
and LT-HSCs accounting for less than 0.1% of the total nucle-
ated BM cells. This microfluidic platform allowed us to simulta-
neously measure a large number of secreted proteins at the
single-cell level from thousands of phenotypically defined cells.
After sorting LSK cells and LT-HSCs (defined as LSK CD150+
CD48) with stringent gating criteria and reanalyzing the sorted
fraction for purity (Figure S1A available online), we loaded the
cells onto chips containing several thousand microchambers.
After 12 hr of incubation with culture medium containing
either lipopolysaccharide (LPS), a TLR-4 ligand, alone or with
Pam3CSK4, a TLR-2 ligand, secreted proteins were quantified
by an ELISA-based method (Ma et al., 2011). At this time, nearly
all LSK cells remained undifferentiated by fluorescence-
activated cell sorting (FACS) analysis (Figure S2). Interestingly,Figure 1. Single-Cell Analysis of Cytokine Production by WT HSPCs in
(A–D) Data from single-cell cytokine chip analysis. The four cell groups analyzed a
LPS, and LSK cells with LPS and Pam3CSK4 stimulation for 12 hr. LSK is define
(A) Polyfunctionality and population-level statistics of the cell types analyzed. The
cell type studied. Different colors represent cells producing different number of c
cell type shows the total percentage of cells secreting detectable amount of any
(B) Comparison of HSCs and LSK cells by individual cytokine. Each plot is compo
four cell groups arranged from left to right are HSCs under LPS and Pam3CSK
stimulation only (light blue), and LSK cells with LPS and Pam3CSK4 stimulation (d
cells identified by the gate (the dotted line), and the bars represent the mean intens
dotted line).
(C) A summary heat map showing the percentage of HSCs and LSK cells that se
(D) Clustering analysis of WT LSK cells under LPS and Pam3CSK4 stimulation wi
two-way hierarchical clustering that groups similar proteins and cells together. Th
represents an individual cytokine, and each column represents an individual cell.
cytokine secretion from purple (undetectable) to yellow (intermediate) to red (ma
(1 to 4) are identified. Each cell group is replotted onto the 2D principal component
of the information from the data. The arrows indicate the directions of the two cy
See also Figures S1–S3.although very few stimulated LT-HSCs produced cytokines, a
significant fraction of LSK cells produced a wide range of cyto-
kines upon TLR stimulation (Figures 1A–1C and S3). Cytokine
production by LSK cells was stimulation dependent, given that
few LSK cells had detectable secretion in the absence of stimu-
lation. Furthermore, although LPS alone was sufficient to stimu-
late 12.9% of LSK cells to produce cytokines, a combination
of LPS and Pam3CSK4 boosted the percentage to 37.9%, and
many more cells secreted multiple cytokines, suggesting an ad-
ditive effect of simultaneously stimulating multiple TLRs (Figures
1A–1C). Among the 12 cytokines studied, IL-6 was the most
prominently induced and was secreted by 21.9% of LPS and
Pam3CSK4-stimulated LSK cells, whereas the production of
the other cytokines ranged from 7%–15% (Figures 1B and 1C).
Among the 12 cytokines in the panel, most are produced by
multiple immune cell types. However, some cytokines, such as
IL-2, IL-4, IL-17, and IFN-g aremainly produced by lymphocytes,
whereas IL-1b, IL-6, IL-12, TNF-a, and GM-CSF are more abun-
dantly produced by cells of the myeloid lineage (Janeway et al.,
2001). Interestingly, when unsupervised clustering analysis was
performed on LSK cells, it identified two main cytokine clusters:
a cytokine cluster (group i) including IL-6, TNF-a, IL-12, and GM-
CSF that resembles the production profile of myeloid cells, and a
cytokine cluster (group ii) including IL-2, IL-4, IL-10, and IFN-g
that resembles the production profile of lymphocytes (Figure 1D).
LSK cells were divided into multiple functional subsets differing
in their ability to produce group i and group ii cytokines, ranging
from nonproducers (Figure 1D, subset 1), group i producers (Fig-
ure 1D, subset 2), group ii producers (Figure 1D, subset 3), to
superproducers of all cytokines (Figure 1D, subset 4). When
the cells from the four subsets were plotted onto the 2D principal
component plane with the two vectors representing the two
cytokine groups, subset 2 cells fell into the group i direction,
and subset 3 cells fell into the group ii direction, whereas subset
4 cells fell between the two vector directions (Figure 1D, bottom),
demonstrating once again the differential cytokine secretion
profiles among LSK cells.
LSK cells represent a heterogeneous population comprising
LT-HSCs, ST-HSCs, MPPs, and LMPPs. They represent cells
along a differentiation tree with successive loss of self-renewal
ability while still retaining the full potential to replenish most, ifResponse to TLR Stimulation
re HSCs with LPS and Pam3CSK4, LSK cells with medium only, LSK cells with
d by LinSca1+cKit+, and HSC is defined by LSK CD150+CD48.
percentage of cells secreting different number of cytokines is shown for each
ytokines from 1 to 12 (labeled with different colors); the number on top of each
of the 12 cytokines.
sed of several thousand individual dots from several thousand single cells. The
4 stimulation (black), LSK cells with no stimulation (cyan), LSK cells with LPS
ark blue). The numbers on top represent the percentage of cytokine-producing
ity of only the cytokine-producing cells (average intensity of the cells above the
crete any individual cytokine under different stimulations.
th results presented as heat maps and scatter plots. The data are analyzed by
e grouping is shown by the tree structure for both proteins and cells. Each row
The result is presented by a heat map with colors representing the amount of
ximum). Two major groups of proteins (i and ii) and four main groups of cells
plane. This reduced space is the one that can explain the largest fraction (65%)
tokine functional groups aligned to the x and y axes.
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et al., 2006). Next, we asked whether the LSK heterogeneity
based on cytokine production profile correlates with known
HSPC subsets. To study this, we separately purified LT-HSCs
(LSK Flt3CD34), ST-HSCs (LSK Flt3CD34+), MPPs (LSK
Flt3intCD34+), and LMPPs (LSK Flt3hiCD34+) from the LSK pop-
ulation and analyzed their cytokine secretion with the single-
cell microfluidic chips (Figures 2 and S4). We confirmed that
LT-HSCs lacked cytokine production with the use of a set of
stem cell markers different from those used in Figure 1 because
of controversy over what set of markers best defines HSCs. In
comparison, ST-HSCs and MPPs were potent cytokine pro-
ducers, whereas more differentiated LMPPs produced rather
modest levels of cytokines (Figures 2A–2C and S4). Furthermore,
similar to unfractionated LSK cells, ST-HSCs and MPPs re-
mained heterogeneous in terms of cytokine production profile
(Figure S4A). These results were succinctly summarized with
principal component analysis in order to reduce the 12-dimen-
tional cytokine intensity data set from six different BM subsets
down to two principal components (Figures 2D and 2E). Principal
component 1 (PC1) represents a measure of the overall cytokine
secretion ability of a cell and is positively correlated with the in-
tensity of each of the 12 cytokines (Figure S4C). When LT-HSCs,
ST-HSCs, MPPs, and LMPPs along with unfractionated LSK
cells and total BM were compared along PC1, a majority of LT-
HSCs and LMPPs were clustered at the lower end of PC1, indi-
cating very low overall cytokine secretions, whereas ST-HSCs
and MPPs contained a large fraction of high cytokine secretors
(Figure 2D). Principal component 2 (PC2) is a measure of cyto-
kine secretion bias and is positively correlated with lymphoid
cytokines (Figure S4D) but negatively correlated with myeloid
cytokines (Figure S4E). When the six cell types were compared
along PC2, LSK cells, ST-HSCs, and MPPs were heterogeneous
with relatively even distribution across PC2, indicating that they
contained a mixture of nonproducers, myeloid cytokine-biased,
lymphoid cytokine-biased, and balanced producers. In compar-
ison, unfractionated BM cells showed moderate myeloid-cyto-
kine bias, and LMPPs showed moderate lymphoid-cytokine
bias (Figure 2E). It is known that HSCs defined by current best
cell-surface markers represent a heterogeneous population
with biased myeloid or lymphoid lineage potential (Beerman
et al., 2010; Challen et al., 2010; Copley et al., 2012). A recent
study using a single-cell barcode technology also demonstrated
the highly heterogeneous nature of the LMPP population (Naik
et al., 2013). To add to the complexity, we have now shown
that ST-HSCs and MPPs contain heterogeneous subsets based
on their cytokine secretion profile. It is reasonable to speculate
that the skewed cytokine production ability of ST-HSCs and
MPPs may also reflect a biased lineage potential. Unfortunately,
the current chip design does not allow us to recover the various
cell subsets on the basis of their cytokine secretion profile for
functional and lineage potential analysis. The possible relation-
ship between the heterogeneous cytokine production ability
and their lineage potential and functional capacity represents a
future direction for research.
Regulation of HSPC Cytokine Production by NF-kB
NF-kB is a family of transcription factors central to the regulation
of inflammation and immune cell activation. Almost three de-4 Cell Stem Cell 14, 1–15, April 3, 2014 ª2014 Elsevier Inc.cades of research has elucidated many key physiological func-
tions of NF-kB in innate and adaptive immune cells as well as
its involvement in the pathogenesis of many immunological dis-
eases (Baltimore, 2011). However, much less is known about the
physiological function of NF-kB in HSPCs during inflammation.
Because both LPS and Pam3CSK4 can activate NF-kB, which
in turn can upregulate the transcription of many inflammatory
cytokines in mature immune cells, we suspected that NF-kB
might also regulate cytokine production in HSPCs. To test this,
we first determined whether the important components of
the TLR/NF-kB pathway were expressed at the protein level in
HSPCs. Using a transgenic mouse that has a knockin of a
RELA-GFP fusion protein at the endogenous locus (De Lorenzi
et al., 2009), we found that all LT-HSCs and LSK cells were
GFP+, indicating that all HSPCs express RELA (also known
as p65) protein, a key subunit of NF-kB (Figure 3A). Then, we
showed that both TLR-2 and TLR-4 receptors were expressed
on the surface of LSK cells, and a subset of them express both
receptors (Figure 3B), a finding consistent with previous reports
(Nagai et al., 2006). Next, we asked whether HSPCs have func-
tional NF-kBactivity upon TLR stimulation. To study this, we took
advantage of a different transgenic NF-kB-GFP reporter mouse,
one with GFP expression under the control of the NF-kB regula-
tory elements (Magness et al., 2004). LPS stimulation in vivo
upregulated GFP expression from 8% basally to 35%–40% in
both LSK cells and LT-HSCs (Figures 3C and 3D). More directly,
when purified LSK cells and LT-HSCs were stimulated with LPS
and Pam3CSK4 in vitro, NF-kB activation was again evident by
both the percent of GFP+ cells and mean fluorescence intensity
(Figures 3E and 3F). These results demonstrate that both LSK
cells and LT-HSCs contain functional TLR/NF-kB signaling that
can be directly activated by TLR-4 and TLR-2 ligands.
To determine whether NF-kB regulates cytokine production in
LSK cells, we took advantage of mice deleted for genes impor-
tant to the NF-kB pathway. NFKB1 (also known as p50) is one
of the main subunits of the NF-kB family of transcription factors,
and p50 deficiency results in defective NF-kB activity in various
immune cells (Sha et al., 1995). In contrast, miR-146a is an
important negative regulator of NF-kB activation by targeting
its upstream signaling transducers TRAF6 and IRAK1. Thus,
deficiency in miR-146a leads to enhanced NF-kB activity (Boldin
et al., 2011; Zhao et al., 2011, 2013). When we subjected LSK
cells from Nfkb1/ mice (p50 knockout [KO]) and Mir146a/
mice (miR KO) to the single-cell chip analysis, we found that pro-
duction of all 12 cytokines was significantly attenuated in p50 KO
LSK cells and enhanced in miR KO LSK cells in comparison to
wild-type (WT) LSK cells (Figures 4A–4C and S3). Although
37.9% ofWT LSK cells produced cytokines under costimulation,
the percentage rose to an impressive 69.7% in miR KO and
dropped to a mere 2.4% in p50 KO LSK cells (Figure 4A).
Furthermore, the percentage of cytokine-producing LSK cells
in Mir146a/ Nfkb1/ (miR/p50 double knockout [DKO]) mice
was less than in WT mice, indicating that the lack of p50 is
dominant over miR-146a deficiency (Figures 4A–4C and S3). In
addition to the percentage of responding cells, the amount of
cytokines produced on a per-cell basis was also enhanced in
miR KO LSK cells and reduced in p50 LSK cells for all the proin-
flammatory cytokines (Figure 4B). These data demonstrate that
cytokine production in LSK cells is regulated by the level of
Figure 2. Single-Cell Analysis of Cytokine Production by Various HSPC Subsets in Response to TLR Stimulation
(A–E) Data from single-cell cytokine chip analysis. The six cell groups analyzed are BM (total BM cells), LSK cells, LMPPs (LSK CD34+Flt3hi), MPPs (LSK
CD34+Flt3int), ST-HSCs (LSK CD34+Flt3), and LT-HSCs (LSK CD34Flt3), all under LPS and Pam3CSK4 stimulation for 12 hr.
(A) Polyfunctionality and population-level statistics of the cell types analyzed. The percentage of cells secreting different number of cytokines is shown for each
cell type studied. Different colors represent cells producing different number of cytokines from 1 to 12 (labeled with different colors); the number on top of each
cell type represents the total percentage of cells secreting detectable amount of any of the 12 cytokines.
(B) Comparison of HSPC subsets by individual cytokines. Four out of 12 cytokines are shown here, and the rest are shown in Figure S4B. Each plot is composed
of several thousand individual dots from several thousand single cells. The six cell groups arranged from left to right are total BM, LSK cells, LMPPs, MPPs,
ST-HSCs, and LT-HSCs under LPS and Pam3CSK4 stimulation. The numbers on top represent the percentage of cytokine-producing cells identified by the gate
(the dotted line), and the bars represent the mean intensity of only the cytokine-producing cells (average intensity of the cells above the dotted line).
(C) A summary heat map showing the percentage of the six groups of cells that secrete any individual cytokine under different stimulations.
(D and E) Principal component analysis of all six cell groups that reduce a 12-dimensional cytokine data set from six different cell groups into two principal
components (PC1 and PC2).
(D) PC1 represents the overall cytokine production capacity of a cell and is positively correlated to the overall intensity of all 12 cytokines (see Figure S4C). After all
12 cytokine intensities of each cell are converted into a single PC1 value, the relative frequency of cells with each PC1 value is calculated for all six cell subsets.
Graphs show the relative frequency of cells (y axis) of the six cell groups against PC1 (x axis). Each cell type is represented by a different color.
(E) PC2 represents the level of biased cytokine production profile and is positively correlated to the lymphoid group of cytokines, including IL-2, IL-17a, IL-4, IL-12,
IL-1b, and IFN-g, but is negatively correlated to the myeloid group of cytokines, including TNF-a, IL-6, and GM-CSF (see Figures S4D and S4E). Graphs show the
relative frequency of cells (y axis) of the six cell groups against PC2 (x axis). Each cell type is represented by a different color.
See also Figure S4.
Cell Stem Cell
HSPCs Regulate Myelopoiesis via Cytokines
Cell Stem Cell 14, 1–15, April 3, 2014 ª2014 Elsevier Inc. 5
Please cite this article in press as: Zhao et al., Conversion of Danger Signals into Cytokine Signals by Hematopoietic Stem and Progenitor Cells for
Regulation of Stress-Induced Hematopoiesis, Cell Stem Cell (2014), http://dx.doi.org/10.1016/j.stem.2014.01.007
AC D
E
F
LP
S 
st
im
ul
at
io
n
N
o 
st
im
ul
at
io
n
N
eg
at
iv
e 
co
nt
ro
l
Sca1
cK
it
CD150
C
D
48
GFP
C
D
15
0
0.18%
GFP
cK
it
10.2%
0.286%
5.73%
7.95%
7.66%
7.47%
1.61%
39.9%
8.33%
36.2%
5.14%
B
HSCLSK
GFP
C
ou
nt
GFP
C
ou
nt
RelA-GFP
Percent GFP+ HSCs
Ne
g C
trl
PB
S
LP
S
0
10
20
30
40
50
G
FP
 P
er
ce
nt
ag
e
Percent GFP+ LSK cells
Ne
g C
trl
PB
S
LP
S
0
10
20
30
40
50
G
FP
 P
er
ce
nt
ag
e
in vivo stimulation
Percent GFP+ HSCs
0HR 6HR
0
5
10
15
G
FP
 P
er
ce
nt
ag
e
Percent GFP+ LSK cells
0HR 4HR 6HR 12HR
0
10
20
30
G
FP
 P
er
ce
nt
ag
e
MFI of GFP+ HSCs
0HR 6HR
0
100
200
300
400
500
G
FP
 M
FI
 (a
rb
itr
ar
y 
un
it)
MFI of GFP+ LSK Cells
0HR 4HR 6HR 12HR
0
100
200
300
400
500
G
FP
 M
FI
 (a
rb
itr
ar
y 
un
it)
in vitro stimulation (hours)
TLR-4TLR-2
C
ou
nt
LSK
TLR-4
TL
R
-2
50.2%
13.4%5.2%
Figure 3. NF-kB Activation through TLRs in HSPCs
(A–F) Data from FACS analysis.
(A) Representative FACS histogram of LSK cells (blue) and HSCs (LSK CD150+CD48; red) from RELA-GFP transgenic mice. LSK cells from a WT C57Bl/6 mice
were used as a negative control (black).
(B) Representative FACS plots of TLR-2 and TLR-4 surface expression of WT LSK cells. Blue represents isotype antibody control, and red represents fluo-
rescence-conjugated antibodies against TLR-2 (left), TLR-4 (middle), or both (right).
(C–F) Determination of TLR and NF-kB functionality in LSK cells and HSCs with mice in which GFP production is under NF-kB regulatory control.
(C and D) Experiments from in vivo stimulation.
(C) LPS-stimulated WT mouse is used as a negative control (top row) for GFP expression. No stimulation (middle row) corresponds to PBS-treated NF-kB-GFP
transgenic reporter mice. LPS stimulation (bottom row) corresponds to LPS-stimulated NF-kB-GFP transgenic reporter mice (2 mg/kg body weight LPS for 6 hr).
(D) Quantification of GFP+ percentages in LSK cells and HSCs from negative control, unstimulated, and LPS-stimulated NF-kB-GFP transgenic reporter
mice (n = 3).
(E and F) Experiments from in vitro stimulation of purified LSK cells and HSCs.
(legend continued on next page)
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to increase or decrease the cytokine production of LSK cells in
response to TLR stimulation. We also measured the coproduc-
tion of any two cytokines at the single-cell level (Figures 4D
and 4E). Correlation coefficients (R values) were calculated for
all cytokine pairs for WT, p50 KO, and miR KO LSK cells, higher
R values indicating tighter coregulation. In general, WT LSK cells
showed higher correlation coefficients than either p50 KO ormiR
KO LSK cells, indicating a better coregulation of these cytokines
(Figure 4E, green blocks). This may be functionally important,
given that many of these cytokines are often produced together
by a single cell; e.g., myeloid cells produce TNF-a, IL-6, and IL-
12 during an inflammatory response, and CD4 TH1 cells produce
IL-2 and IFN-g. Imbalance in cytokine levels could lead to unde-
sired effects and pathologies. When we performed a principal
component analysis on LSK cells of all genotypes, a myeloid
cytokine group including IL-6, TNF-a, IL-1b, and GM-CSF and
a lymphoid cytokine group including IL-2, IL-4, and IL-17a
were again identified (Figure 4F). Plotting the measurements
onto the dominant 2D principal component space revealed
diminished production of both groups of cytokines in p50 KO
LSK cells and enhanced production in miR KO LSK cells. Inter-
estingly, enhancement in the myeloid component was even
more prominent in miR KO LSK cells, suggesting miR-146a-defi-
cient LSK cells have especially enhanced myeloid cytokine
production. Overall, these results demonstrate that TLR-stimula-
tion-mediated cytokine production in HSPCs is exquisitely
regulated by the level of NF-kB activity.
Functional Significance of HSPC-Produced Cytokines in
Regulating Myelopoiesis In Vitro
Cytokines produced by HSPCs are also produced by mature
immune cells in the BM and periphery. However, we hypothesize
that the location of HSPCs in the stem cell niche may represent
an inherent advantage, allowing HSPC-produced cytokines to
efficiently regulate their own fate in a more timely fashion during
an infection or inflammatory challenge. To assess the functional
significance of HSPC-produced cytokines, we first compared
the cytokine production capacity of LSK cells with that of more
differentiated progenitor cells and mature immune cells. To
this end, purified LSK cells and lineage-committed progenitor
cells (LincKit+Sca1 and LincKitSca1+) from BM as well as
CD11b+myeloid, CD4+ T, CD8+ T, and B220+ B cells from spleen
were stimulated with LPS plus Pam3CSK4 for 24 hr. Then,
culture medium was collected for multiplexed ELISA in order to
measure a panel of 15 cytokines. Surprisingly, in the absence
of survival and proliferative advantage after stimulation (Fig-
ure S5A), LSK cells produced far more cytokines in both quantity
and breadth thanmaturemyeloid and lymphoid cells in 24 hr with
LPS and Pam3CSK4 stimulation. More impressively, even with
much stronger stimuli, such as CpG, anti-CD3 and anti-CD28,
or 100-fold more LPS, T, B, and myeloid cells were still signifi-
cantly less potent cytokine producers than LSK cells (Figure 5A).
In addition, LSK cells produced a wide range of myeloid and(E) Representative FACS histograms of LSK cells and HSCs sorted from NF-kB-G
and red represents cells stimulated in vitro with LPS (100 ng/ml) for 6 hr.
(F) Quantification of GFP+ percentages andGFPmean fluorescence intensity of LS
mean ± SEM.lymphoid cytokines, whereas mature myeloid cells and lympho-
cytes showed narrower cytokine production profile.
Next, we determined whether the cytokines produced by
HSPCs are able to influence hematopoiesis in vitro. First, we
showed that a fraction of LT-HSCs, LSK cells, and myeloid
progenitor cells expressed various cytokine receptors, including
IL-6Ra, IFN-gR, TNF-R1, and TNF-R2, on their surfaces (Fig-
ure S6A). This is consistent with previous studies that provided
direct and indirect evidence of cytokine receptor expression in
HSPCs (Baldridge et al., 2010, 2011; Maeda et al., 2009; Pronk
et al., 2011). Next, we measured myeloid differentiation of LSK
cells under LPS and Pam3CSK4 stimulation. Using an IL-6
neutralizing antibody, we were able to determine the effect of
taking away IL-6 produced by LSK cells on myelopoiesis (Fig-
ures 5B and 5C). Interestingly, in comparison to the isotype
antibody control, the neutralization of IL-6 had a significant effect
on myeloid differentiation. Specifically, the percent of CD11b+
cells produced from LSK cells decreased by about 50%, and
the number of CD11b+ cells showed a 2-fold reduction over a
4-day period (Figures 5B and 5C). To extend the study to
include several other abundantly produced cytokines, we found
that the neutralization of TNF-a or GM-CSF, but not IFN-g, also
had an inhibitory effect on the generation of myeloid cells (Fig-
ures 5D and 5E). Interestingly, neutralization of IL-6, IFN-g, or
GM-CSF all decreased the number of LSK cells, suggesting
that these cytokines produced by LSK cells have a positive
effect on their own proliferation and/or survival (Figure 5E). It is
worth noting that we have previously shown that IL-6 can directly
induce LSK cell proliferation by BrdU incorporation (Zhao et al.,
2013). To further demonstrate the functional importance of
HSPC-produced cytokines, we compared cytokines produced
by BM cells that were depleted of HSPCs to that of total BM
cells in inducing myelopoiesis. To this end, we stimulated
equal number of total BM cells and Sca1-depleted BM cells
with LPS and Pam3CSK4 in vitro for 24 hr and then used the
conditioned media to stimulate LSK cells. We saw up to 40%
reduction in the number CD11b+ myeloid cells after only
2 days of incubation with conditioned medium from Sca1-
depleted BM cells (Figure 5F). This suggests that HSPCs, ac-
counting for less than 1% of total BM cells, make a significant
contribution to the cytokine milieu and have a stimulatory
effect on myelopoiesis. Instead of depleting cytokine, we next
askedwhether increased cytokine production by LSK cells could
enhance myelopoiesis. To this end, we used miR-146a-deficient
LSK cells that showed exaggerated cytokine production (Fig-
ure 4). Purified LSK cells from WT or miR KO mice were stimu-
lated with LPS and Pam3CSK4 in vitro for 24 hr, and then
the conditioned media were used to stimulate newly purified
WT LSK cells. After 2 days, we saw a modest but consistent in-
crease in numbers of both LSK cells and CD11b+ cells when WT
LSK cells were cultured with miR KO-LSK-cell-conditioned
medium in comparison to WT-LSK-cell-conditioned medium
(Figure 5G). This suggests that with just 24 hr of cytokine accu-
mulation, the exaggerated cytokine production by miR KO LSKFP transgenic reporter mice. Blue represents unstimulated LSK cells or HSCs
K cells at 0, 4, 6, and 12 hr and HSCs at 0 and 6 hr (n = 3). Data are presented as
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Figure 4. Regulation of HSPC Cytokine Production by NF-kB
(A–F) Data from single-cell cytokine chip analysis. LSK cells were sorted from WT, Nfkb1/ (p50 KO),Mir146a/ (miR KO), and Nfkb1/Mir146a/ (miR/p50
DKO) mice and were stimulated with LPS and Pam3CSK4 for 12 hr.
(A) Polyfunctionality and population level statistics of LSK cells of different genetic models. The percentage of LSK cells secreting a different number of cytokines
is shown for each cell type studied. Different colors represent cells producing different number of cytokines from 1 to 12 (labeled by different colors); the number
on top of each cell type represents the total percentage of cells secreting detectable amount of any cytokine.
(legend continued on next page)
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proliferation and/or survival. Consistent with this in vitro finding,
miR KO mice exhibit a significant myeloproliferative disease
after chronic inflammatory stimulation as a result of enhanced
HSPC proliferation and myeloid differentiation, whereas deleting
IL-6 in miR KO mice effectively ameliorates the myeloprolifera-
tive condition (Zhao et al., 2013). Complementing our previous
reports that have shown the involvement of hyperactivated
T cells and myeloid cells in miR-146a-deficiency-mediated
pathologies (Zhao et al., 2011, 2013), this study shows that
exaggerated cytokine production by miR-146a-deficient HSPCs
is also a contributor to enhanced myelopoiesis in miR-146a
KO mice.
Functional Significance of HSPC-Produced Cytokines in
Regulating Myelopoiesis In Vivo
In addition to in vitro functional significance, we next determined
whether HSPC-produced cytokines are important in regulating
hematopoiesis in vivo. Because current technology does not
allow us to delete a cytokine specifically and selectively in stem
and progenitor cells while allowing cytokine production inmature
cells, to overcome this hurdle, we have created leucopenic
conditions in vivo in which mature myeloid and lymphoid cells
are severely depleted, whereas stem and progenitor cells are
preserved. We created these conditions in mice by injecting a
chemotherapeutic drug, 5-flurouracil (5-FU) (Figures 6A–6C) or
by transplanting stem and progenitor cells after lethal irradiation
(Figures 6D–6F). LPS was injected into mice in order to stimulate
myelopoiesis when neutropenia became the most severe, as
measured by periodic sampling of peripheral blood. 5-FU is a
chemotherapeutic drug that induces a significant reduction in
mature cells in both BM and periphery while stimulating stem
and progenitor cells to cycle (Harrison and Lerner, 1991). After
5-FU injection, myeloid cells started to decline, and, by day 5,
80% of myeloid cells were depleted in WT, miR-146a KO, IL-6
KO, and miR-146a/IL-6 DKO mice (Figure 6A). At this time,
low-dose LPS was injected in order to stimulate myelopoiesis.
Consistent with in vitro studies, IL-6 KO mice showed a 2-fold
decrease in CD11b+ and Gr1+ myeloid cells, whereas miR KO
mice showed a modest increase in comparison to WT mice (Fig-
ures 6B and 6C). In addition, DKOmice showed a similar level of
reduction as IL-6 KOmice, indicating that loss of IL-6 is the domi-
nant factor. To perform stem cell transplant, 500,000 purified
LincKit+ cells from WT, miR KO, IL-6 KO, or miR/IL-6 DKO(B) Comparison of the cytokine secretion capacity of LSK cells from different ge
protein with the four different mouse models arranged from left to right (p50 KO, g
several thousand individual dots from several thousand single cells. The number
(the dotted line), and the bars represent the mean intensity of only the positive c
(C) A summary heat map showing the percentage of LSK cells that secrete any i
(D) 2D scatter plots showing protein pair correlations. Results from p50 KO (gree
(R value) of the two cytokines for the different mouse models are shown on the p
(E) A half matrix summarizing the comparison of correlation coefficients (R values
square block, intercepted by two cytokines with one on the top and one to the
represents the case when WT LSK has the highest correlation, such as IL-6 versu
such as IL-6 versus IFN-g. Correlations for all protein pairs from the p50 KO LSK
(F) Principal component analysis of LSK cells from the four genetic models. The
reduced space is the one that can explain the most (>60%) information of the dat
aligned to the x and y axes.
See also Figure S3.mice were injected into lethally irradiated WT recipient mice. All
four groups of mice showed severe leucopenia 6 days after irra-
diation and cell injection, and approximately 8,000 myeloid cells
and 20,000 total white blood cells were left in the peripheral
blood. This represented less than 1% of the normal level and
4% of the number of transplanted HSPCs (Figures 6D–6F). LPS
stimulation promoted myelopoiesis that was mildly increased in
mice receiving miR KO HSPCs but was significantly attenuated
in mice receiving IL-6 KO or miR/IL-6 DKO HSPCs, indicating
that IL-6 produced by HSPCs is an important factor in promoting
myeloid cell recovery during neutropenia (Figures 6D–6F).
Overall, these in vivo experiments show that, in mice with severe
leucopenia, LPS-stimulated production of cytokines, especially
IL-6, by endogenous or transplanted HSPCs has a significant
positive impact on stress-induced myelopoiesis.
Within the BM niche, we speculate that the cytokines released
by HSPCs upon TLR stimulation can act on themselves or neigh-
boring HSPCs. To further delineate whether HSPC-produced
cytokines mediate hematopoiesis predominantly through an
autocrine or paracrine fashion, we injected NF-kB-GFP reporter
mice with both LPS and BrdU in order to determine the relation-
ship between cytokine-producing HSPCs and proliferating
HSPCs. GFP expression, an indicator of NF-kB activation and
cytokine production, and BrdU incorporation, a marker of prolif-
eration, were costained in myeloid progenitor cells, LSK cells,
and LT-HSCs at 4, 12, and 24 hr (Figure 6G). The result showed
that LSK cells and LT-HSCs rapidly turned on NF-kB in response
to LPS stimulation, whereas myeloid progenitor cells went into
cycle quickly. As time elapsed, LT-HSCs and LSK cells started
to proliferate, whereas NF-kB activity gradually dampened.
Interestingly, throughout the stimulation, cells with NF-kB activ-
ity and cells that rapidly proliferated represented two largely
nonoverlapping populations in all the stem and progenitor sub-
sets. Although this result has multiple potential interpretations,
the fact that we have been unable to capture a large fraction
of cells that are simultaneously positive for BrdU and GFP
throughout the 24 hr interval suggests to us the following
mechanism: LPS-mediated NF-kB activation in HSPCs does
not appear to directly turn on a proliferation program, and,
instead, cytokines are induced that, in turn, act on cytokine re-
ceptors on neighboring HSPCs to stimulate proliferation and dif-
ferentiation. The nature of this type of paracrine signaling and the
distinction between the proliferative and the NF-kB-activated
subsets within HSPCs require further investigation.netic models. Each plot represents cytokine intensity scatter plots for a single
reen; miR/p50 DKO, yellow; WT, blue; miR KO, red). Each plot is composed of
s on top represent the percentage of cytokine-producing cells above the gate
ytokine-producing cells (average intensity of the cells above the dotted line).
ndividual cytokine.
n), WT (blue), and miR KO (red) LSK cells are plotted. Correlation coefficients
lots.
) of any given cytokine pairs betweenWT, p50 KO, and miR KO LSK cells. Each
right, represents correlation coefficients between the two cytokines. Green
s GM-CSF, and red represents when miR KO LSK has the highest correlation,
cells are always lower than either WT or miR KO.
data are plotted onto the 2D space by the top two principal components. This
a. The directions of the two protein groups are represented by the two vectors
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Figure 5. In Vitro Analysis of Functional Significance of HSPC-Produced Cytokines
(A) Multiplexed ELISA quantification of cytokines in bulk cell-culture medium in order to compare cytokine production of different FACS-purified cell subsets
stimulated for 24 hr with various stimulations. Cell types include LSK cells, LSK+ (LinSca1cKit+), and LS+K (LinSca1+cKit) sorted fromBMs and CD4+ T,
CD8+ T, CD19+ B, and CD11b+ myeloid cells sorted from spleens. Stimulations include LPS/Pam (100 ng/ml LPS and 1 mg/ml Pam3CSK4), LPS/Pam/stem cell
(legend continued on next page)
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In this study, we have shown that ST-HSCs andMPPs can trans-
late danger signals arising from an infection into cytokine signals
that can directly regulate stress-induced hematopoiesis. Signif-
icantly, the cytokine production ability of HSPCs trumps both
mature myeloid and lymphoid cells in terms of speed, magni-
tude, and breadth. In the BM stem cell niche, this property of
HSPCs may play an important role in providing a rapid response
time from the encounter of an infection to the output of myeloid
cells. In addition to residing in the BM, HSPCs are known
to egress from the marrow and traffic through the blood and
lymphatic circulation to peripheral organs, including spleen,
liver, lymph nodes, gut, and adipose tissues, where they may
be exposed to a heavy burden of danger signals. These extrame-
dullary sites may provide excellent opportunities for HSPCs to
coordinate rapid stress-induced hematopoiesis upon TLR stim-
ulation (Han et al., 2010; Jaiswal andWeissman, 2009;Massberg
et al., 2007; Wesemann et al., 2013).
Given that all the cytokines produced by HSPCs are also pro-
duced by mature immune cells and some nonhematopoietic
cells, isolating the effect of cytokines produced by HSPCs
from mature cells in vivo is difficult, if not impossible, given cur-
rent technical limitations in specifically deleting a gene in HSCs
while turning it back on in mature cells. Therefore, we have relied
on in vitro studies to demonstrate the functional importance of
HSPC-produced cytokines in regulating myelopoiesis. In addi-
tion, there are situations when mature immune cells are signifi-
cantly depleted, such as during sepsis, after chemotherapy,
and during the initial recovering phase of stem cell transplant.
During these situations, when mature immune cells are depleted
and HSPCs are overrepresented, the ability of HSPCs to
respond to stress directly in order to produce cytokines may
become critical in mediating rapid hematopoietic cell recovery.
We have created these situations in mice to mimic neutropenic
conditions after chemotherapy or stem cell transplant and
have shown that the ability of HSPCs to produce IL-6 is particu-
larly important in mediating stress-induced myelopoiesis. In clin-
ical practice, G-CSF and GM-CSF are used in certain situations
after chemotherapy or stem cell transplant to stimulate neutro-
phil recovery in neutropenic patients who are susceptible to fatal
infections (Bennett et al., 2013). A better understanding of the
cytokine-mediated hematopoiesis in neutropenic conditionsfactor (SCF; 100 ng/ml LPS, 1 mg/ml Pam3CSK4, and 50 ng/ml SCF), CpG (1 mM),
medium; BM, culture medium from unstimulated total BM cells. Data are presente
represented in white, and high level represented in red. Cytokines are clustered
(B–E) Analysis of in vitro myelopoiesis from WT LSK cells by FACS. Sorted WT L
(50 ng/ml) in the presence of cytokine-neutralizing antibodies. Control, isotype ant
anti-TNF-a neutralizing antibodies.
(B and C) Time course of myelopoiesis from WT LSK cells in the presence of ant
(D and E) Myelopoiesis from WT LSK cells in the presence of various neutralizing
myeloid cells and LSK cells. The representative FACS plots (B and D); quantifica
(F and G) FACS analysis of in vitro myelopoiesis from WT LSK cells in the presen
(F) WT total BM cells or WT BM cells depleted of Sca1+ cells were stimulated wit
culturingmedium. Then, the culturingmediumwas used to stimulate freshly purifie
(G) WT or miR-146a KO LSK cells were stimulated with LPS and Pam3CSK4 for 2
culturing mediumwas used to stimulate freshly purifiedWT LSK cells. The numbe
mean ± SEM.
See also Figure S5.will provide insight in the development of potentially more effec-
tive hematopoietic stimulating factors.
In addition to neutropenic conditions, we reason that this stem
and progenitor cell property is also important under physiolog-
ical conditions, despite of the rarity of HSPCs among differenti-
ated hematopoietic cells. First, the speed, magnitude, and
breadth of the cytokines produced by HSPCs in comparison to
mature immune cells are impressive. Furthermore, this has not
taken into the account the unique location of HSPCs in the
stem cell niche. Location and organization of HSPCs within the
BM niche have long been appreciated to play an important role
in their self-renewal and proliferative properties (Shen and Nils-
son, 2012). Perhaps groups of HSPCs residing in close proximity
represent a unique advantage for rapid autocrine or paracrine-
mediated hematopoiesis. Through BrdU incorporation in NF-
kB-GFP reporter mice, we have shown that HSPCs with NF-kB
activity and that are actively proliferating are largely two distinct
populations. We speculate that a potential paracrine regulatory
signaling may be at work within the BM that involves one subset
of HSPCs responding to TLR stimulation by rapidly turning on
NF-kB and producing copious amounts of cytokines and a
neighboring cell population with cytokine receptors that can un-
dergo rapid proliferation and differentiation in response to cyto-
kine stimulation. In support of the notion, although some LSK
cells express both TLR-4 and IL-6Ra, it appears that a fraction
of LSK cells express only the TLR or the cytokine receptor (Fig-
ure S6B), suggesting that HSPCs contain heterogeneous sub-
sets with intrinsic differences in their ability to respond to TLR
and cytokine stimuli.
The questions regarding the extent of involvement of HSPC-
produced cytokines in hematopoiesis in a nonneutropenic host
and the nature of HSPC heterogeneity on the basis of differential
cytokine production or receptor expression remain open and will
be an area of significant interest for future studies. In addition, we
are also currently redesigning the microfluidic platform in order
to recover individual cells from the chip after proteomic analysis
for subsequent lineage and functional analysis. Furthermore,
there are perhaps limitations in the in vitro on-chip stimulation,
which may not provide the optimal conditions for culturing undif-
ferentiated HSPCs. This may result in a reduction in the cells’
functional robustness and an underestimate of the true percent-
age of cytokine-producing cells in vivo, despite our poststimula-
tion analysis to ensure that HSPCs remain phenotypicallyLPS (10 mg/ml), CD3/28 (1 mg/ml anti-CD3 and 1 mg/ml anti-CD28). Blank, fresh
d as a heat map with low cytokine level represented in blue, intermediate level
into groups.
SK cells were stimulated with LPS (100 ng/ml), Pam3CSK4 (1 mg/ml), and SCF
ibody control; all Abs, a combination of anti-IL-6, anti-IFN-g, anti-GM-CSF, and
i-IL-6 neutralizing antibody.
antibodies. Cells were analyzed on day 3 by FACS for percent and number of
tion (n = 3; C and E).
ce of conditioned medium.
h LPS and Pam3CSK4 for 24 hr in order to induce cytokine production into the
dWT LSK cells. Number ofmyeloid and LSK cells was analyzed on day 2 (n = 8).
4 hr in order to induce cytokine production into the culturing medium. Then, the
r of myeloid and LSK cells was analyzed on day 2 (n = 3). Data are presented as
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Figure 6. In Vivo Analysis of Functional Significance of HSPC-Produced Cytokines
(A–C) For 5-FU-induced neutropenia, WT, miR-146a KO, IL-6 KO, and miR-146a/IL-6 DKO mice were injected with 5-FU (250 mg/kg of body weight, i.p.).
(A) Peripheral blood was analyzed on days 0, 2, 4, and 5 by FACS in order to determine the number of CD11b+ myeloid cells. On day 5, LPS (0.3 mg/kg
of body weight, i.p.) was injected, and mice were bled 24 hr later in order to study LPS-induced myelopoiesis by analyzing the number of CD11b+ (B) or Gr1+
(C) cells.
(legend continued on next page)
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scopy. The ability to recover individual cells poststimulation will
allow us to better assess cell viability.
Functions of NF-kB in immune cells have been extensively
studied. However, knowledge of the functional role of NF-kB in
HSPCs has been limited. In this study, we have connected a
known function of NF-kB, the regulation of cytokine production,
to two unexpected multipotent hematopoietic cell populations,
ST-HSCs and MPPs. What is also intriguing is that some
LT-HSCs appear able to respond to TLR stimulation by the acti-
vation of NF-kB, and all HSCs appear to have at least the p65
subunit of NF-kB. Thus, despite NF-kB by itself being insufficient
to enable cytokine secretion in LT-HSCs, NF-kB is present from
the inception of hematopoiesis and may regulate other aspects
of HSC biology.
EXPERIMENTAL PROCEDURES
Animal Models
All mice (WT, Nfkb1/, Mir146a/, Il6/, Nfkb1/Mir146a/, Il6/
Mir146a/, RELA-GFP knockin, and NF-kB-eGFP reporter mice) were on a
C57BL/6 genetic background and housed under a specific pathogen-free con-
dition at the California Institute of Technology. Mice used for all experiments
were age- and sex-matched 6- to 8-week-old female mice. All experiments
were approved by the institutional Animal Care and Use Committee of the
California Institute of Technology.
FACS Sort
In general, 15 to 20 mice of the same genotype were used for FACS sorting in
order to obtain sufficient stem and progenitor cells. First, BM cells were sub-
jected to magnetic bead selection (Miltenyi Biotec) according to manufac-
turer’s protocol in order to deplete lineage-positive cells, and then they were
sorted on a BD FACSAria sorter at the California Institute of Technology
FACS Core. More details can be found in the Supplemental Experimental
Procedures.
Single-Cell Cytokine Chip Analysis
We integrated upstream FACS purification techniques with the single-cell
barcode chip in order to study the functional proteomics from phenotypically
defined single cells. The chips used in this study have > 5,000 microchambers
of about 100 picoliter volume to enable sensitive detection of proteins. Within
each microchamber, a panel of 12 cytokines (TNF-a, GM-CSF, IL-6, IL-12p40,
IFN-g, IL-2, IL-4, IL-10, TGF-b1, CCL-2, IL-17A, and IL-1b) can be simulta-
neously measured by sandwich ELISA-like assay. Themanufacture procedure
of the chip has been described in our previous study (Ma et al., 2011), and the
detailed experimental steps can be found in the Supplemental Experimental
Procedures. In brief, FACS-purified cells were cultured at 37C in 5% CO2
cell incubator with medium alone, medium plus LPS, or medium plus LPS
and Pam3CSK4 for 12 hr. At the end of stimulation, the chip was imaged
with a high-resolution bright-field microscope. Cell number in each chamber
was counted, and cell viability was assessed to exclude fragmented or non-
light-reflective cells by trained personnel in a blind manner. Then, cells were
washed off, and the chips were developed via an immuno-sandwich assay.
A GenePix 4400A microarray scanner was used to scan slides, and data
were analyzed with GenePix Pro 7. Each single-cell chip analysis of a
specific cell subset, genotype, and stimulating condition was performed at
least two times.(D–F) For stem cell transplant studies, LincKit+ cells were purified from the BM o
mouse were injected intravenously into lethally irradiated WT recipient mice. On
neutropenia. LPS was injected (0.3 mg/kg of body weight, i.p.), and, 48 hr later,
number of total white blood cells (D), CD11b+ cells (E), and Gr1+ cells (F).
(G) LPS (2 mg/kg of body weight, i.p.) and BrdU (1 mg, i.p.) were injected into NF-k
12, and 24 hr. Representative FACS plots of GFP expression and BrdU incorporat
See also Figure S6.Mutliplexed Cytokine Analysis of Bulk Cell-Culture Medium
For multiplexed cytokine analysis of bulk cell-culture medium, 100,000 cells of
each FACS-purified subset were stimulated in 100 ml medium with various
stimulations for 24 hr in a 96-well plate. Then, the medium was collected
and concentrated by 4-fold before being subjected to multiplexed ELISA
quantification of 15 different cytokines and chemokines. For multiplexed
ELISA quantification, the detection method was identical to the single-cell
chip analysis described above. The difference is that the sample here consists
of culturing medium only. In brief, the ELISA chip was first blocked with 3%
BSA in PBS buffer and then hybridized with an antibody-single-stranded
DNA conjugate cocktail and washed with 3% BSA in PBS followed by the
application of a medium sample. The assay was completed by applying sec-
ondary biotinylated antibodies and streptavidin-cy3 in sequence. Multiplexed
cytokine analysis of a specific cell subset, genotype, and stimulating condition
was performed at least two times.
In Vitro Analysis of Myeloid Differentiation
For analysis of myeloid differentiation under cytokine-neutralizing antibodies,
sorted LSK cells (15,000 cells per 100 ml medium) were stimulated with LPS
(100 ng/ml), Pam3CSK4 (1 mg/ml), and stem cell factor (50 ng/ml) in the pres-
ence of various cytokine-neutralizing antibodies. Antibody concentrations
used were isotype control (1 mg/ml), anti-iFN-g (1 mg/ml), anti-iL-6 (1 mg/ml),
anti-GM-CSF (5 mg/ml), and anti-TNF-a (5 mg/ml; eBioscience). Cells were
analyzed on day 3 by FACS for the percent and number of myeloid cells and
LSK cells. For the analysis of myeloid differentiation under conditioned
medium, WT or miR-146a KO LSK cells (30,000 cells per 100 ml medium)
were stimulated with LPS (100 ng/ml) and Pam3CSK4 (1 mg/ml) for 24 hr in
order to induce cytokine production into the culturing medium. Then, the
culturing medium from either WT or miR KO LSK cells was collected and
used to stimulate freshly purified WT LSK cells. The number of myeloid and
LSK cells was analyzed after 2 days by FACS. All experiments were performed
two times with three biological replicates, each of which was sorted from
pooled BM cells of six to ten mice.
In Vivo Analysis of Myeloid Differentiation
For 5-FU-induced leucopenia, WT, miR-146a KO, IL-6 KO, and miR-146a/IL-6
DKO mice were injected with 5-FU (250 mg/kg of body weight, intraperitone-
ally [i.p.] injected; Sigma-Aldrich). Peripheral blood was obtained on days 0, 2,
4, and 5 for FACS analysis in order to determine the severity of neutropenia. On
day 5, LPS (0.3 mg/kg of body weight, i.p.) was injected, and mice were bled
24 hr later for FACS analysis. For stem cell transplant study after lethal irradi-
ation, LincKit+ cells were purified from the BM of WT, miR-146a KO, IL-6 KO,
and miR-146a/IL-6 DKO mice. 500,000 cells were injected intravenously into
each lethally irradiated (1,000 rad in one dose) WT recipient mice. On day 6,
mice were bled for FACS analysis and LPS injection (0.3 mg/kg of bodyweight,
i.p.) was given; 48 hr later, mice were bled again for FACS analysis. Data
represent cumulative results from two independent mouse experiments.
Computational Algorithm and Statistical Analysis
In Figures 3 and 5, F tests were used to compare variances, and then the
appropriate two-sided Student’s t tests were applied. All figures with error
bars were graphed as mean ± SEM. For all heat maps, scale bars represent
mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
For all single-cell cytokine chip analysis, custom-written software routines
in R languagewere used to process, analyze, and visualize the single-cell func-
tional assay results. In brief, the algorithm converts raw fluorescence images
into numerical fluorescence intensity values for each assayed protein within
a given microchamber matched with the number of cells. The number of
cells within each microchamber was determined manually by microscopy.f WT, miR-146a KO, IL-6 KO, and miR-146a/IL-6 DKO mice. 500,000 cells per
day 6, mice were bled for FACS analysis in order to determine the degree of
mice were bled in order to study LPS-induced myelopoiesis by analyzing the
B-GFP transgenic reporter mice, which were harvested for FACS analysis at 4,
ion of LSK+ cells, LSK cells, and HSCs. Data are presented as mean ± SEM.
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used to set the gate in order to separate nonproducing cells from cytokine-pro-
ducing cells. Detailed statistical analysismethod for principal component anal-
ysis (Figures 1D, 2D, 2F, and 4F) can be found in the Supplemental Experi-
mental Procedures and our previous publication (Ma et al., 2011). These
types of statistical analysis and graphical representations are routinely used
to analyze large-scale multidimensional data sets from numerous cell subsets
(Bendall et al., 2011).SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
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